{"f81e21d2e34c6d393614aae215c7463bff3de059": [["AbsTRACT background Although the COVID-19 pandemic exposes frontline caregivers to severe prolonged stresses and trauma, there has been little clarity on how healthcare organisations can structure support to address these mental health needs.", [["trauma", "DISEASE", 113, 119], ["AbsTRACT background", "TEST", 0, 19], ["severe prolonged stresses", "PROBLEM", 83, 108], ["trauma", "PROBLEM", 113, 119], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["prolonged stresses", "OBSERVATION", 90, 108], ["little", "OBSERVATION_MODIFIER", 136, 142], ["clarity", "OBSERVATION_MODIFIER", 143, 150]]], ["In highrisk, high-pressure fields, frontline professionals may perceive mental health support as coming at the expense of urgent frontline work goals (ie, patient care) and as clashing with their central professional identities (ie, as expert, self-reliant ironmen/women).", [["patient", "ORGANISM", 155, 162], ["women", "ORGANISM", 265, 270], ["patient", "SPECIES", 155, 162], ["women", "SPECIES", 265, 270], ["high-pressure fields", "TREATMENT", 13, 33], ["frontline professionals", "TREATMENT", 35, 58], ["mental health support", "TREATMENT", 72, 93], ["high", "OBSERVATION_MODIFIER", 13, 17], ["pressure", "OBSERVATION_MODIFIER", 18, 26]]], ["Findings To address these pervasive goal and identity conflicts in professional organisations, we translate the results of a multiyear research study examining the US Army's efforts to transform its mental health support during the wars in Iraq and Afghanistan.", [["a multiyear research study", "TEST", 123, 149]]], ["We highlight parallels between providing support to frontline military units and frontline healthcare units during COVID-19 and surface implications for structuring mental health supports during a crisis.", [["frontline military units", "TREATMENT", 52, 76], ["frontline healthcare units", "TREATMENT", 81, 107], ["COVID", "TREATMENT", 115, 120], ["a crisis", "PROBLEM", 195, 203]]], ["Conclusion Addressing frontline caregivers' mental health needs is a vital part of health delivery organisations' response to COVID-19, but without thoughtful organisational design, well-intentioned efforts may fall short.", [["COVID", "TEST", 126, 131]]], ["An approach that assigns individual mental health personnel to support specific frontline units may be particularly promising.InTRoduCTIonThe COVID-19 pandemic has unleashed extraordinary stresses on frontline caregivers, from personal exposure risk and fears of infecting loved ones to extreme and unfamiliar workloads while facing moral dilemmas and intense suffering in patient care.", [["patient", "ORGANISM", 373, 380], ["patient", "SPECIES", 373, 380], ["specific frontline units", "TREATMENT", 71, 95]]], ["Healthcare organisations' ability to support frontline caregivers' mental health needs is widely considered essential as the pandemic draws ongoing waves of critically ill patients to their doors.", [["critically ill", "DISEASE", 157, 171], ["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180]]], ["1 However, the call to care for others often eclipses caregivers' attention to their own well-being, and even under typical circumstances, they suffer from high rates of burnout, stress, trauma and suicide.", [["burnout", "DISEASE", 170, 177], ["trauma", "DISEASE", 187, 193], ["stress", "PROBLEM", 179, 185], ["trauma", "PROBLEM", 187, 193], ["suicide", "PROBLEM", 198, 205]]], ["2 These challenges are amplified by the pandemic; for instance, a survey of COVID-19 caregivers in China found that 72% reported distress; 50% reported depression; and 45% reported anxiety.", [["depression", "DISEASE", 152, 162], ["anxiety", "DISEASE", 181, 188], ["distress", "PROBLEM", 129, 137], ["depression", "PROBLEM", 152, 162], ["anxiety", "PROBLEM", 181, 188]]], ["4 Yet, there has been little clarity on why this is the case and what alternatives may be better.InTRoduCTIonTranslating findings from organisational scholarship on professionals working in organisations during rapid change, this paper informs the vital question of how to support professional caregivers' mental health needs by elucidating professionals' reactions to organisationally sponsored mental health services.", [["little clarity", "OBSERVATION_MODIFIER", 22, 36]]], ["Organisational scholarship has demonstrated how professionals experience goal and identity conflicts that undermine frontline professional cooperation with organisational support efforts.", [["organisational support efforts", "TREATMENT", 156, 186]]], ["5 6 Frontline leaders and workers, especially in fields characterised by high stress and high risk, may perceive mental health supports as distracting from all-consuming frontline work goals (ie, patient care) and as going against their valued professional identities (ie, as expert, self-reliant ironmen/women).", [["patient", "ORGANISM", 196, 203], ["women", "ORGANISM", 305, 310], ["patient", "SPECIES", 196, 203], ["women", "SPECIES", 305, 310], ["high stress", "PROBLEM", 73, 84], ["high stress", "OBSERVATION", 73, 84]]], ["Because most traditional organisational mental health structures put the onus on employees to seek help and separate mental health personnel from frontline units, they neglect to create opportunities to develop the familiarity and contextualised awareness between mental health personnel and frontline units that can help to align seemingly conflicting goals and bridge identity differences.", [["frontline units", "TREATMENT", 292, 307]]], ["First, we synthesise organisational research on professionals in organisations to articulate how goal and identity conflicts arise within organisations and elucidate why these conflicts can undermine well-intended organisational efforts to support professionals during a crisis.", [["a crisis", "PROBLEM", 269, 277]]], ["Second, we describe findings from a major multiyear ethnographic research study examining an effort to deliver mental health support in a professional arena with strong parallels to healthcare during COVID-19: the US Army during the wars in Iraq and Afghanistan.Translating Research and EvidenceThis in-depth translation of a research study in a parallel context illustrates the problems that professional goal and identity conflict can pose for providing crisis-related mental health support and surfaces an alternative approach that is rooted in research and theory on organisational design.", [["a major multiyear ethnographic research study", "TEST", 34, 79], ["mental health support", "TREATMENT", 111, 132], ["a research study", "TEST", 324, 340], ["mental health support", "TREATMENT", 471, 492], ["an alternative approach", "TREATMENT", 506, 529]]], ["Third, we discuss the implications of the Army study for healthcare organisations and highlight the potential for skilful organisational design to help address goal and identity conflicts by assigning mental health personnel to support specific frontline units.", [["the Army study", "TEST", 38, 52]]], ["These lessons from organisational scholarship and the US Army's experience provide critical insight into how healthcare organisations can structure mental health support for frontline caregivers during COVID-19.oRgAnIsATIonAl bARRIERs To mEnTAl hEAlTh suppoRT: goAl And IdEnTITy ConFlICT In pRoFEssIonAl oRgAnIsATIonsScholarship on professionals in organisations elucidates two important barriers to the use and effectiveness of employee mental health support during crises: goal conflict and identity differences between frontline units and professional mental health personnel, described in detail as follows.goal conflictClassic organisational scholarship finds goal conflict is endemic within organisations, as specialised units and different professional groups often have their own interests and prioritise their own goals which may conflict.", [["conflict", "OBSERVATION", 616, 624], ["organisational scholarship", "OBSERVATION", 632, 658]]], ["[5] [6] [7] Even when shared organisational goals exist, such as to support the mental health of an organisation's workforce while ensuring quality service delivery, entrenchment in one's own group's perspective from their professional training and position in the organisational structure can make shared goals difficult to achieve.", [["their professional training", "TREATMENT", 217, 244]]], ["Both frontline unit leaders and staff may view mental health support as detracting from patient care goals; for example, research in surgery finds perceptions of a zero-sum conflict between being 'ironmen' who are fully dedicated to patient care 24/7 and complying with wellness-oriented interventions that limit work hours to promote sleep and prevent burnout.", [["burnout", "DISEASE", 353, 360], ["patient", "ORGANISM", 88, 95], ["patient", "ORGANISM", 233, 240], ["patient", "SPECIES", 88, 95], ["patient", "SPECIES", 233, 240], ["burnout", "PROBLEM", 353, 360]]], ["10 Such goal conflicts are likely further heightened in a crisis that accentuates time constraints, as COVID-19 has done.", [["a crisis", "PROBLEM", 56, 64], ["COVID", "TEST", 103, 108]]], ["Taking time away from care delivery for mental health may be seen as creating further team burdens on the unit, a common saying within healthcare being 'if you are not rounding, you are being rounded on', implying the only acceptable excuse for not providing patient care is becoming a patient oneself.", [["patient", "ORGANISM", 259, 266], ["patient", "ORGANISM", 286, 293], ["patient", "SPECIES", 259, 266], ["patient", "SPECIES", 286, 293], ["care delivery", "TREATMENT", 22, 35]]], ["By contrast, in line with their own professional training, mental health personnel may prioritise the mental health needs of caregivers over frontline units' near-term patient care goals.goal conflictOrganisational research has identified a number of mechanisms through which goal conflict can be addressed.", [["patient", "ORGANISM", 168, 175], ["patient", "SPECIES", 168, 175], ["frontline units' near-term patient care", "TREATMENT", 141, 180], ["conflict", "OBSERVATION", 192, 200]]], ["These include, for example, establishing formal rules and guidelines for interaction across groups 7 ; establishing cross-functional teams, task forces and departments 11 ; implementing collaborative incentives 12 ; and deploying colocation or matrix structures.", [["matrix structures", "ANATOMY", 244, 261], ["matrix structures", "CELLULAR_COMPONENT", 244, 261], ["deploying colocation or matrix structures", "TREATMENT", 220, 261]]], ["18 For example, in many healthcare specialties, training and culture prize professional identities in which one is tough, desensitised and self-reliant in response to traumatic situations.", [["traumatic situations", "PROBLEM", 167, 187]]], ["These qualities are largely considered part of being a good professional caregiver, what has been described as the 'historic \"iron doc\" culture' of medicine.", [["iron", "CHEMICAL", 126, 130], ["iron", "CHEMICAL", 126, 130]]], ["The prevalent labeling of frontline caregivers as 'heroes' as they serve amid COVID-19 may further buttress this identity, perhaps making it even harder to overcome the stigma of admitting a need for support and to relate positively with mental health personnel.Identity conflictBecause identity runs deep in individuals, goal conflicts arising across groups with different identities can be difficult to ameliorate through rational means alone.", [["support", "TREATMENT", 200, 207], ["identity runs deep in individuals", "PROBLEM", 287, 320], ["deep", "OBSERVATION_MODIFIER", 301, 305]]], ["For example, research has documented how inviting physician and hospital administrator groups prioritising different goals (eg, providing quality patient care and managing a profitable hospital) to a strategic planning retreat without addressing identity differences can backfire and further fuel their conflict.", [["patient", "ORGANISM", 146, 153], ["patient", "SPECIES", 146, 153], ["a strategic planning retreat", "TREATMENT", 198, 226]]], ["20 Similarly, because there are likely identity differences between mental health personnel and frontline caregivers, particularly those in emergency and intensive care units known for their stoicism amid trauma, there is potential that mental health resources go underused and underappreciated because they are considered out of touch with the realities of frontline units' unique professional identities.Identity conflictIn sum, organisational scholarship on professionals in organisations suggests goal conflict and identity differences between mental health and frontline caregiver professional groups may pose substantial barriers to the use and usefulness of mental health support during COVID-19.AlIgnIng mEnTAl hEAlTh suppoRT wITh FRonTlInE unITs: ThE us ARmy And AnChoREd pERsonAlIsATIonWith goal and identity conflict posing stark challenges to providing mental health services to frontline professionals, integrative solutions that equip organisations with practical strategies to address conflicting goals and identity differences are vital.", [["trauma", "DISEASE", 205, 211], ["their stoicism amid trauma", "PROBLEM", 185, 211], ["integrative solutions", "TREATMENT", 916, 937], ["practical strategies", "TREATMENT", 968, 988]]], ["To shed light on potentially useful strategies for structuring mental health support during COVID-19, we further describe findings from a major multiyear ethnographic research study conducted from 2012 to 2015 examining an effort to deliver mental health support in a professional arena with strong parallels to healthcare during COVID-19: the US Army during the wars in Iraq and Afghanistan.", [["useful strategies", "TREATMENT", 29, 46], ["mental health support", "TREATMENT", 241, 262]]], ["[21] [22] [23] [24] [25] Translating Research and Evidence us Army case: anchored personalisation During the wars in Iraq and Afghanistan, the US Army sought to transform its mental health services to better support soldiers' needs, given increased rates of post-traumatic stress disorder and suicide.", [["post-traumatic stress disorder", "DISEASE", 258, 288], ["anchored personalisation", "PROBLEM", 73, 97], ["post-traumatic stress disorder", "PROBLEM", 258, 288], ["suicide", "PROBLEM", 293, 300], ["post-traumatic stress disorder", "OBSERVATION", 258, 288]]], ["However, much like healthcare workers during COVID-19, soldiers in the US Army faced the dual challenge of prolonged periods of high personal risk and stress, combined with intense demands to be 'field ready' and 'tough.", [["stress", "PROBLEM", 151, 157]]], ["Mental health support provoked resistance from soldiers' supervisory commanders, who often discouraged soldiers from using mental health services, fought treatment recommendations (eg, to allow a soldier to sit out of a stressful training exercise) and emphasised long-standing prejudices about mental health personnel (eg, calling them 'Berkeley hippies').", [["a stressful training exercise", "TREATMENT", 218, 247]]], ["Meanwhile, mental health personnel, stereotyping commanders as 'bullies', remained removed from soldiers' unique units and work environments, and made recommendations often considered inappropriate for valued mission-readiness goals or unnecessarily damaging to soldier career aspirations.AlIgnIng mEnTAl hEAlTh suppoRT wITh FRonTlInE unITs: ThE us ARmy And AnChoREd pERsonAlIsATIonHowever, this research also uncovered an alternative approach that resolved the pervasive and long-standing goal and identity conflicts between mental health support and frontline unit supervisors and members.", [["AlIgnIng mEnTAl hEAlTh suppoRT wITh FRonTlInE unITs", "DNA", 289, 340]]], ["In working with and learning about specific units, mental health personnel were able to design support that was sensitive to the specific mental health needs of soldiers in their units, as well as their career aspirations and unit goals (eg, discretely assigning a soldier to a less stressful role during a training exercise).", [["a training exercise", "TREATMENT", 305, 324]]], ["In so doing, feelings of stigma began to change; for example, using mental health services started being framed as 'a sign of strength' or 'being man enough to get help', which aligned with the professional identities of many in all-male combat units.", [["man", "SPECIES", 146, 149], ["stigma", "PROBLEM", 25, 31], ["stigma", "OBSERVATION", 25, 31]]], ["At the same time, this approach ensured this personalisation was balanced by 'anchoring', in which the mental health personnel who were assigned to different units regularly came together, helping one another remain anchored in their professional goals of supporting mental health and resist the demands of frontline units' leadership that sometimes ran counter to soldier well-being.AlIgnIng mEnTAl hEAlTh suppoRT wITh FRonTlInE unITs: ThE us ARmy And AnChoREd pERsonAlIsATIonThe concept of anchored personalisation for mental health support provision is rooted in organisational scholarship on personalisation.", [["AlIgnIng mEnTAl hEAlTh suppoRT wITh FRonTlInE unITs", "DNA", 384, 435], ["mental health support provision", "TREATMENT", 521, 552]]], ["Research on personalisation, defined as regular, individuated one-on-one contact across groups, has been found to reduce intergroup stereotyping and lead to increased perspectivetaking as members of different groups develop familiarity with and knowledge about one another as people rather than stereotypes in a variety of contexts.", [["people", "ORGANISM", 276, 282], ["people", "SPECIES", 276, 282]]], ["26 Such perspective-taking can enable people to break out of their entrenched worldviews to find integrative solutions that are win-win for both groups.", [["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44]]], ["However, personalisation can also become problematic if personalised contact with the other group leads to co-optation and indoctrination into the other group's perspective, a phenomenon exhibited among bankers through 'regulatory capture' 27 and affirmative action officers protecting their organisations over advocating for employees.", [["a phenomenon", "PROBLEM", 174, 186]]], ["21sTRuCTuRIng mEnTAl hEAlTh suppoRT AmId CoVId-19Although there are certainly differences between professional soldiers who train to endure prolonged traumatic situations at war and frontline caregivers suddenly confronting unexpected traumatic situations brought by the COVID-19 pandemic, there are two central insights from the US Army's experience structuring mental health support that are especially relevant for the challenge of providing mental health support for frontline caregivers.", [["prolonged traumatic situations", "PROBLEM", 140, 170], ["unexpected traumatic situations", "PROBLEM", 224, 255]]], ["First, if personalisation is vital to breaking down barriers to mental health across professional differences, then relying on it to happen by chance is likely insufficient, particularly in high-risk, high-pressure fields like the military and healthcare.", [["high-pressure fields", "PROBLEM", 201, 221]]], ["Because organisational structures shape the types of interactions members have with others inside their organisations, when properly designed, the right structures can offer opportunities for regular interaction, familiarity and personal relationships between members of the organisation outside one's home group.", [["right structures", "ANATOMY", 147, 163], ["shape", "OBSERVATION_MODIFIER", 34, 39], ["right", "ANATOMY_MODIFIER", 147, 152]]], ["29 In healthcare, organisational design is a critical lever for structuring and institutionalising effective care delivery.", [["institutionalising effective care delivery", "TREATMENT", 80, 122]]], ["30 Intentional organisational design may be a key lever through which healthcare organisations can ensure mental health offerings achieve their intended impact.sTRuCTuRIng mEnTAl hEAlTh suppoRT AmId CoVId-19The second central insight emerging from the US Army case is that the specific strategy of assigning mental health personnel to a few specific frontline units may be particularly advantageous.", [["CoVId-19", "CHEMICAL", 199, 207], ["CoVId-19", "CHEMICAL", 199, 207], ["CoVId", "TEST", 199, 204]]], ["Because it enables anchored personalisation, this strategy may help mitigate goal conflict and identity challenges related to mental health support usage in healthcare, such as limited time and a culture of 'toughing it out', that make mental health resources so difficult for caregivers to seek out and use in practice.", [["this strategy", "TREATMENT", 45, 58], ["a culture", "TEST", 194, 203]]], ["If unit staff, and particularly unit leaders, become more familiar with a dedicated mental health support person through personalised interactions, together they can break down stigma and stereotypes, take one another's perspectives and become partners in jointly devising contextualised ways of supporting unit staff well-being that are customised and minimally disruptive to patient care.", [["patient", "ORGANISM", 377, 384], ["person", "SPECIES", 106, 112], ["patient", "SPECIES", 377, 384]]], ["Doing so may also help personnel frame mental health services in ways that resonate with specific units to encourage use, such as by relabeling mental health as 'psychosocial support' or 'resiliency coaching', or by tapping into the self-sacrificing identity of many caregivers through emphasising how use of mental health support may enable sustained high quality care for patients.", [["patients", "ORGANISM", 374, 382], ["patients", "SPECIES", 374, 382], ["mental health support", "TREATMENT", 309, 330]]], ["31 Customisation of mental health support is particularly critical because the specific stresses brought on by COVID-19 vary across Translating Research and Evidence different departments and units.", [["mental health support", "TREATMENT", 20, 41]]], ["For example, the mental health needs of a COVID-19 intensive care unit with nurses isolated behind closed doors with gravely ill patients may differ from those of emergency department staff interacting with large numbers of patients whose COVID-19 status may yet be unknown.", [["gravely ill", "DISEASE", 117, 128], ["patients", "ORGANISM", 129, 137], ["patients", "ORGANISM", 224, 232], ["patients", "SPECIES", 129, 137], ["patients", "SPECIES", 224, 232], ["COVID", "TEST", 239, 244]]], ["In addition, time constraints across units vary; for example, especially busy units may require more proactive identification of who needs help, such as from assigned peer 'buddies' or leaders, while others may require daily decompression huddles with their assigned mental health personnel purposefully making themselves available afterward to do one-on-one follow-ups.", [["daily decompression huddles", "TREATMENT", 219, 246]]], ["At the same time, ensuring mental health personnel maintain connection with those in similar roles serving other units can help them stand firm on the importance of supporting mental health goals, even when time demands and the culture of medicine may default to relegating mental health back to the sidelines.ConClusIonAddressing caregivers' mental health needs is a vital part of health delivery organisations' response to the COVID-19 crisis, but without thoughtful organisational design, even wellintentioned efforts may fail.", [["the culture of medicine", "TREATMENT", 224, 247], ["the COVID", "TEST", 425, 434]]], ["Organisational research elucidates how goal and identity conflict can undermine such efforts in professional organisations and has explored possible solutions that can be built into the design of mental health support.", [["mental health support", "TREATMENT", 196, 217]]], ["Based on findings from a in-depth study of the US Army's evolution of its mental healthcare support for frontline units, a design that assigns individual mental health personnel to support specific frontline units may be particularly promising during COVID-19.", [["a in-depth study", "TEST", 23, 39], ["frontline units", "TREATMENT", 104, 119], ["specific frontline units", "TREATMENT", 189, 213], ["COVID", "TEST", 251, 256]]], ["Because it enables anchored personalisation, this design can help professional caregivers and mental health personnel bridge their differences and devise innovative solutions that increase the use and usefulness of mental health support.", [["innovative solutions", "TREATMENT", 154, 174], ["mental health support", "TREATMENT", 215, 236]]], ["Implementation of versions of anchored personalisation in response to COVID-19 is already occurring, with examples in systems such as University of California's Zuckerberg San Francisco General Hospital and Yale New Haven Hospital.", [["anchored personalisation", "PROBLEM", 30, 54], ["COVID", "TEST", 70, 75]]], ["Perhaps such efforts will also help revitalise how mental health, stress, trauma exposure and burnout are addressed in healthcare delivery, even after this crisis, to better support the frontline caregivers who serve patients day after day.", [["trauma", "DISEASE", 74, 80], ["burnout", "DISEASE", 94, 101], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 217, 225]]]], "PMC7373678": [], "35e9db94099acc5ce344cdf3a2189d69616a12e9": [["\u25a0 INTRODUCTIONVarious natural and synthetic materials have been used as potential carrier biomaterials of cell or therapeutic agents for tissue regeneration.", [["cell", "ANATOMY", 106, 110], ["tissue", "ANATOMY", 137, 143], ["cell", "CELL", 106, 110], ["tissue", "TISSUE", 137, 143], ["INTRODUCTIONVarious natural and synthetic materials", "TREATMENT", 2, 53], ["potential carrier biomaterials of cell", "TREATMENT", 72, 110], ["therapeutic agents", "TREATMENT", 114, 132], ["tissue regeneration", "PROBLEM", 137, 156]]], ["1\u22126 Hydrogels with highly hydrated polymeric networks are ideal carriers for encapsulating cells and drugs.", [["cells", "ANATOMY", 91, 96], ["1\u22126 Hydrogels", "SIMPLE_CHEMICAL", 0, 13], ["cells", "CELL", 91, 96], ["Hydrogels", "TREATMENT", 4, 13], ["highly hydrated polymeric networks", "TREATMENT", 19, 53], ["encapsulating cells and drugs", "TREATMENT", 77, 106]]], ["7\u221212 However, most conventional hydrogels that allow cells encapsulation are based on static chemical crosslinking and lack dynamic properties such as self-healing and injectability.", [["cells", "ANATOMY", 53, 58], ["cells", "CELL", 53, 58], ["conventional hydrogels", "TREATMENT", 19, 41], ["cells encapsulation", "TREATMENT", 53, 72], ["static chemical crosslinking", "TREATMENT", 86, 114], ["lack dynamic properties", "TREATMENT", 119, 142], ["self-healing and injectability", "TREATMENT", 151, 181]]], ["13\u221215 These limitations preclude the delivery of cargo agents by the hydrogel carriers to anatomically deep and enclosed defects via minimally invasive procedures, which have become increasingly popular because of demands for aesthetic appearance and expeditious postsurgery recovery.", [["13\u221215", "CHEMICAL", 0, 5], ["cargo agents", "TREATMENT", 49, 61], ["the hydrogel carriers", "TREATMENT", 65, 86], ["anatomically deep and enclosed defects", "PROBLEM", 90, 128], ["minimally invasive procedures", "TREATMENT", 133, 162], ["aesthetic appearance", "PROBLEM", 226, 246], ["defects", "OBSERVATION", 121, 128], ["minimally", "OBSERVATION_MODIFIER", 133, 142], ["invasive", "OBSERVATION_MODIFIER", 143, 151]]], ["16 Furthermore, the rigid and nondegradable nature of chemically crosslinked hydrogels hinders the recruitment and infiltration of host cells into implanted hydrogels, thereby limiting the extent of in situ regeneration and integration of implanted biomaterials into host tissues.", [["cells", "ANATOMY", 136, 141], ["tissues", "ANATOMY", 272, 279], ["host cells", "CELL", 131, 141], ["tissues", "TISSUE", 272, 279], ["host cells", "CELL_TYPE", 131, 141], ["the rigid", "PROBLEM", 16, 25], ["chemically crosslinked hydrogels", "TREATMENT", 54, 86], ["infiltration of host cells into implanted hydrogels", "TREATMENT", 115, 166], ["situ regeneration", "TREATMENT", 202, 219], ["integration of implanted biomaterials", "TREATMENT", 224, 261], ["chemically", "OBSERVATION_MODIFIER", 54, 64], ["crosslinked hydrogels", "OBSERVATION", 65, 86], ["recruitment", "OBSERVATION_MODIFIER", 99, 110], ["infiltration", "OBSERVATION", 115, 127], ["host cells", "OBSERVATION", 131, 141], ["implanted hydrogels", "OBSERVATION", 147, 166], ["extent", "OBSERVATION_MODIFIER", 189, 195], ["situ regeneration", "OBSERVATION", 202, 219], ["implanted biomaterials", "OBSERVATION", 239, 261], ["host tissues", "OBSERVATION", 267, 279]]], ["17, 18 Many previous studies have demonstrated the fabrication of dynamic hydrogels stabilized by reversible physical cross-linking including hydrogen bonds, hydrophobic interactions, ionic interactions, ligand\u2212ion coordination, dipole\u2212dipole interactions, and host\u2212guest complexations.", [["hydrogen", "CHEMICAL", 142, 150], ["ligand\u2212ion", "SIMPLE_CHEMICAL", 204, 214], ["dipole\u2212dipole", "SIMPLE_CHEMICAL", 229, 242], ["Many previous studies", "TEST", 7, 28], ["dynamic hydrogels", "TREATMENT", 66, 83], ["reversible physical cross-linking", "PROBLEM", 98, 131], ["ionic interactions", "TREATMENT", 184, 202], ["dynamic hydrogels stabilized", "OBSERVATION", 66, 94], ["reversible", "OBSERVATION_MODIFIER", 98, 108], ["physical cross-linking", "OBSERVATION", 109, 131], ["hydrogen bonds", "OBSERVATION", 142, 156]]], ["19\u221237 These physically cross-linked hydrogels exhibit many desirable properties including self-healing and injectability.", [["19\u221237", "CHEMICAL", 0, 5], ["These physically cross-linked hydrogels", "PROBLEM", 6, 45], ["self-healing", "PROBLEM", 90, 102], ["healing", "OBSERVATION_MODIFIER", 95, 102]]], ["38\u221244 However, because of the weak nature of physical cross-linking and the stringent demands of cell-friendly preparation, few studies have reported physical hydrogels that are sufficiently cytocompatible and stable to allow for encapsulation and long-term culture of cells and to provide continued support to the encapsulated cells in vivo after delivery.\u25a0 INTRODUCTIONIn this study, we develop unique cell-infiltratable and injectable (Ci-I) gelatin hydrogels, which are stabilized largely by the physical cross-linking of host\u2212guest complexation and are further reinforced by limited chemical cross-linking (Scheme 1), and then demonstrate the outstanding properties of these Ci-I gelatin hydrogels.", [["cell", "ANATOMY", 97, 101], ["cells", "ANATOMY", 269, 274], ["cells", "ANATOMY", 328, 333], ["cell", "ANATOMY", 404, 408], ["cell", "CELL", 97, 101], ["cells", "CELL", 269, 274], ["cells", "CELL", 328, 333], ["cell", "CELL", 404, 408], ["host\u2212guest", "SIMPLE_CHEMICAL", 526, 536], ["Ci-I gelatin hydrogels", "SIMPLE_CHEMICAL", 680, 702], ["encapsulated cells", "CELL_TYPE", 315, 333], ["physical cross-linking", "PROBLEM", 45, 67], ["few studies", "TEST", 124, 135], ["physical hydrogels", "PROBLEM", 150, 168], ["encapsulation", "TREATMENT", 230, 243], ["long-term culture of cells", "TREATMENT", 248, 274], ["the encapsulated cells", "TREATMENT", 311, 333], ["delivery", "TREATMENT", 348, 356], ["this study", "TEST", 374, 384], ["unique cell", "PROBLEM", 397, 408], ["injectable (Ci-I) gelatin hydrogels", "TREATMENT", 427, 462], ["these Ci-I gelatin hydrogels", "TREATMENT", 674, 702]]], ["Our Ci-I gelatin hydrogels can be preformed with encapsulated therapeutic cells and drugs first, maintained under culture conditions for a desired period, and injected to target sites in the gel form at a prescribed time because of their excellent injectability and remoldability.", [["cells", "ANATOMY", 74, 79], ["sites", "ANATOMY", 178, 183], ["cells", "CELL", 74, 79], ["therapeutic cells", "CELL_TYPE", 62, 79], ["Our Ci-I gelatin hydrogels", "TREATMENT", 0, 26], ["encapsulated therapeutic cells", "TREATMENT", 49, 79], ["drugs", "TREATMENT", 84, 89], ["excellent", "OBSERVATION_MODIFIER", 238, 247], ["injectability", "OBSERVATION", 248, 261]]], ["Furthermore, the reversible physical cross-links of the Ci-I hydrogels also support infiltration of cells into the hydrogels that are loaded with chemoattractant drugs.", [["cells", "ANATOMY", 100, 105], ["Ci-I", "CHEMICAL", 56, 60], ["cells", "CELL", 100, 105], ["the Ci-I hydrogels", "TREATMENT", 52, 70], ["infiltration of cells", "PROBLEM", 84, 105], ["the hydrogels", "TREATMENT", 111, 124], ["chemoattractant drugs", "TREATMENT", 146, 167], ["reversible", "OBSERVATION_MODIFIER", 17, 27], ["infiltration", "OBSERVATION", 84, 96], ["chemoattractant drugs", "OBSERVATION", 146, 167]]], ["These unique capabilities of Ci-I hydrogels offer great convenience during surgical procedures and significantly expedite clinical operations.", [["Ci-I", "CHEMICAL", 29, 33], ["Ci-I hydrogels", "TREATMENT", 29, 43], ["surgical procedures", "TREATMENT", 75, 94], ["clinical operations", "TREATMENT", 122, 141]]], ["We further evaluated the efficacy of the Ci-I gelation hydrogels as carriers of therapeutic drugs and cells for treating an enclosed bone abnormality in steroid-associated osteonecrosis (SAON) of the femoral head.\u25a0 INTRODUCTIONSteroids are widely used for treating various clinical conditions, such as rheumatoid arthritis, organ transplantation, and respiratory syndrome.", [["cells", "ANATOMY", 102, 107], ["bone", "ANATOMY", 133, 137], ["SAON", "ANATOMY", 187, 191], ["femoral head", "ANATOMY", 200, 212], ["organ", "ANATOMY", 324, 329], ["bone abnormality", "DISEASE", 133, 149], ["steroid", "CHEMICAL", 153, 160], ["osteonecrosis", "DISEASE", 172, 185], ["SAON", "DISEASE", 187, 191], ["rheumatoid arthritis", "DISEASE", 302, 322], ["organ transplantation, and respiratory syndrome", "DISEASE", 324, 371], ["steroid", "CHEMICAL", 153, 160], ["cells", "CELL", 102, 107], ["bone", "TISSUE", 133, 137], ["steroid", "SIMPLE_CHEMICAL", 153, 160], ["femoral head", "MULTI-TISSUE_STRUCTURE", 200, 212], ["organ", "ORGAN", 324, 329], ["the Ci-I gelation hydrogels", "TREATMENT", 37, 64], ["therapeutic drugs", "TREATMENT", 80, 97], ["cells", "TREATMENT", 102, 107], ["an enclosed bone abnormality", "PROBLEM", 121, 149], ["steroid-associated osteonecrosis (SAON) of the femoral head", "PROBLEM", 153, 212], ["INTRODUCTIONSteroids", "TREATMENT", 215, 235], ["various clinical conditions", "PROBLEM", 265, 292], ["rheumatoid arthritis", "PROBLEM", 302, 322], ["organ transplantation", "TREATMENT", 324, 345], ["respiratory syndrome", "PROBLEM", 351, 371], ["bone", "ANATOMY", 133, 137], ["abnormality", "OBSERVATION", 138, 149], ["steroid", "OBSERVATION_MODIFIER", 153, 160], ["osteonecrosis", "OBSERVATION", 172, 185], ["femoral", "ANATOMY_MODIFIER", 200, 207], ["head", "ANATOMY", 208, 212], ["rheumatoid arthritis", "OBSERVATION", 302, 322], ["organ", "ANATOMY", 324, 329], ["transplantation", "OBSERVATION", 330, 345], ["respiratory syndrome", "OBSERVATION", 351, 371]]], ["45\u221249 However, long-term steroid treatments may lead to SAON, commonly affecting large joints such as the hip.", [["joints", "ANATOMY", 87, 93], ["hip", "ANATOMY", 106, 109], ["steroid", "CHEMICAL", 25, 32], ["SAON", "DISEASE", 56, 60], ["steroid", "CHEMICAL", 25, 32], ["SAON", "CANCER", 56, 60], ["joints", "MULTI-TISSUE_STRUCTURE", 87, 93], ["hip", "ORGANISM_SUBDIVISION", 106, 109], ["long-term steroid treatments", "TREATMENT", 15, 43], ["SAON", "PROBLEM", 56, 60], ["joints", "ANATOMY", 87, 93], ["hip", "ANATOMY", 106, 109]]], ["50\u221252 A surgical core decompression (CD) procedure is typically performed on patients with early stage SAON to remove the necrotic bone and implant bone substitute in the drilled tunnel to prevent subsequent decreases in bone mineral density and support bone regeneration.", [["necrotic bone", "ANATOMY", 122, 135], ["bone", "ANATOMY", 148, 152], ["bone", "ANATOMY", 221, 225], ["bone", "ANATOMY", 254, 258], ["necrotic", "DISEASE", 122, 130], ["patients", "ORGANISM", 77, 85], ["necrotic bone", "TISSUE", 122, 135], ["bone", "TISSUE", 148, 152], ["bone mineral", "MULTI-TISSUE_STRUCTURE", 221, 233], ["bone", "TISSUE", 254, 258], ["patients", "SPECIES", 77, 85], ["A surgical core decompression (CD) procedure", "TREATMENT", 6, 50], ["early stage SAON", "PROBLEM", 91, 107], ["the necrotic bone", "PROBLEM", 118, 135], ["implant bone substitute", "TREATMENT", 140, 163], ["the drilled tunnel", "TREATMENT", 167, 185], ["subsequent decreases in bone mineral density", "PROBLEM", 197, 241], ["bone regeneration", "PROBLEM", 254, 271], ["decompression", "OBSERVATION", 22, 35], ["necrotic", "OBSERVATION_MODIFIER", 122, 130], ["bone", "ANATOMY", 131, 135], ["implant bone", "OBSERVATION", 140, 152], ["drilled tunnel", "OBSERVATION", 171, 185], ["prevent", "UNCERTAINTY", 189, 196], ["subsequent", "OBSERVATION_MODIFIER", 197, 207], ["decreases", "OBSERVATION_MODIFIER", 208, 217], ["bone", "ANATOMY", 221, 225], ["mineral density", "OBSERVATION", 226, 241], ["support bone regeneration", "OBSERVATION", 246, 271]]], ["53, 54 Since the lack of endogenous stem cells and aberrant accumulation of adipose tissues were recognized as main characteristics of SAON in previous studies, 55, 56 here, we evaluated the feasibility of the Ci-I gelatin hydrogels encapsulating mesenchymal stem cells (MSCs) and a hydrophobic small molecule, icaritin, as a bone substitute to treat rat SAON (Scheme 1).", [["stem cells", "ANATOMY", 36, 46], ["adipose tissues", "ANATOMY", 76, 91], ["mesenchymal stem cells", "ANATOMY", 247, 269], ["MSCs", "ANATOMY", 271, 275], ["bone", "ANATOMY", 326, 330], ["icaritin", "CHEMICAL", 311, 319], ["SAON", "DISEASE", 355, 359], ["icaritin", "CHEMICAL", 311, 319], ["stem cells", "CELL", 36, 46], ["adipose tissues", "TISSUE", 76, 91], ["mesenchymal stem cells", "CELL", 247, 269], ["MSCs", "CELL", 271, 275], ["icaritin", "SIMPLE_CHEMICAL", 311, 319], ["bone", "TISSUE", 326, 330], ["rat", "ORGANISM", 351, 354], ["endogenous stem cells", "CELL_TYPE", 25, 46], ["mesenchymal stem cells", "CELL_TYPE", 247, 269], ["MSCs", "CELL_TYPE", 271, 275], ["rat", "SPECIES", 351, 354], ["rat", "SPECIES", 351, 354], ["endogenous stem cells", "PROBLEM", 25, 46], ["aberrant accumulation of adipose tissues", "PROBLEM", 51, 91], ["the Ci-I gelatin hydrogels", "TREATMENT", 206, 232], ["a hydrophobic small molecule", "PROBLEM", 281, 309], ["icaritin", "TREATMENT", 311, 319], ["a bone substitute", "TREATMENT", 324, 341], ["endogenous stem cells", "OBSERVATION", 25, 46], ["aberrant", "OBSERVATION_MODIFIER", 51, 59], ["accumulation", "OBSERVATION_MODIFIER", 60, 72], ["adipose tissues", "OBSERVATION", 76, 91], ["mesenchymal stem cells", "OBSERVATION", 247, 269], ["bone", "ANATOMY", 326, 330]]], ["Our in vivo animal research showed that the MSCs and icaritin-laden Ci-I gelatin hydrogels can prevent a decrease in bone mineral density (BMD) and promote in situ bone regeneration.", [["MSCs", "ANATOMY", 44, 48], ["bone", "ANATOMY", 117, 121], ["bone", "ANATOMY", 164, 168], ["icaritin", "CHEMICAL", 53, 61], ["icaritin", "CHEMICAL", 53, 61], ["MSCs", "CELL", 44, 48], ["icaritin", "SIMPLE_CHEMICAL", 53, 61], ["Ci-I gelatin hydrogels", "SIMPLE_CHEMICAL", 68, 90], ["bone", "TISSUE", 117, 121], ["bone", "TISSUE", 164, 168], ["MSCs", "CELL_TYPE", 44, 48], ["the MSCs", "PROBLEM", 40, 48], ["icaritin-laden Ci-I gelatin hydrogels", "TREATMENT", 53, 90], ["a decrease in bone mineral density (BMD)", "PROBLEM", 103, 143], ["MSCs", "ANATOMY", 44, 48], ["decrease", "OBSERVATION_MODIFIER", 105, 113], ["bone", "ANATOMY", 117, 121], ["mineral density", "OBSERVATION", 122, 137], ["situ bone regeneration", "OBSERVATION", 159, 181]]], ["Moreover, the icaritin-laden hydrogels enhanced the recruitment and infiltration of cells from the surrounding host tissues to the implantation sites, further confirming the efficacy of our Ci-I Scheme 1.", [["cells", "ANATOMY", 84, 89], ["tissues", "ANATOMY", 116, 123], ["icaritin", "CHEMICAL", 14, 22], ["icaritin", "CHEMICAL", 14, 22], ["icaritin", "SIMPLE_CHEMICAL", 14, 22], ["cells", "CELL", 84, 89], ["host tissues", "TISSUE", 111, 123], ["the icaritin-laden hydrogels", "TREATMENT", 10, 38], ["infiltration of cells", "TREATMENT", 68, 89], ["the implantation sites", "TREATMENT", 127, 149], ["laden", "OBSERVATION_MODIFIER", 23, 28], ["hydrogels", "OBSERVATION_MODIFIER", 29, 38], ["enhanced", "OBSERVATION_MODIFIER", 39, 47], ["recruitment", "OBSERVATION_MODIFIER", 52, 63], ["infiltration of cells", "OBSERVATION", 68, 89], ["host tissues", "OBSERVATION", 111, 123], ["implantation", "OBSERVATION", 131, 143]]], ["Preparation of the Cell-Infiltratable and Injectable (Ci-I) Gelatin Hydrogels and the Treatment of SAON with Ci-I Hydrogels as the Carrier of Therapeutic Cargoes (Cells and Drug) in the Rat Model hydrogels for promoting in situ regeneration.", [["Cell", "ANATOMY", 19, 23], ["Cells", "ANATOMY", 163, 168], ["Ci-I", "CHEMICAL", 109, 113], ["Cell", "CELL", 19, 23], ["SAON", "SIMPLE_CHEMICAL", 99, 103], ["Ci-I Hydrogels", "SIMPLE_CHEMICAL", 109, 123], ["Cells", "CELL", 163, 168], ["the Cell", "TREATMENT", 15, 23], ["Infiltratable and Injectable (Ci-I) Gelatin Hydrogels", "TREATMENT", 24, 77], ["the Treatment of SAON", "TREATMENT", 82, 103], ["Ci-I Hydrogels", "TREATMENT", 109, 123], ["Therapeutic Cargoes (Cells and Drug)", "TREATMENT", 142, 178], ["the Rat Model hydrogels", "TREATMENT", 182, 205], ["situ regeneration", "OBSERVATION", 223, 240]]], ["To the best of our knowledge, this is the first study demonstrating the feasibility of using injectable hydrogels encapsulating stem cells and small molecules to treat bone disorders in deep and enclosed anatomical locations, e.g., SAON at the hip.\u25a0 RESULTS AND DISCUSSIONPrefabricated Ci-I Hydrogels Adapt to Injection Site Geometry and Maintain Initial Mechanical Properties after Injection.", [["stem cells", "ANATOMY", 128, 138], ["bone", "ANATOMY", 168, 172], ["hip", "ANATOMY", 244, 247], ["bone disorders", "DISEASE", 168, 182], ["SAON", "DISEASE", 232, 236], ["stem cells", "CELL", 128, 138], ["bone", "TISSUE", 168, 172], ["hip", "ORGANISM_SUBDIVISION", 244, 247], ["stem cells", "CELL_TYPE", 128, 138], ["the first study", "TEST", 38, 53], ["injectable hydrogels encapsulating stem cells", "TREATMENT", 93, 138], ["small molecules", "PROBLEM", 143, 158], ["bone disorders", "PROBLEM", 168, 182], ["SAON at the hip", "PROBLEM", 232, 247], ["DISCUSSIONPrefabricated Ci-I Hydrogels", "TREATMENT", 262, 300], ["Injection Site Geometry", "TREATMENT", 310, 333], ["Initial Mechanical Properties after Injection", "TREATMENT", 347, 392], ["encapsulating stem cells", "OBSERVATION", 114, 138], ["small molecules", "OBSERVATION", 143, 158], ["bone", "ANATOMY", 168, 172], ["deep", "ANATOMY_MODIFIER", 186, 190], ["anatomical", "ANATOMY_MODIFIER", 204, 214], ["hip", "ANATOMY", 244, 247]]], ["Gelatin has been extensively used for various biomedical applications because of its biocompatibility, bioactivity, biodegradability, and availability.", [["Gelatin", "CHEMICAL", 0, 7], ["Gelatin", "GENE_OR_GENE_PRODUCT", 0, 7], ["Gelatin", "TREATMENT", 0, 7], ["various biomedical applications", "TREATMENT", 38, 69]]], ["57, 58 Gelatin hydrogels are especially useful as carrier materials of therapeutic cells and drugs.", [["cells", "ANATOMY", 83, 88], ["Gelatin hydrogels", "SIMPLE_CHEMICAL", 7, 24], ["cells", "CELL", 83, 88], ["therapeutic cells", "CELL_TYPE", 71, 88], ["Gelatin hydrogels", "TREATMENT", 7, 24], ["therapeutic cells", "TREATMENT", 71, 88], ["drugs", "TREATMENT", 93, 98]]], ["59\u221261 However, the preparation of conventional chemically cross-linked gelatin hydrogels entails chemical modifications of the gelatin, and the obtained hydrogels are brittle with restricted network dynamics.", [["gelatin hydrogels", "SIMPLE_CHEMICAL", 71, 88], ["gelatin", "SIMPLE_CHEMICAL", 127, 134], ["network", "MULTI-TISSUE_STRUCTURE", 191, 198], ["conventional chemically cross-linked gelatin hydrogels", "TREATMENT", 34, 88], ["the gelatin", "TREATMENT", 123, 134], ["the obtained hydrogels", "TREATMENT", 140, 162]]], ["62\u221264 Therefore, in this study, we developed a strategy to prepare gelatin hydrogels containing both chemical and physical cross-linking based on unmodified gelatin.", [["62\u221264", "CHEMICAL", 0, 5], ["gelatin hydrogels", "SIMPLE_CHEMICAL", 67, 84], ["gelatin", "SIMPLE_CHEMICAL", 157, 164], ["this study", "TEST", 20, 30], ["a strategy to prepare gelatin hydrogels", "TREATMENT", 45, 84], ["physical cross-linking", "TREATMENT", 114, 136], ["unmodified gelatin", "TREATMENT", 146, 164]]], ["First, the synthesized free diffusing photocross-linkable Ac-\u03b2-CDs (acryloyl \u03b2-cyclodextrin, 1.5 acryloyl groups per Ac-\u03b2-CD molecule on average, i.e., a fraction of Ac-\u03b2-CDs bear more than one acryloyl group, Figure S1 ) were coupled to the aromatic residues of gelatin (e.g., phenylalanine, tyrosine, and tryptophan) via host\u2212guest interactions.", [["Ac-\u03b2-CDs", "CHEMICAL", 58, 66], ["acryloyl \u03b2-cyclodextrin", "CHEMICAL", 68, 91], ["acryloyl", "CHEMICAL", 97, 105], ["Ac-\u03b2-CD", "CHEMICAL", 117, 124], ["Ac-\u03b2-CDs", "CHEMICAL", 166, 174], ["gelatin", "CHEMICAL", 263, 270], ["phenylalanine", "CHEMICAL", 278, 291], ["tyrosine", "CHEMICAL", 293, 301], ["tryptophan", "CHEMICAL", 307, 317], ["Ac-\u03b2-CDs", "CHEMICAL", 58, 66], ["acryloyl \u03b2-cyclodextrin", "CHEMICAL", 68, 91], ["acryloyl", "CHEMICAL", 97, 105], ["Ac-\u03b2-CD", "CHEMICAL", 117, 124], ["Ac-\u03b2-CDs", "CHEMICAL", 166, 174], ["acryloyl", "CHEMICAL", 194, 202], ["phenylalanine", "CHEMICAL", 278, 291], ["tyrosine", "CHEMICAL", 293, 301], ["tryptophan", "CHEMICAL", 307, 317], ["Ac-\u03b2-CDs", "SIMPLE_CHEMICAL", 58, 66], ["acryloyl \u03b2-cyclodextrin", "SIMPLE_CHEMICAL", 68, 91], ["Ac-\u03b2-CD", "SIMPLE_CHEMICAL", 117, 124], ["Ac-\u03b2-CDs", "SIMPLE_CHEMICAL", 166, 174], ["acryloyl", "SIMPLE_CHEMICAL", 194, 202], ["gelatin", "SIMPLE_CHEMICAL", 263, 270], ["phenylalanine", "SIMPLE_CHEMICAL", 278, 291], ["tyrosine", "AMINO_ACID", 293, 301], ["tryptophan", "SIMPLE_CHEMICAL", 307, 317], ["host\u2212guest", "SIMPLE_CHEMICAL", 323, 333], ["\u03b2", "PROTEIN", 169, 170], ["diffusing photocross", "TEST", 28, 48], ["Ac", "TEST", 58, 60], ["\u03b2", "TEST", 61, 62], ["CDs", "TEST", 63, 66], ["acryloyl \u03b2-cyclodextrin", "TREATMENT", 68, 91], ["1.5 acryloyl groups", "TREATMENT", 93, 112], ["Ac", "TEST", 117, 119], ["Ac", "TEST", 166, 168], ["gelatin", "TREATMENT", 263, 270], ["phenylalanine", "TREATMENT", 278, 291], ["tyrosine", "TREATMENT", 293, 301], ["tryptophan", "TREATMENT", 307, 317], ["aromatic residues", "OBSERVATION", 242, 259]]], ["Subsequently, UV-initiated polymerization of the Ac-\u03b2-CDs led to Ci-I hydrogels exhibited a sol\u2212gel transition during switching between alternating high (1000%, unshaded region) and low (1%, shaded region) shear strain in the rheological test at 37\u00b0C. (c) A preformed Ci-I gelatin hydrogel was drawn into a syringe and then injected through a G21 needle into a culture plate well (used as the mold) to be remolded to the shape of the cell culture well. (d) Ci-I gelatin hydrogels sustained over 95% of compressive strain without rupture before or after injection. (e) Stress vs strain curves from a cyclic compression test of Ci-I hydrogels (peak strain, 60%; loading speed, 1 mm/s) at 37\u00b0C (inset: plot in the strain range 50\u221260%). the formation of gelatin hydrogels containing two types of crosslinks: (1) the physical host\u2212guest complexations between the aromatic residues of the gelatin and oligomerized Ac-\u03b2-CDs, which are distributed throughout the entire hydrogel network; and (2) the chemical cross-links (due to the fraction of Ac-\u03b2-CDs bearing more than one acryloyl group) among the oligomerized Ac-\u03b2-CDs, the distribution of which is sparse and localized because of the inefficient reaction among the bulky Ac-\u03b2-CDs.", [["cell", "ANATOMY", 434, 438], ["UV", "CHEMICAL", 14, 16], ["Ac-\u03b2-CDs", "CHEMICAL", 49, 57], ["rupture", "DISEASE", 529, 536], ["gelatin hydrogels", "CHEMICAL", 750, 767], ["Ac-\u03b2-CDs", "CHEMICAL", 908, 916], ["Ac-\u03b2-CDs", "CHEMICAL", 1037, 1045], ["Ac-\u03b2-CDs", "CHEMICAL", 1107, 1115], ["Ac-\u03b2-CDs", "CHEMICAL", 49, 57], ["Ci-I", "CHEMICAL", 65, 69], ["Ac-\u03b2-CDs", "CHEMICAL", 908, 916], ["Ac-\u03b2-CDs", "CHEMICAL", 1037, 1045], ["acryloyl", "CHEMICAL", 1068, 1076], ["Ac-\u03b2-CDs", "CHEMICAL", 1107, 1115], ["Ac-\u03b2-CDs", "SIMPLE_CHEMICAL", 49, 57], ["Ci-I hydrogels", "SIMPLE_CHEMICAL", 65, 79], ["Ci-I gelatin hydrogel", "SIMPLE_CHEMICAL", 268, 289], ["cell", "CELL", 434, 438], ["gelatin hydrogels", "SIMPLE_CHEMICAL", 750, 767], ["gelatin", "SIMPLE_CHEMICAL", 883, 890], ["Ac-\u03b2-CDs", "SIMPLE_CHEMICAL", 908, 916], ["Ac-\u03b2-CDs", "SIMPLE_CHEMICAL", 1037, 1045], ["acryloyl", "SIMPLE_CHEMICAL", 1068, 1076], ["Ac-\u03b2-CDs", "SIMPLE_CHEMICAL", 1107, 1115], ["Ac-\u03b2-CDs", "SIMPLE_CHEMICAL", 1219, 1227], ["Ac-\u03b2-CDs", "DNA", 49, 57], ["\u03b2-CDs", "PROTEIN", 911, 916], ["\u03b2", "PROTEIN", 1040, 1041], ["CDs", "PROTEIN", 1042, 1045], ["\u03b2-CDs", "PROTEIN", 1110, 1115], ["UV", "TREATMENT", 14, 16], ["the Ac", "TREATMENT", 45, 51], ["Ci-I hydrogels", "PROBLEM", 65, 79], ["a sol\u2212gel transition", "PROBLEM", 90, 110], ["low (1%, shaded region) shear strain", "PROBLEM", 182, 218], ["the rheological test", "TEST", 222, 242], ["A preformed Ci-I gelatin hydrogel", "TREATMENT", 256, 289], ["a syringe", "TREATMENT", 305, 314], ["a G21 needle", "TREATMENT", 341, 353], ["a culture plate", "TREATMENT", 359, 374], ["the cell culture", "TEST", 430, 446], ["(d) Ci-I gelatin hydrogels", "TREATMENT", 453, 479], ["compressive strain", "PROBLEM", 502, 520], ["rupture", "PROBLEM", 529, 536], ["injection", "TREATMENT", 553, 562], ["Stress vs strain curves", "PROBLEM", 568, 591], ["a cyclic compression test", "TEST", 597, 622], ["Ci-I hydrogels", "PROBLEM", 626, 640], ["peak strain", "TEST", 642, 653], ["loading speed", "TEST", 660, 673], ["gelatin hydrogels", "TREATMENT", 750, 767], ["the gelatin", "TREATMENT", 879, 890], ["oligomerized Ac-\u03b2-CDs", "TREATMENT", 895, 916], ["Ac", "TEST", 1037, 1039], ["the oligomerized Ac", "TEST", 1090, 1109], ["the inefficient reaction", "PROBLEM", 1178, 1202], ["sol\u2212gel transition", "OBSERVATION", 92, 110], ["low", "OBSERVATION_MODIFIER", 182, 185], ["compressive strain", "OBSERVATION", 502, 520], ["without", "UNCERTAINTY", 521, 528], ["rupture", "OBSERVATION", 529, 536], ["gelatin hydrogels", "OBSERVATION", 750, 767], ["aromatic residues", "OBSERVATION", 858, 875], ["bulky", "OBSERVATION_MODIFIER", 1213, 1218]]], ["The following experiments demonstrated that these gelatin hydrogels not only possessed unique dynamic properties including self-healing, shear-thinning, injectability, and cell infiltration capability due to the physical host\u2212guest crosslinking but also showed adequate stability because of the localized chemical cross-linking for supporting long-term 3D culture of encapsulated cells.", [["cell", "ANATOMY", 172, 176], ["cells", "ANATOMY", 380, 385], ["gelatin hydrogels", "SIMPLE_CHEMICAL", 50, 67], ["cell", "CELL", 172, 176], ["cells", "CELL", 380, 385], ["long-term 3D culture", "CELL_LINE", 343, 363], ["encapsulated cells", "CELL_TYPE", 367, 385], ["these gelatin hydrogels", "TREATMENT", 44, 67], ["self-healing", "PROBLEM", 123, 135], ["shear-thinning", "PROBLEM", 137, 151], ["injectability", "PROBLEM", 153, 166], ["cell infiltration capability", "PROBLEM", 172, 200], ["the localized chemical cross-linking", "TREATMENT", 291, 327], ["encapsulated cells", "PROBLEM", 367, 385], ["thinning", "OBSERVATION_MODIFIER", 143, 151], ["cell infiltration", "OBSERVATION", 172, 189], ["encapsulated cells", "OBSERVATION", 367, 385]]], ["These hydrogels are therefore referred to as the \"cell-infiltratable and injectable gelatin hydrogels\" (Ci-I gelatin hydrogels) in the following sections.\u25a0 RESULTS AND DISCUSSIONThe rheological measurements further demonstrated the presence of both physical and chemical cross-linking within the Ci-I gelatin hydrogels.", [["cell", "ANATOMY", 50, 54], ["infiltratable", "ANATOMY", 55, 68], ["sections", "ANATOMY", 145, 153], ["Ci-I gelatin", "CHEMICAL", 104, 116], ["cell", "CELL", 50, 54], ["gelatin hydrogels", "SIMPLE_CHEMICAL", 84, 101], ["Ci-I gelatin hydrogels", "SIMPLE_CHEMICAL", 104, 126], ["These hydrogels", "TREATMENT", 0, 15], ["injectable gelatin hydrogels", "TREATMENT", 73, 101], ["Ci-I gelatin hydrogels", "TREATMENT", 104, 126], ["The rheological measurements", "TEST", 178, 206], ["the Ci-I gelatin hydrogels", "TREATMENT", 292, 318], ["both", "OBSERVATION_MODIFIER", 244, 248], ["physical", "OBSERVATION", 249, 257], ["chemical cross-", "OBSERVATION", 262, 277], ["gelatin hydrogels", "OBSERVATION", 301, 318]]], ["The Ci-I hydrogels showed an obvious frequency-dependent increase in the modulus (Figure 1a ), indicating the involvement of the physical host\u2212guest complexation between gelatinous aromatic groups and \u03b2-CDs in stabilizing the hydrogel network.", [["\u03b2-CDs", "CHEMICAL", 201, 206], ["gelatinous aromatic groups", "SIMPLE_CHEMICAL", 170, 196], ["\u03b2-CDs", "SIMPLE_CHEMICAL", 201, 206], ["hydrogel network", "MULTI-TISSUE_STRUCTURE", 226, 242], ["The Ci-I hydrogels", "TEST", 0, 18], ["gelatinous aromatic groups", "TREATMENT", 170, 196], ["the hydrogel network", "TREATMENT", 222, 242], ["obvious", "OBSERVATION_MODIFIER", 29, 36], ["frequency", "OBSERVATION_MODIFIER", 37, 46], ["dependent", "OBSERVATION_MODIFIER", 47, 56], ["increase", "OBSERVATION_MODIFIER", 57, 65], ["modulus", "OBSERVATION_MODIFIER", 73, 80], ["gelatinous", "OBSERVATION_MODIFIER", 170, 180], ["aromatic groups", "OBSERVATION", 181, 196]]], ["The further rheological studies revealed a \"sol\u2212gel\" transition of the Ci-I hydrogels under alternating high/low shear strain (Scheme 1).", [["Ci-I", "CHEMICAL", 71, 75], ["The further rheological studies", "TEST", 0, 31], ["a \"sol\u2212gel\" transition", "PROBLEM", 41, 63], ["the Ci-I hydrogels", "PROBLEM", 67, 85], ["alternating high/low shear strain", "PROBLEM", 92, 125], ["low shear", "OBSERVATION_MODIFIER", 109, 118]]], ["The Ci-I hydrogels switched to the \"sol\" state (G\u2033 > G\u2032) under a high shear strain of \u223c1000% and immediately recovered to the \"gel\" state (G\u2032 > G\u2033) under a subsequent low shear strain of 1% ( Figure 1b) .", [["G\u2033 > G\u2032", "SIMPLE_CHEMICAL", 48, 55], ["The Ci-I hydrogels", "TREATMENT", 0, 18], ["a high shear strain", "TREATMENT", 63, 82], ["a subsequent low shear strain", "TREATMENT", 154, 183], ["high shear", "OBSERVATION_MODIFIER", 65, 75], ["low shear", "OBSERVATION_MODIFIER", 167, 176]]], ["Moreover, even after repeated high/low shear loading cycles, the storage modulus (G\u2032) of the Ci-I hydrogels consistently recovered to \u223c80% (1050 Pa) of that of the freshly prepared unloaded samples (1373 Pa) (Figure 1b ).", [["samples", "ANATOMY", 190, 197], ["Ci-I", "CHEMICAL", 93, 97], ["Ci-I", "GENE_OR_GENE_PRODUCT", 93, 97], ["repeated high/low shear loading cycles", "TREATMENT", 21, 59], ["the storage modulus", "TEST", 61, 80], ["the Ci", "TEST", 89, 95]]], ["This slight reduction in storage modulus is likely attributed to the partial disruption of chemical cross-linking under loading.", [["This slight reduction in storage modulus", "PROBLEM", 0, 40], ["chemical cross-linking under loading", "TREATMENT", 91, 127], ["slight", "OBSERVATION_MODIFIER", 5, 11], ["reduction", "OBSERVATION_MODIFIER", 12, 21], ["storage modulus", "OBSERVATION", 25, 40], ["likely attributed to", "UNCERTAINTY", 44, 64], ["partial", "OBSERVATION_MODIFIER", 69, 76], ["disruption", "OBSERVATION", 77, 87], ["chemical cross-linking", "OBSERVATION", 91, 113]]], ["This excellent shear-thinning and self-healing capability enables the injection of Ci-I hydrogels without significantly compromising their mechanical properties.", [["Ci-I", "CHEMICAL", 83, 87], ["Ci-I", "CHEMICAL", 83, 87], ["thinning", "PROBLEM", 21, 29], ["self-healing capability", "PROBLEM", 34, 57], ["Ci-I hydrogels", "TREATMENT", 83, 97], ["excellent", "OBSERVATION_MODIFIER", 5, 14], ["shear", "OBSERVATION_MODIFIER", 15, 20], ["thinning", "OBSERVATION_MODIFIER", 21, 29], ["mechanical properties", "OBSERVATION", 139, 160]]], ["The prefabricated Ci-I hydrogel disks injected through a G21 needle into cylindrical models were efficiently remolded to regain the original disk morphology ( Figure 1c) .", [["Ci-I", "CHEMICAL", 18, 22], ["The prefabricated Ci-I hydrogel disks", "TREATMENT", 0, 37], ["a G21 needle into cylindrical models", "TREATMENT", 55, 91]]], ["Moreover, the compression test showed that the injection did not significantly affect the mechanical properties of the Ci-I gelatin hydrogels, and the injected hydrogels could still sustain over 95% compressive strain without rupture as could the noninjected hydrogels ( Figure 1d ).", [["rupture", "DISEASE", 226, 233], ["Ci-I gelatin hydrogels", "SIMPLE_CHEMICAL", 119, 141], ["the compression test", "TEST", 10, 30], ["the injection", "TREATMENT", 43, 56], ["the Ci-I gelatin hydrogels", "TREATMENT", 115, 141], ["the injected hydrogels", "TREATMENT", 147, 169], ["compressive strain", "PROBLEM", 199, 217], ["rupture", "PROBLEM", 226, 233]]], ["Furthermore, after the first loading\u2212unloading cycle, the Ci-I hydrogels exhibited almost coinciding loading\u2212unloading stress versus strain curves obtained from the remaining loading cycles (peak strain: 60%), suggesting excellent resistance to excessive cyclic compression ( Figure 1e ).", [["the first loading\u2212unloading cycle", "TREATMENT", 19, 52], ["the Ci-I hydrogels", "TREATMENT", 54, 72], ["strain curves", "TEST", 133, 146], ["peak strain", "TEST", 191, 202], ["excessive cyclic compression", "PROBLEM", 245, 273], ["excellent resistance", "OBSERVATION", 221, 241], ["excessive", "OBSERVATION_MODIFIER", 245, 254], ["cyclic compression", "OBSERVATION", 255, 273]]], ["Previous studies 65\u221268 proved that well-designed injectable hydrogels could prevent encapsulated cells from damage of shear force during the injection through the syringe needle.", [["cells", "ANATOMY", 97, 102], ["cells", "CELL", 97, 102], ["encapsulated cells", "CELL_TYPE", 84, 102], ["Previous studies", "TEST", 0, 16], ["injectable hydrogels", "TREATMENT", 49, 69], ["encapsulated cells", "PROBLEM", 84, 102], ["damage of shear force", "TREATMENT", 108, 129], ["the syringe needle", "TREATMENT", 159, 177], ["encapsulated cells", "OBSERVATION", 84, 102]]], ["To study whether our Ci-I gelatin hydrogels could maintain the viability of the encapsulated cell during the injection, we cultured hMSC-laden Ci-I gelatin hydrogels in vitro for 1 day before injecting the hydrogels through a G21 needle, and the injected hydrogels were further cultured in vitro for another 5 days.", [["cell", "ANATOMY", 93, 97], ["hMSC", "ANATOMY", 132, 136], ["Ci-I gelatin hydrogels", "SIMPLE_CHEMICAL", 21, 43], ["cell", "CELL", 93, 97], ["hMSC", "CELL", 132, 136], ["Ci-I gelatin hydrogels", "SIMPLE_CHEMICAL", 143, 165], ["cultured hMSC", "CELL_LINE", 123, 136], ["our Ci-I gelatin hydrogels", "TREATMENT", 17, 43], ["the injection", "TREATMENT", 105, 118], ["hMSC", "TEST", 132, 136], ["Ci-I gelatin hydrogels", "TREATMENT", 143, 165], ["the hydrogels", "TREATMENT", 202, 215], ["a G21 needle", "TREATMENT", 224, 236], ["the injected hydrogels", "TREATMENT", 242, 264], ["encapsulated cell", "OBSERVATION", 80, 97]]], ["Figure S3 shows that the cell viability is still >90% even after injection, demonstrating the effective protection of the encapsulated cells by the injectable Ci-I gelatin hydrogels.\u25a0 RESULTS AND DISCUSSIONCi-I Hydrogels Mediate Sustained Delivery of a Hydrophobic Chemoattractant and Support Infiltration of Cells.", [["cell", "ANATOMY", 25, 29], ["cells", "ANATOMY", 135, 140], ["Cells", "ANATOMY", 309, 314], ["Ci-I", "CHEMICAL", 159, 163], ["cell", "CELL", 25, 29], ["cells", "CELL", 135, 140], ["Ci-I gelatin hydrogels", "SIMPLE_CHEMICAL", 159, 181], ["Cells", "CELL", 309, 314], ["encapsulated cells", "CELL_TYPE", 122, 140], ["the cell viability", "TEST", 21, 39], ["injection", "TREATMENT", 65, 74], ["the encapsulated cells", "TREATMENT", 118, 140], ["the injectable Ci-I gelatin hydrogels", "TREATMENT", 144, 181], ["a Hydrophobic Chemoattractant", "TREATMENT", 251, 280], ["Support Infiltration of Cells", "TREATMENT", 285, 314], ["cell viability", "OBSERVATION", 25, 39], ["encapsulated cells", "OBSERVATION", 122, 140]]], ["Sustained delivery of small hydrophobic molecules via hydrogels is typically challenging because the hydrophilic nature and large mesh size of hydrogel networks make loading and long-term release of small hydrophobic molecules rather difficult.", [["small hydrophobic molecules via hydrogels", "PROBLEM", 22, 63], ["large mesh size of hydrogel networks", "TREATMENT", 124, 160], ["long-term release", "TREATMENT", 178, 195], ["small hydrophobic molecules", "PROBLEM", 199, 226], ["small", "OBSERVATION_MODIFIER", 22, 27], ["hydrophobic molecules", "OBSERVATION", 28, 49], ["hydrophilic", "OBSERVATION_MODIFIER", 101, 112], ["large", "OBSERVATION_MODIFIER", 124, 129], ["mesh", "OBSERVATION", 130, 134], ["size", "OBSERVATION_MODIFIER", 135, 139], ["hydrogel networks", "OBSERVATION", 143, 160], ["small", "OBSERVATION_MODIFIER", 199, 204], ["hydrophobic molecules", "OBSERVATION", 205, 226]]], ["Because a significant excess of Ac-\u03b2-CDs (compared with gelatinous aromatic residues) were used to fabricate Ci-I hydrogels, there were a considerable number of unoccupied \u03b2- CD moieties conjugated to the hydrogel network. \u03b2-CD is commonly used in the pharmaceutical industry to improve the solubility of hydrophobic drugs.", [["Ac-\u03b2-CDs", "CHEMICAL", 32, 40], ["\u03b2-CD", "CHEMICAL", 223, 227], ["Ac-\u03b2-CDs", "CHEMICAL", 32, 40], ["\u03b2- CD", "CHEMICAL", 172, 177], ["\u03b2-CD", "CHEMICAL", 223, 227], ["Ac-\u03b2-CDs", "SIMPLE_CHEMICAL", 32, 40], ["Ci-I hydrogels", "SIMPLE_CHEMICAL", 109, 123], ["\u03b2- CD moieties", "SIMPLE_CHEMICAL", 172, 186], ["\u03b2-CD", "SIMPLE_CHEMICAL", 223, 227], ["\u03b2", "PROTEIN", 35, 36], ["\u03b2- CD moieties", "PROTEIN", 172, 186], ["Ac", "TEST", 32, 34], ["CDs", "PROBLEM", 37, 40], ["gelatinous aromatic residues", "PROBLEM", 56, 84], ["unoccupied \u03b2- CD moieties", "TREATMENT", 161, 186], ["the hydrogel network", "TREATMENT", 201, 221], ["hydrophobic drugs", "TREATMENT", 305, 322], ["significant", "OBSERVATION_MODIFIER", 10, 21], ["excess", "OBSERVATION_MODIFIER", 22, 28], ["CD", "OBSERVATION", 225, 227]]], ["69\u221271 We utilized the empty \u03b2-CD cavities in Ci-I hydrogels to deliver a small hydrophobic chemical molecule, icaritin, which can reduce SAON incidence by inhibiting both thrombosis and lipid deposition.", [["69\u221271", "CHEMICAL", 0, 5], ["icaritin", "CHEMICAL", 110, 118], ["SAON", "DISEASE", 137, 141], ["thrombosis", "DISEASE", 171, 181], ["icaritin", "CHEMICAL", 110, 118], ["Ci-I hydrogels", "SIMPLE_CHEMICAL", 45, 59], ["icaritin", "SIMPLE_CHEMICAL", 110, 118], ["SAON", "SIMPLE_CHEMICAL", 137, 141], ["lipid", "SIMPLE_CHEMICAL", 186, 191], ["the empty \u03b2-CD cavities", "TREATMENT", 18, 41], ["Ci-I hydrogels", "TREATMENT", 45, 59], ["a small hydrophobic chemical molecule", "TREATMENT", 71, 108], ["icaritin", "TREATMENT", 110, 118], ["both thrombosis", "PROBLEM", 166, 181], ["lipid deposition", "TREATMENT", 186, 202], ["small", "OBSERVATION_MODIFIER", 73, 78], ["both", "OBSERVATION_MODIFIER", 166, 170], ["thrombosis", "OBSERVATION", 171, 181], ["lipid deposition", "OBSERVATION", 186, 202]]], ["72 The icaritin-laden Ci-I gelatin hydrogels were capable of releasing icaritin continuously for up to 2 weeks (Figure 2a) .", [["icaritin", "CHEMICAL", 7, 15], ["icaritin", "CHEMICAL", 71, 79], ["icaritin", "CHEMICAL", 7, 15], ["icaritin", "CHEMICAL", 71, 79], ["icaritin", "SIMPLE_CHEMICAL", 7, 15], ["Ci-I gelatin hydrogels", "SIMPLE_CHEMICAL", 22, 44], ["icaritin", "SIMPLE_CHEMICAL", 71, 79], ["The icaritin-laden Ci-I gelatin hydrogels", "TREATMENT", 3, 44], ["releasing icaritin", "TREATMENT", 61, 79]]], ["Therefore, these findings demonstrate that the injectable Ci-I gelation hydrogels can serve as a promising delivery vehicle of small hydrophobic molecular drugs for treating pathological conditions including SAON in a minimally invasive fashion.\u25a0 RESULTS AND DISCUSSIONOur previous research also showed that an anabolic and potent molecule icaritin can function as a chemoattractant to induce the directed migration of MSCs within a short time frame.", [["MSCs", "ANATOMY", 419, 423], ["Ci-I", "CHEMICAL", 58, 62], ["SAON", "DISEASE", 208, 212], ["icaritin", "CHEMICAL", 340, 348], ["Ci-I", "CHEMICAL", 58, 62], ["icaritin", "CHEMICAL", 340, 348], ["icaritin", "SIMPLE_CHEMICAL", 340, 348], ["MSCs", "CELL", 419, 423], ["icaritin", "PROTEIN", 340, 348], ["MSCs", "CELL_TYPE", 419, 423], ["the injectable Ci-I gelation hydrogels", "TREATMENT", 43, 81], ["small hydrophobic molecular drugs", "TREATMENT", 127, 160], ["treating pathological conditions", "PROBLEM", 165, 197], ["SAON", "TREATMENT", 208, 212], ["an anabolic and potent molecule icaritin", "TREATMENT", 308, 348], ["a chemoattractant", "TREATMENT", 365, 382], ["the directed migration of MSCs", "PROBLEM", 393, 423], ["small", "OBSERVATION_MODIFIER", 127, 132], ["hydrophobic molecular drugs", "OBSERVATION", 133, 160]]], ["72 The dynamic and weak cross-links based on host\u2212guest complexation of our Ci-I gelatin hydrogel can potentially support cell infiltration and migration.", [["cell", "ANATOMY", 122, 126], ["host\u2212guest", "SIMPLE_CHEMICAL", 45, 55], ["cell", "CELL", 122, 126], ["host\u2212guest complexation", "TREATMENT", 45, 68], ["our Ci-I gelatin hydrogel", "TREATMENT", 72, 97], ["cell infiltration", "PROBLEM", 122, 139], ["weak", "OBSERVATION_MODIFIER", 19, 23], ["support cell infiltration", "OBSERVATION", 114, 139], ["migration", "OBSERVATION_MODIFIER", 144, 153]]], ["To demonstrate this, we seeded MSCs on the surface of Ci-I hydrogels with or without the loaded icaritin. enzymes might not be significant enough to support such extensive cell infiltration within the short period of 24 h.", [["MSCs", "ANATOMY", 31, 35], ["surface", "ANATOMY", 43, 50], ["cell", "ANATOMY", 172, 176], ["icaritin", "CHEMICAL", 96, 104], ["icaritin", "CHEMICAL", 96, 104], ["MSCs", "CELL", 31, 35], ["surface", "CELLULAR_COMPONENT", 43, 50], ["icaritin", "SIMPLE_CHEMICAL", 96, 104], ["cell", "CELL", 172, 176], ["MSCs", "CELL_TYPE", 31, 35], ["Ci-I hydrogels", "TREATMENT", 54, 68], ["the loaded icaritin", "TREATMENT", 85, 104], ["enzymes", "TEST", 106, 113], ["extensive cell infiltration", "PROBLEM", 162, 189], ["might not be", "UNCERTAINTY", 114, 126], ["extensive", "OBSERVATION_MODIFIER", 162, 171], ["cell infiltration", "OBSERVATION", 172, 189]]], ["We speculated that the cell infiltration was likely facilitated by the disruption of the weak host\u2212guest cross-links in Ci-I hydrogels by cellular forces.", [["cell", "ANATOMY", 23, 27], ["cellular", "ANATOMY", 138, 146], ["cell", "CELL", 23, 27], ["Ci-I", "GENE_OR_GENE_PRODUCT", 120, 124], ["cellular", "CELL", 138, 146], ["the cell infiltration", "PROBLEM", 19, 40], ["cell infiltration", "OBSERVATION", 23, 40], ["weak", "OBSERVATION_MODIFIER", 89, 93], ["cellular forces", "OBSERVATION", 138, 153]]], ["Therefore, we speculate that, once implanted into the defect sites, the icaritin-laden Ci-I gelatin hydrogels can promote the recruitment and infiltration of endogenous cells into the hydrogel matrix, thereby speeding up the repair and regeneration of bone defects.\u25a0 RESULTS AND DISCUSSIONCi-I Hydrogel Attenuates the Adverse Effect of High-Dosage Corticosteroid during Stem Cell Differentiation.", [["cells", "ANATOMY", 169, 174], ["hydrogel matrix", "ANATOMY", 184, 199], ["bone", "ANATOMY", 252, 256], ["Cell", "ANATOMY", 375, 379], ["icaritin", "CHEMICAL", 72, 80], ["Ci-I", "CHEMICAL", 87, 91], ["bone defects", "DISEASE", 252, 264], ["icaritin", "CHEMICAL", 72, 80], ["icaritin", "SIMPLE_CHEMICAL", 72, 80], ["Ci-I", "GENE_OR_GENE_PRODUCT", 87, 91], ["cells", "CELL", 169, 174], ["hydrogel matrix", "CELLULAR_COMPONENT", 184, 199], ["bone", "TISSUE", 252, 256], ["Corticosteroid", "SIMPLE_CHEMICAL", 348, 362], ["Stem Cell", "CELL", 370, 379], ["endogenous cells", "CELL_TYPE", 158, 174], ["the defect sites", "PROBLEM", 50, 66], ["the icaritin-laden Ci-I gelatin hydrogels", "TREATMENT", 68, 109], ["the recruitment and infiltration of endogenous cells into the hydrogel matrix", "TREATMENT", 122, 199], ["the repair", "TREATMENT", 221, 231], ["bone defects", "PROBLEM", 252, 264], ["High-Dosage Corticosteroid", "TREATMENT", 336, 362], ["defect", "OBSERVATION", 54, 60], ["infiltration", "OBSERVATION", 142, 154], ["endogenous cells", "OBSERVATION", 158, 174], ["hydrogel matrix", "OBSERVATION", 184, 199], ["repair", "OBSERVATION", 225, 231], ["bone", "ANATOMY", 252, 256], ["defects", "OBSERVATION", 257, 264], ["Stem Cell Differentiation", "OBSERVATION", 370, 395]]], ["We then evaluated the efficacy of the Ci-I hydrogel as an injectable carrier of therapeutic cells to treat SAON by examining the osteogenesis of MSCs encapsulated in the Ci-I gelatin hydrogels in the presence of a high concentration of Quantitative analysis of micro-CT for the bone in the \"peri-tunnel\" (b) and \"within tunnel\" (c) space.", [["cells", "ANATOMY", 92, 97], ["SAON", "ANATOMY", 107, 111], ["MSCs", "ANATOMY", 145, 149], ["bone", "ANATOMY", 278, 282], ["SAON", "DISEASE", 107, 111], ["Ci-I", "CHEMICAL", 38, 42], ["cells", "CELL", 92, 97], ["SAON", "SIMPLE_CHEMICAL", 107, 111], ["MSCs", "CELL", 145, 149], ["bone", "TISSUE", 278, 282], ["therapeutic cells", "CELL_TYPE", 80, 97], ["MSCs", "CELL_TYPE", 145, 149], ["the Ci-I hydrogel", "TREATMENT", 34, 51], ["therapeutic cells", "TREATMENT", 80, 97], ["the osteogenesis of MSCs", "PROBLEM", 125, 149], ["the Ci-I gelatin hydrogels", "TREATMENT", 166, 192], ["micro-CT", "TEST", 261, 269], ["osteogenesis", "OBSERVATION", 129, 141], ["bone", "ANATOMY", 278, 282]]], ["One-way ANOVA with Tukey's post hoc tests were used to analyze the data (n = 6, P < 0.001). (d) Goldener's Trichrome staining of the bonelike tissue within the bone tunnel.", [["bonelike tissue", "ANATOMY", 133, 148], ["bone", "ANATOMY", 160, 164], ["bonelike tissue", "TISSUE", 133, 148], ["bone tunnel", "MULTI-TISSUE_STRUCTURE", 160, 171], ["Tukey's post hoc tests", "TEST", 19, 41], ["the data", "TEST", 63, 71], ["Trichrome staining of the bonelike tissue", "PROBLEM", 107, 148], ["bonelike tissue", "OBSERVATION", 133, 148], ["bone", "ANATOMY", 160, 164], ["tunnel", "OBSERVATION", 165, 171]]], ["Scale bar: 500 \u03bcm (micro-CT images in part a); 100 \u03bcm (HE staining in part a and Goldener's staining in part d).\u25a0 RESULTS AND DISCUSSIONcorticosteroid.", [["CT images", "TEST", 25, 34]]], ["The majority of MSCs encapsulated in the Ci-I gelatin hydrogels were viable and spread to adopt a stellate morphology after 2 weeks of culture (Figure 3a) , indicating that the dynamic Ci-I hydrogel network provides a permissive 3D environment to facilitate cell\u2212matrix interactions.", [["MSCs", "ANATOMY", 16, 20], ["stellate", "ANATOMY", 98, 106], ["cell\u2212matrix", "ANATOMY", 258, 269], ["MSCs", "CELL", 16, 20], ["Ci-I", "GENE_OR_GENE_PRODUCT", 185, 189], ["MSCs", "CELL_TYPE", 16, 20], ["MSCs", "PROBLEM", 16, 20], ["the Ci-I gelatin hydrogels", "TREATMENT", 37, 63], ["culture", "TEST", 135, 142], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["MSCs", "OBSERVATION", 16, 20], ["encapsulated", "OBSERVATION_MODIFIER", 21, 33]]], ["Then, we evaluated the differentiation of MSCs encapsulated in hydrogels under different culture conditions.", [["MSCs", "ANATOMY", 42, 46], ["MSCs", "CELL", 42, 46], ["MSCs", "CELL_TYPE", 42, 46], ["MSCs", "PROBLEM", 42, 46], ["hydrogels", "TREATMENT", 63, 72], ["different culture conditions", "TEST", 79, 107]]], ["Previous studies showed that dexamethasone (Dex), a clinically used corticosteroid, improved the osteogenesis of MSCs at low concentration but promoted the adipogenesis of MSCs at high concentration.", [["MSCs", "ANATOMY", 113, 117], ["MSCs", "ANATOMY", 172, 176], ["dexamethasone", "CHEMICAL", 29, 42], ["Dex", "CHEMICAL", 44, 47], ["dexamethasone", "CHEMICAL", 29, 42], ["Dex", "CHEMICAL", 44, 47], ["dexamethasone", "SIMPLE_CHEMICAL", 29, 42], ["Dex", "SIMPLE_CHEMICAL", 44, 47], ["MSCs", "CELL", 113, 117], ["MSCs", "CELL", 172, 176], ["MSCs", "CELL_TYPE", 113, 117], ["MSCs", "CELL_TYPE", 172, 176], ["Previous studies", "TEST", 0, 16], ["dexamethasone (Dex", "TREATMENT", 29, 47], ["corticosteroid", "TREATMENT", 68, 82], ["the osteogenesis of MSCs", "PROBLEM", 93, 117], ["osteogenesis", "OBSERVATION", 97, 109]]], ["73, 74 Our RT-PCR data indeed showed that a low media concentration of Dex (100 nM, \"100Dex\") promoted the expression of osteogenic markers (ALP and Runx2), whereas a high media concentration (500 nM, \"500Dex\") of Dex up-regulated the expression of adipogenic markers of the MSCs encapsulated in hydrogels (CEBP\u03b1 and PPAR\u03b3) (Figure 3b ).", [["MSCs", "ANATOMY", 275, 279], ["Dex", "CHEMICAL", 71, 74], ["Dex", "CHEMICAL", 214, 217], ["Dex", "CHEMICAL", 71, 74], ["Dex", "CHEMICAL", 214, 217], ["Dex", "SIMPLE_CHEMICAL", 71, 74], ["ALP", "GENE_OR_GENE_PRODUCT", 141, 144], ["Runx2", "GENE_OR_GENE_PRODUCT", 149, 154], ["Dex", "SIMPLE_CHEMICAL", 214, 217], ["MSCs", "CELL", 275, 279], ["CEBP\u03b1", "GENE_OR_GENE_PRODUCT", 307, 312], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 317, 322], ["osteogenic markers", "PROTEIN", 121, 139], ["ALP", "PROTEIN", 141, 144], ["Runx2", "PROTEIN", 149, 154], ["adipogenic markers", "PROTEIN", 249, 267], ["MSCs", "CELL_TYPE", 275, 279], ["CEBP\u03b1", "PROTEIN", 307, 312], ["PPAR\u03b3", "PROTEIN", 317, 322], ["Our RT-PCR data", "TEST", 7, 22], ["a low media concentration of Dex", "TREATMENT", 42, 74], ["osteogenic markers", "TEST", 121, 139], ["a high media concentration", "TREATMENT", 165, 191], ["Dex", "TREATMENT", 214, 217], ["the MSCs", "PROBLEM", 271, 279], ["hydrogels", "TEST", 296, 305], ["CEBP", "TEST", 307, 311], ["osteogenic markers", "OBSERVATION", 121, 139], ["MSCs", "ANATOMY", 275, 279]]], ["In contrast, media supplementation of icaritin effectively suppressed the expression of adipogenic marker genes and promoted that of osteogenic marker gene, alkaline phosphatase (ALP), of the encapsulated MSCs under a high media concentration of Dex (Figure 3b , Figure S4 for corresponding images) and (b) cells positive for both Osterix and Runx2 using immunofluorescent staining.", [["MSCs", "ANATOMY", 205, 209], ["cells", "ANATOMY", 307, 312], ["icaritin", "CHEMICAL", 38, 46], ["Dex", "CHEMICAL", 246, 249], ["icaritin", "CHEMICAL", 38, 46], ["Dex", "CHEMICAL", 246, 249], ["icaritin", "SIMPLE_CHEMICAL", 38, 46], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 157, 177], ["ALP", "GENE_OR_GENE_PRODUCT", 179, 182], ["MSCs", "CELL", 205, 209], ["Dex", "SIMPLE_CHEMICAL", 246, 249], ["cells", "CELL", 307, 312], ["Osterix", "GENE_OR_GENE_PRODUCT", 331, 338], ["Runx2", "GENE_OR_GENE_PRODUCT", 343, 348], ["adipogenic marker genes", "DNA", 88, 111], ["osteogenic marker gene", "DNA", 133, 155], ["alkaline phosphatase", "PROTEIN", 157, 177], ["ALP", "PROTEIN", 179, 182], ["MSCs", "CELL_TYPE", 205, 209], ["Osterix", "PROTEIN", 331, 338], ["Runx2", "PROTEIN", 343, 348], ["media supplementation of icaritin", "TREATMENT", 13, 46], ["osteogenic marker gene", "TEST", 133, 155], ["alkaline phosphatase", "TEST", 157, 177], ["ALP", "TEST", 179, 182], ["the encapsulated MSCs", "PROBLEM", 188, 209], ["a high media concentration of Dex", "TREATMENT", 216, 249], ["corresponding images", "TEST", 277, 297], ["(b) cells", "TEST", 303, 312], ["immunofluorescent staining", "TEST", 355, 381]]], ["The data were analyzed with one-way ANOVA with Tukey's post hoc test (n = 4). (c) Immunofluorescent staining at week 6 after SAON surgical treatment in SD rats (negative control group in Figure S5 ).", [["SAON", "CHEMICAL", 125, 129], ["SAON", "CHEMICAL", 125, 129], ["SD rats", "ORGANISM", 152, 159], ["rats", "SPECIES", 155, 159], ["The data", "TEST", 0, 8], ["Tukey's post hoc test", "TEST", 47, 68], ["Immunofluorescent staining", "TEST", 82, 108], ["SAON surgical treatment", "TREATMENT", 125, 148]]], ["Representative Western Blot images from three independent experiments for osteogenic markers (osteocalcin and active \u03b2-catenin) (d), and adipogenic markers (CEBP\u03b1 and PPAR\u03b3), proliferative marker (PCNA), inflammatory marker (tyrosine-kinase transmembrane receptor for CSF1), and indicator for osteonecrosis (c-Src) (e) (n = 3 per condition; Lane 1, blank repair; Lane 2, Gel; Lane 3, icaritin+Gel; Lane 4, icaritin+MSC+Gel).", [["tyrosine", "CHEMICAL", 225, 233], ["osteonecrosis", "DISEASE", 293, 306], ["tyrosine", "CHEMICAL", 225, 233], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 94, 105], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 117, 126], ["CEBP\u03b1", "GENE_OR_GENE_PRODUCT", 157, 162], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 167, 172], ["PCNA", "GENE_OR_GENE_PRODUCT", 197, 201], ["tyrosine-kinase transmembrane receptor", "GENE_OR_GENE_PRODUCT", 225, 263], ["CSF1", "GENE_OR_GENE_PRODUCT", 268, 272], ["c-Src", "GENE_OR_GENE_PRODUCT", 308, 313], ["Lane 3", "SIMPLE_CHEMICAL", 376, 382], ["icaritin+Gel", "SIMPLE_CHEMICAL", 384, 396], ["Lane 4", "SIMPLE_CHEMICAL", 398, 404], ["icaritin+MSC", "SIMPLE_CHEMICAL", 406, 418], ["osteogenic markers", "PROTEIN", 74, 92], ["osteocalcin", "PROTEIN", 94, 105], ["\u03b2-catenin", "PROTEIN", 117, 126], ["adipogenic markers", "PROTEIN", 137, 155], ["CEBP\u03b1", "PROTEIN", 157, 162], ["PPAR\u03b3", "PROTEIN", 167, 172], ["proliferative marker", "PROTEIN", 175, 195], ["PCNA", "PROTEIN", 197, 201], ["inflammatory marker", "PROTEIN", 204, 223], ["tyrosine-kinase transmembrane receptor", "PROTEIN", 225, 263], ["CSF1", "PROTEIN", 268, 272], ["Src", "PROTEIN", 310, 313], ["Blot images", "TEST", 23, 34], ["osteogenic markers", "TEST", 74, 92], ["osteocalcin", "TEST", 94, 105], ["adipogenic markers", "TEST", 137, 155], ["CEBP", "TEST", 157, 161], ["PPAR", "TEST", 167, 171], ["proliferative marker", "TEST", 175, 195], ["PCNA", "TEST", 197, 201], ["inflammatory marker", "TEST", 204, 223], ["tyrosine-kinase transmembrane receptor", "TREATMENT", 225, 263], ["osteonecrosis", "PROBLEM", 293, 306], ["Lane", "TREATMENT", 341, 345], ["blank repair", "TREATMENT", 349, 361], ["Lane", "TREATMENT", 363, 367], ["icaritin+Gel", "TREATMENT", 384, 396], ["Lane", "TREATMENT", 398, 402], ["icaritin+MSC+Gel", "TREATMENT", 406, 422], ["inflammatory", "OBSERVATION_MODIFIER", 204, 216], ["osteonecrosis", "OBSERVATION", 293, 306]]], ["Injection of Ci-I gelatin hydrogels, which were loaded with both MSCs and icaritin (\"icaritin+MSC+Gel\"), activated \u03b2-catenin and osteocalcin signaling but inhibited the inflammatory response and adipogenesis.", [["MSCs", "ANATOMY", 65, 69], ["MSC", "ANATOMY", 94, 97], ["icaritin", "CHEMICAL", 74, 82], ["icaritin", "CHEMICAL", 74, 82], ["Ci-I gelatin hydrogels", "SIMPLE_CHEMICAL", 13, 35], ["MSCs", "CELL", 65, 69], ["icaritin", "SIMPLE_CHEMICAL", 74, 82], ["icaritin", "SIMPLE_CHEMICAL", 85, 93], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 115, 124], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 129, 140], ["MSCs", "CELL_TYPE", 65, 69], ["MSC", "CELL_TYPE", 94, 97], ["\u03b2-catenin", "PROTEIN", 115, 124], ["osteocalcin", "PROTEIN", 129, 140], ["Ci-I gelatin hydrogels", "TREATMENT", 13, 35], ["both MSCs", "TREATMENT", 60, 69], ["icaritin (\"icaritin", "TREATMENT", 74, 93], ["activated \u03b2-catenin and osteocalcin signaling", "PROBLEM", 105, 150], ["the inflammatory response", "PROBLEM", 165, 190], ["adipogenesis", "PROBLEM", 195, 207], ["inflammatory response", "OBSERVATION", 169, 190]]], ["The quantitative data are shown in Figure S6 . (f) Sequential labeling of newly formed bone with calcein green (CG) and xylenol orange (XO) in the methyl methacrylate-embedded icaritin+MSC+Gel sample at week 3 postsurgery.", [["bone", "ANATOMY", 87, 91], ["MSC", "ANATOMY", 185, 188], ["calcein green", "CHEMICAL", 97, 110], ["xylenol orange", "CHEMICAL", 120, 134], ["methyl methacrylate", "CHEMICAL", 147, 166], ["icaritin", "CHEMICAL", 176, 184], ["calcein green", "CHEMICAL", 97, 110], ["xylenol orange", "CHEMICAL", 120, 134], ["methyl methacrylate", "CHEMICAL", 147, 166], ["icaritin", "CHEMICAL", 176, 184], ["bone", "TISSUE", 87, 91], ["calcein green", "SIMPLE_CHEMICAL", 97, 110], ["CG", "SIMPLE_CHEMICAL", 112, 114], ["xylenol orange", "SIMPLE_CHEMICAL", 120, 134], ["XO", "SIMPLE_CHEMICAL", 136, 138], ["methyl methacrylate", "SIMPLE_CHEMICAL", 147, 166], ["icaritin", "SIMPLE_CHEMICAL", 176, 184], ["MSC", "CELL", 185, 188], ["icaritin", "PROTEIN", 176, 184], ["MSC", "CELL_TYPE", 185, 188], ["The quantitative data", "TEST", 0, 21], ["newly formed bone", "PROBLEM", 74, 91], ["calcein green (CG)", "TREATMENT", 97, 115], ["xylenol orange (XO)", "TREATMENT", 120, 139], ["the methyl methacrylate", "TREATMENT", 143, 166], ["embedded icaritin", "TREATMENT", 167, 184], ["MSC+Gel sample", "TREATMENT", 185, 199], ["bone", "ANATOMY", 87, 91]]], ["OB, old bone; T, bone tunnel. (g) Representative images of CG and XO staining (n = 4 images per group) for calculating the bone formation rate.", [["OB", "ANATOMY", 0, 2], ["bone", "ANATOMY", 8, 12], ["bone", "ANATOMY", 17, 21], ["bone", "ANATOMY", 123, 127], ["OB", "TISSUE", 0, 2], ["bone", "TISSUE", 8, 12], ["T", "MULTI-TISSUE_STRUCTURE", 14, 15], ["bone tunnel", "MULTI-TISSUE_STRUCTURE", 17, 28], ["XO", "SIMPLE_CHEMICAL", 66, 68], ["bone", "TISSUE", 123, 127], ["old bone; T, bone tunnel", "PROBLEM", 4, 28], ["Representative images of CG and XO staining", "TEST", 34, 77], ["calculating the bone formation rate", "TEST", 107, 142], ["bone", "ANATOMY", 8, 12], ["bone", "ANATOMY", 17, 21], ["tunnel", "OBSERVATION", 22, 28], ["bone", "ANATOMY", 123, 127]]], ["OB, old bone; T, bone tunnel.", [["OB", "ANATOMY", 0, 2], ["bone", "ANATOMY", 8, 12], ["bone", "ANATOMY", 17, 21], ["OB", "TISSUE", 0, 2], ["bone", "TISSUE", 8, 12], ["T", "MULTI-TISSUE_STRUCTURE", 14, 15], ["bone tunnel", "MULTI-TISSUE_STRUCTURE", 17, 28], ["old bone; T, bone tunnel", "PROBLEM", 4, 28], ["bone", "ANATOMY", 8, 12], ["bone", "ANATOMY", 17, 21], ["tunnel", "OBSERVATION", 22, 28]]], ["The quantitative analyses of the bone formation rate at week 3 (h) and week 6 (i) postsurgery were obtained by analyzing the images in part g.", [["bone", "ANATOMY", 33, 37], ["bone", "TISSUE", 33, 37], ["the bone formation rate", "TEST", 29, 52], ["the images", "TEST", 121, 131], ["bone", "ANATOMY", 33, 37]]], ["The data were analyzed with one-way ANOVA with Tukey's post hoc test (n = 4). ***P < 0.001; scale bar, 100 \u03bcm (part c).", [["The data", "TEST", 0, 8], ["Tukey's post hoc test", "TEST", 47, 68], ["scale bar", "TEST", 92, 101]]], ["\"500Dex+icaritin (M)\").", [["icaritin", "CHEMICAL", 8, 16], ["500Dex+icaritin", "SIMPLE_CHEMICAL", 1, 16]]], ["The upregulation of another osteogenic marker gene Runx2 is insignificant.", [["Runx2", "GENE_OR_GENE_PRODUCT", 51, 56], ["osteogenic marker gene", "DNA", 28, 50], ["Runx2", "DNA", 51, 56], ["another osteogenic marker gene Runx2", "PROBLEM", 20, 56], ["osteogenic marker", "OBSERVATION", 28, 45], ["gene Runx2", "OBSERVATION", 46, 56], ["insignificant", "OBSERVATION_MODIFIER", 60, 73]]], ["We speculated that it was because the Runx2 gene expression data were collected at late time points, day 7 and 14, while the Runx2 is typically upregulated in MSCs at early time points upon osteogenic induction, and correlation between osteogenesis of MSCs and Runx2 expression becomes less significant at late time points.", [["MSCs", "ANATOMY", 159, 163], ["MSCs", "ANATOMY", 252, 256], ["Runx2", "GENE_OR_GENE_PRODUCT", 38, 43], ["Runx2", "GENE_OR_GENE_PRODUCT", 125, 130], ["MSCs", "CELL", 159, 163], ["MSCs", "CELL", 252, 256], ["Runx2", "GENE_OR_GENE_PRODUCT", 261, 266], ["Runx2 gene", "DNA", 38, 48], ["Runx2", "PROTEIN", 125, 130], ["MSCs", "CELL_TYPE", 159, 163], ["MSCs", "CELL_TYPE", 252, 256], ["Runx2", "PROTEIN", 261, 266], ["the Runx2 gene expression data", "PROBLEM", 34, 64], ["MSCs", "PROBLEM", 159, 163], ["osteogenic induction", "TREATMENT", 190, 210], ["osteogenesis of MSCs", "PROBLEM", 236, 256], ["Runx2 expression", "PROBLEM", 261, 277], ["upregulated", "OBSERVATION", 144, 155], ["osteogenic induction", "OBSERVATION", 190, 210]]], ["75 Furthermore, the Ci-I gelatin hydrogels that were loaded with a bolus dose of icaritin (\"500Dex+icaritin (H)\") without icaritin supplementation produced similar expression levels of the differentiation marker genes as those of \"500Dex+icaritin (M)\", which received fresh icaritin supplementation after each media change (Figure 3b ).", [["icaritin", "CHEMICAL", 81, 89], ["icaritin", "CHEMICAL", 99, 107], ["H", "CHEMICAL", 109, 110], ["icaritin", "CHEMICAL", 122, 130], ["icaritin", "CHEMICAL", 274, 282], ["icaritin", "CHEMICAL", 81, 89], ["icaritin", "CHEMICAL", 99, 107], ["icaritin", "CHEMICAL", 122, 130], ["icaritin", "CHEMICAL", 274, 282], ["icaritin", "SIMPLE_CHEMICAL", 81, 89], ["icaritin", "SIMPLE_CHEMICAL", 99, 107], ["icaritin", "SIMPLE_CHEMICAL", 122, 130], ["500Dex+icaritin", "SIMPLE_CHEMICAL", 231, 246], ["icaritin", "SIMPLE_CHEMICAL", 274, 282], ["differentiation marker genes", "DNA", 189, 217], ["the Ci-I gelatin hydrogels", "TREATMENT", 16, 42], ["a bolus dose", "TREATMENT", 65, 77], ["icaritin (\"500Dex+icaritin", "TREATMENT", 81, 107], ["icaritin supplementation", "TREATMENT", 122, 146], ["fresh icaritin supplementation", "TREATMENT", 268, 298], ["each media change", "TREATMENT", 305, 322]]], ["Von Kossa staining (Figure 3c ) and the Runx2, OCN, CEBP\u03b1, and PPAR\u03b3 immunohistochemical staining (Figure 3d ) showed trends consistent with that of the RT-PCR.", [["Runx2", "GENE_OR_GENE_PRODUCT", 40, 45], ["OCN", "GENE_OR_GENE_PRODUCT", 47, 50], ["CEBP\u03b1", "GENE_OR_GENE_PRODUCT", 52, 57], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 63, 68], ["Runx2", "PROTEIN", 40, 45], ["OCN", "PROTEIN", 47, 50], ["CEBP\u03b1", "PROTEIN", 52, 57], ["PPAR\u03b3", "PROTEIN", 63, 68], ["Von Kossa staining", "TEST", 0, 18], ["Figure 3c", "TEST", 20, 29], ["the Runx2", "TEST", 36, 45], ["CEBP\u03b1", "TEST", 52, 57], ["PPAR", "TEST", 63, 67], ["immunohistochemical staining", "TEST", 69, 97], ["the RT-PCR", "TEST", 149, 159], ["PPAR", "ANATOMY", 63, 67], ["consistent with", "UNCERTAINTY", 125, 140]]], ["These results demonstrate that the Ci-I gelatin hydrogels are likely capable of mediating sustained delivery of small hydrophobic molecular drugs (e.g., icaritin) to counteract the adverse effects (e.g., bone necrosis) of high-concentration corticosteroids in the long term.\u25a0 RESULTS AND DISCUSSIONCodelivery of MSC and Icaritin via Ci-I Hydrogels Enhances Bone Regeneration in SAON Model.", [["bone", "ANATOMY", 204, 208], ["MSC", "ANATOMY", 312, 315], ["Bone", "ANATOMY", 357, 361], ["icaritin", "CHEMICAL", 153, 161], ["necrosis", "DISEASE", 209, 217], ["corticosteroids", "CHEMICAL", 241, 256], ["Icaritin", "CHEMICAL", 320, 328], ["Ci-I", "CHEMICAL", 333, 337], ["icaritin", "CHEMICAL", 153, 161], ["corticosteroids", "CHEMICAL", 241, 256], ["Icaritin", "CHEMICAL", 320, 328], ["icaritin", "SIMPLE_CHEMICAL", 153, 161], ["bone", "TISSUE", 204, 208], ["high-concentration corticosteroids", "SIMPLE_CHEMICAL", 222, 256], ["MSC", "CELL", 312, 315], ["Icaritin", "SIMPLE_CHEMICAL", 320, 328], ["Ci-I Hydrogels", "SIMPLE_CHEMICAL", 333, 347], ["Bone", "TISSUE", 357, 361], ["MSC", "CELL_TYPE", 312, 315], ["the Ci-I gelatin hydrogels", "TREATMENT", 31, 57], ["small hydrophobic molecular drugs", "TREATMENT", 112, 145], ["icaritin", "TREATMENT", 153, 161], ["the adverse effects", "PROBLEM", 177, 196], ["bone necrosis", "PROBLEM", 204, 217], ["high-concentration corticosteroids", "TREATMENT", 222, 256], ["MSC", "TEST", 312, 315], ["Icaritin via Ci-I Hydrogels", "TREATMENT", 320, 347], ["small", "OBSERVATION_MODIFIER", 112, 117], ["hydrophobic molecular drugs", "OBSERVATION", 118, 145], ["bone", "ANATOMY", 204, 208], ["necrosis", "OBSERVATION", 209, 217], ["long term", "OBSERVATION_MODIFIER", 264, 273], ["MSC", "ANATOMY", 312, 315], ["Bone", "ANATOMY", 357, 361], ["Regeneration", "OBSERVATION", 362, 374]]], ["We further evaluated the efficacy of Ci-I gelatin hydrogels encapsulated with MSCs and icaritin to boost bone regeneration in a SAON model.", [["MSCs", "ANATOMY", 78, 82], ["bone", "ANATOMY", 105, 109], ["icaritin", "CHEMICAL", 87, 95], ["icaritin", "CHEMICAL", 87, 95], ["Ci-I gelatin hydrogels", "SIMPLE_CHEMICAL", 37, 59], ["MSCs", "CELL", 78, 82], ["icaritin", "SIMPLE_CHEMICAL", 87, 95], ["bone", "TISSUE", 105, 109], ["MSCs", "CELL_TYPE", 78, 82], ["Ci-I gelatin hydrogels", "TREATMENT", 37, 59], ["MSCs", "TREATMENT", 78, 82], ["icaritin", "TREATMENT", 87, 95], ["boost bone regeneration", "TREATMENT", 99, 122], ["a SAON model", "TREATMENT", 126, 138], ["bone", "ANATOMY", 105, 109], ["regeneration", "OBSERVATION", 110, 122]]], ["Figure 4a showed that the injection of Ci-I gelatin hydrogels helped to prevent a decrease in BMD around the tunnel compared to the nontreated control group (no hydrogel implantation, \"Blank\").", [["Ci-I gelatin hydrogels", "SIMPLE_CHEMICAL", 39, 61], ["the injection of Ci-I gelatin hydrogels", "TREATMENT", 22, 61], ["a decrease in BMD", "PROBLEM", 80, 97], ["the tunnel", "TREATMENT", 105, 115], ["hydrogel implantation", "TREATMENT", 161, 182], ["decrease", "OBSERVATION_MODIFIER", 82, 90], ["tunnel", "OBSERVATION", 109, 115], ["no", "UNCERTAINTY", 158, 160], ["hydrogel implantation", "OBSERVATION", 161, 182]]], ["The \"icaritin+MSC+Gel\" group showed significantly enhanced new bone formation in the tunnel ( Figure 4a ).", [["MSC", "ANATOMY", 14, 17], ["bone", "ANATOMY", 63, 67], ["icaritin", "CHEMICAL", 5, 13], ["icaritin", "CHEMICAL", 5, 13], ["icaritin", "SIMPLE_CHEMICAL", 5, 13], ["MSC", "CELL", 14, 17], ["bone", "TISSUE", 63, 67], ["The \"icaritin+MSC+Gel\" group", "TEST", 0, 28], ["significantly enhanced new bone formation", "PROBLEM", 36, 77], ["new", "OBSERVATION_MODIFIER", 59, 62], ["bone formation", "OBSERVATION", 63, 77], ["tunnel", "ANATOMY", 85, 91]]], ["Quantitative measurement of the micro-CT images showed that the \"icaritin+MSC+Gel\" group exhibited significant elevation in BV/TV, trabecular number, while trabecular thickness and a reduction in trabecular separation, as compared to the other groups, in both the peri-tunnel native bone ( Figure 4b ) and neobone tissue inside the tunnel (Figure 4c ).", [["MSC", "ANATOMY", 74, 77], ["BV", "ANATOMY", 124, 126], ["trabecular", "ANATOMY", 131, 141], ["trabecular", "ANATOMY", 156, 166], ["trabecular", "ANATOMY", 196, 206], ["bone", "ANATOMY", 283, 287], ["neobone tissue", "ANATOMY", 306, 320], ["icaritin", "CHEMICAL", 65, 73], ["icaritin", "SIMPLE_CHEMICAL", 65, 73], ["BV", "ORGANISM_SUBSTANCE", 124, 126], ["trabecular", "TISSUE", 131, 141], ["trabecular", "TISSUE", 156, 166], ["trabecular", "TISSUE", 196, 206], ["bone", "TISSUE", 283, 287], ["neobone tissue", "TISSUE", 306, 320], ["the micro-CT images", "TEST", 28, 47], ["the \"icaritin", "TEST", 60, 73], ["MSC", "PROBLEM", 74, 77], ["significant elevation in BV/TV, trabecular number", "PROBLEM", 99, 148], ["trabecular thickness", "PROBLEM", 156, 176], ["a reduction in trabecular separation", "PROBLEM", 181, 217], ["significant", "OBSERVATION_MODIFIER", 99, 110], ["elevation", "OBSERVATION", 111, 120], ["BV", "ANATOMY", 124, 126], ["trabecular", "OBSERVATION_MODIFIER", 131, 141], ["number", "OBSERVATION_MODIFIER", 142, 148], ["trabecular thickness", "OBSERVATION", 156, 176], ["reduction", "OBSERVATION_MODIFIER", 183, 192], ["trabecular separation", "OBSERVATION", 196, 217], ["both", "ANATOMY_MODIFIER", 255, 259], ["peri-tunnel", "ANATOMY_MODIFIER", 264, 275], ["native bone", "ANATOMY", 276, 287], ["tunnel", "ANATOMY", 332, 338]]], ["Using Goldener's Trichrome staining, we also further confirmed that the bone tunnel was filled with neobone in the \"icaritin+MSC +Gel\" group ( Figure 4d ).", [["bone", "ANATOMY", 72, 76], ["neobone", "ANATOMY", 100, 107], ["MSC", "ANATOMY", 125, 128], ["icaritin", "CHEMICAL", 116, 124], ["neobone", "CHEMICAL", 100, 107], ["icaritin", "CHEMICAL", 116, 124], ["bone", "TISSUE", 72, 76], ["neobone", "SIMPLE_CHEMICAL", 100, 107], ["icaritin", "SIMPLE_CHEMICAL", 116, 124], ["Goldener's Trichrome staining", "TREATMENT", 6, 35], ["the bone tunnel", "TREATMENT", 68, 83], ["neobone", "TREATMENT", 100, 107], ["the \"icaritin", "TREATMENT", 111, 124], ["bone", "ANATOMY", 72, 76], ["tunnel", "OBSERVATION", 77, 83]]], ["In contrast, only fibrous tissue was formed in the other groups without supplementation of icaritin (Figure 4d) .\u25a0 RESULTS AND DISCUSSIONWe further examined the harvested samples to assess the bone regeneration within the drilled tunnel.", [["fibrous tissue", "ANATOMY", 18, 32], ["samples", "ANATOMY", 171, 178], ["bone", "ANATOMY", 193, 197], ["icaritin", "CHEMICAL", 91, 99], ["icaritin", "CHEMICAL", 91, 99], ["fibrous tissue", "TISSUE", 18, 32], ["icaritin", "SIMPLE_CHEMICAL", 91, 99], ["bone", "TISSUE", 193, 197], ["fibrous tissue", "PROBLEM", 18, 32], ["supplementation of icaritin", "TREATMENT", 72, 99], ["the harvested samples", "TEST", 157, 178], ["the bone regeneration", "PROBLEM", 189, 210], ["fibrous tissue", "OBSERVATION", 18, 32], ["bone", "ANATOMY", 193, 197], ["regeneration", "OBSERVATION", 198, 210], ["drilled tunnel", "OBSERVATION", 222, 236]]], ["Immunofluorescent staining against Ki67, a marker widely used to identify proliferating cells, showed significantly more Ki67 positive cells in the tunnel region injected with the Ci-I gelatin hydrogels, which were loaded with both MSCs and icaritin (\"icaritin+MSC +Gel\"), as compared to that of either hydrogel alone (\"Gel\") or hydrogel plus icaritin (\"icaritin+Gel\") treatment groups ( Figure 5a) .", [["cells", "ANATOMY", 88, 93], ["Ki67 positive cells", "ANATOMY", 121, 140], ["tunnel region", "ANATOMY", 148, 161], ["MSCs", "ANATOMY", 232, 236], ["MSC", "ANATOMY", 261, 264], ["icaritin", "CHEMICAL", 241, 249], ["icaritin", "CHEMICAL", 343, 351], ["icaritin", "CHEMICAL", 354, 362], ["icaritin", "CHEMICAL", 241, 249], ["icaritin", "CHEMICAL", 343, 351], ["Ki67", "GENE_OR_GENE_PRODUCT", 35, 39], ["cells", "CELL", 88, 93], ["Ki67", "GENE_OR_GENE_PRODUCT", 121, 125], ["cells", "CELL", 135, 140], ["MSCs", "CELL", 232, 236], ["icaritin", "SIMPLE_CHEMICAL", 241, 249], ["icaritin", "SIMPLE_CHEMICAL", 252, 260], ["MSC", "CELL", 261, 264], ["icaritin", "SIMPLE_CHEMICAL", 343, 351], ["icaritin", "SIMPLE_CHEMICAL", 354, 362], ["Ki67", "PROTEIN", 35, 39], ["proliferating cells", "CELL_TYPE", 74, 93], ["Ki67 positive cells", "CELL_TYPE", 121, 140], ["MSCs", "CELL_TYPE", 232, 236], ["MSC", "CELL_TYPE", 261, 264], ["Immunofluorescent staining", "TEST", 0, 26], ["Ki67", "TEST", 35, 39], ["a marker", "TEST", 41, 49], ["proliferating cells", "PROBLEM", 74, 93], ["significantly more Ki67 positive cells in the tunnel region", "PROBLEM", 102, 161], ["the Ci-I gelatin hydrogels", "TREATMENT", 176, 202], ["both MSCs", "TREATMENT", 227, 236], ["icaritin (\"icaritin", "TREATMENT", 241, 260], ["hydrogel plus icaritin (\"icaritin+Gel\"", "TREATMENT", 329, 367], ["proliferating cells", "OBSERVATION", 74, 93], ["significantly more", "OBSERVATION_MODIFIER", 102, 120], ["Ki67 positive cells", "OBSERVATION", 121, 140], ["tunnel", "ANATOMY", 148, 154], ["region", "ANATOMY_MODIFIER", 155, 161]]], ["Moreover, the \"icaritin+MSC+Gel\" group also exhibited the most intense staining against key osteogenic markers, Runx2 and Osterix (Figure 5b,c) .", [["MSC", "ANATOMY", 24, 27], ["icaritin", "CHEMICAL", 15, 23], ["icaritin", "CHEMICAL", 15, 23], ["icaritin", "SIMPLE_CHEMICAL", 15, 23], ["MSC", "CELL", 24, 27], ["Runx2", "GENE_OR_GENE_PRODUCT", 112, 117], ["Osterix", "GENE_OR_GENE_PRODUCT", 122, 129], ["c", "GENE_OR_GENE_PRODUCT", 141, 142], ["osteogenic markers", "PROTEIN", 92, 110], ["Runx2", "PROTEIN", 112, 117], ["Osterix", "PROTEIN", 122, 129], ["Figure 5b,c)", "PROTEIN", 131, 143], ["osteogenic markers", "TEST", 92, 110], ["Runx2", "TEST", 112, 117], ["Osterix (Figure 5b", "TEST", 122, 140], ["most intense", "OBSERVATION_MODIFIER", 58, 70], ["osteogenic markers", "OBSERVATION", 92, 110]]], ["At week 3 after the hydrogel implantation, the expressions of active \u03b2-catenin and OCN were upregulated in the \"icaritin+MSC+Gel\" group (Figure 5d and Figure S6a ) compared to those of the other groups, and this may have contributed to the enhanced bone formation.", [["MSC", "ANATOMY", 121, 124], ["bone", "ANATOMY", 249, 253], ["icaritin", "CHEMICAL", 112, 120], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 69, 78], ["OCN", "GENE_OR_GENE_PRODUCT", 83, 86], ["bone", "TISSUE", 249, 253], ["\u03b2-catenin", "PROTEIN", 69, 78], ["OCN", "PROTEIN", 83, 86], ["the hydrogel implantation", "TREATMENT", 16, 41], ["active \u03b2-catenin", "TREATMENT", 62, 78], ["the \"icaritin+MSC+Gel\" group", "TREATMENT", 107, 135], ["the enhanced bone formation", "PROBLEM", 236, 263], ["bone", "ANATOMY", 249, 253]]], ["In contrast, PPAR\u03b3 expression was dramatically decreased (Figure 5e and Figure S6b ), indicating suppressed adipogenesis, and this is consistent with our previous in vitro findings (Figure 3d) .", [["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 13, 18], ["PPAR\u03b3", "PROTEIN", 13, 18], ["suppressed adipogenesis", "PROBLEM", 97, 120], ["dramatically", "OBSERVATION_MODIFIER", 34, 46], ["decreased", "OBSERVATION_MODIFIER", 47, 56], ["suppressed adipogenesis", "OBSERVATION", 97, 120], ["consistent with", "UNCERTAINTY", 134, 149]]], ["The icaritin-laden hydrogels (\"icaritin+MSC+Gel\" and \"icaritin +Gel\") also exhibited significantly elevated expression of another proliferation marker, proliferating cell nuclear antigen (PCNA), in addition to Ki67 at week 6 ( Figure 5a and Figure S4 ), regardless of MSC supplementation.", [["MSC", "ANATOMY", 40, 43], ["MSC", "ANATOMY", 268, 271], ["icaritin", "CHEMICAL", 4, 12], ["icaritin", "CHEMICAL", 31, 39], ["icaritin", "CHEMICAL", 4, 12], ["icaritin", "SIMPLE_CHEMICAL", 4, 12], ["icaritin", "SIMPLE_CHEMICAL", 31, 39], ["icaritin", "SIMPLE_CHEMICAL", 54, 62], ["proliferating cell nuclear antigen", "GENE_OR_GENE_PRODUCT", 152, 186], ["PCNA", "GENE_OR_GENE_PRODUCT", 188, 192], ["Ki67", "GENE_OR_GENE_PRODUCT", 210, 214], ["MSC", "CELL", 268, 271], ["proliferating cell nuclear antigen", "PROTEIN", 152, 186], ["PCNA", "PROTEIN", 188, 192], ["Ki67", "PROTEIN", 210, 214], ["MSC", "CELL_TYPE", 268, 271], ["The icaritin-laden hydrogels", "TREATMENT", 0, 28], ["icaritin+MSC", "TREATMENT", 31, 43], ["significantly elevated expression", "PROBLEM", 85, 118], ["another proliferation marker", "PROBLEM", 122, 150], ["Ki67", "TEST", 210, 214], ["MSC supplementation", "TREATMENT", 268, 287], ["laden hydrogels", "OBSERVATION", 13, 28], ["MSC supplementation", "OBSERVATION", 268, 287]]], ["In addition, the \"icaritin+MSC+Gel\" group showed slightly reduced expression of c-Src, a detrimental factor that has been identified as a therapeutic target for osteonecrosis.", [["MSC", "ANATOMY", 27, 30], ["osteonecrosis", "DISEASE", 161, 174], ["icaritin", "CHEMICAL", 18, 26], ["icaritin", "GENE_OR_GENE_PRODUCT", 18, 26], ["MSC", "CELL", 27, 30], ["c-Src", "GENE_OR_GENE_PRODUCT", 80, 85], ["icaritin", "PROTEIN", 18, 26], ["MSC", "CELL_TYPE", 27, 30], ["c", "PROTEIN", 80, 81], ["Src", "PROTEIN", 82, 85], ["the \"icaritin", "TEST", 13, 26], ["slightly reduced expression of c-Src", "PROBLEM", 49, 85], ["a detrimental factor", "PROBLEM", 87, 107], ["osteonecrosis", "PROBLEM", 161, 174], ["osteonecrosis", "OBSERVATION", 161, 174]]], ["55 CSF-1R, a tyrosine-kinase transmembrane receptor, 76 was greatly reduced in the \"icaritin +MSC+Gel\" and \"icaritin+Gel\" groups, indicating the potential immunoregulative effect of icaritin, as reported by a previous study.", [["MSC", "ANATOMY", 94, 97], ["tyrosine", "CHEMICAL", 13, 21], ["icaritin", "CHEMICAL", 84, 92], ["icaritin", "CHEMICAL", 108, 116], ["icaritin", "CHEMICAL", 182, 190], ["tyrosine", "CHEMICAL", 13, 21], ["icaritin", "CHEMICAL", 84, 92], ["icaritin", "CHEMICAL", 182, 190], ["CSF-1R", "GENE_OR_GENE_PRODUCT", 3, 9], ["icaritin", "SIMPLE_CHEMICAL", 84, 92], ["MSC", "CELL", 94, 97], ["icaritin+Gel", "SIMPLE_CHEMICAL", 108, 120], ["icaritin", "SIMPLE_CHEMICAL", 182, 190], ["55 CSF-1R", "PROTEIN", 0, 9], ["tyrosine-kinase transmembrane receptor", "PROTEIN", 13, 51], ["CSF", "TEST", 3, 6], ["a tyrosine-kinase transmembrane receptor", "TEST", 11, 51], ["Gel\" groups", "PROBLEM", 117, 128], ["the potential immunoregulative effect of icaritin", "PROBLEM", 141, 190], ["a previous study", "TEST", 207, 223], ["reduced", "OBSERVATION_MODIFIER", 68, 75], ["MSC", "ANATOMY", 94, 97], ["icaritin", "OBSERVATION", 182, 190]]], ["77 More importantly, this finding suggests that icaritin and MSCs delivered by Ci-I hydrogels can potentially mitigate the foreign body response to biomaterial implantations, thereby facilitating further translational applications.", [["MSCs", "ANATOMY", 61, 65], ["body", "ANATOMY", 131, 135], ["icaritin", "CHEMICAL", 48, 56], ["Ci-I", "CHEMICAL", 79, 83], ["icaritin", "CHEMICAL", 48, 56], ["icaritin", "SIMPLE_CHEMICAL", 48, 56], ["MSCs", "CELL", 61, 65], ["Ci-I", "GENE_OR_GENE_PRODUCT", 79, 83], ["body", "ORGANISM_SUBDIVISION", 131, 135], ["MSCs", "CELL_TYPE", 61, 65], ["icaritin and MSCs", "PROBLEM", 48, 65], ["Ci-I hydrogels", "TREATMENT", 79, 93], ["the foreign body response", "PROBLEM", 119, 144], ["biomaterial implantations", "TREATMENT", 148, 173], ["further translational applications", "TREATMENT", 196, 230], ["icaritin", "OBSERVATION", 48, 56], ["foreign body", "OBSERVATION", 123, 135], ["biomaterial implantations", "OBSERVATION", 148, 173]]], ["76 By using calcein green (CG) and xylenol orange (XO) to dynamically assess the bone formation rate, at week 3 and 6 postsurgery we found that treatment with hydrogel alone (\"Gel\") did not affect bone formation within the bone tunnel (Figure 5f\u2212i) .", [["bone", "ANATOMY", 81, 85], ["bone", "ANATOMY", 197, 201], ["bone", "ANATOMY", 223, 227], ["calcein green", "CHEMICAL", 12, 25], ["xylenol orange", "CHEMICAL", 35, 49], ["calcein green", "CHEMICAL", 12, 25], ["xylenol orange", "CHEMICAL", 35, 49], ["calcein green", "SIMPLE_CHEMICAL", 12, 25], ["CG", "SIMPLE_CHEMICAL", 27, 29], ["xylenol orange", "SIMPLE_CHEMICAL", 35, 49], ["XO", "SIMPLE_CHEMICAL", 51, 53], ["bone", "TISSUE", 81, 85], ["bone", "TISSUE", 197, 201], ["bone", "TISSUE", 223, 227], ["calcein green (CG)", "TREATMENT", 12, 30], ["xylenol orange (XO)", "TREATMENT", 35, 54], ["the bone formation rate", "TEST", 77, 100], ["treatment with hydrogel alone", "TREATMENT", 144, 173], ["bone", "ANATOMY", 81, 85], ["bone", "ANATOMY", 223, 227]]], ["Incorporation of icaritin in the injected hydrogels (\"icaritin+Gel\") significantly increased the bone formation rate compared to either blank repair or the \"Gel\" group (Figure 5f\u2212i) .", [["bone", "ANATOMY", 97, 101], ["icaritin", "CHEMICAL", 17, 25], ["icaritin", "CHEMICAL", 54, 62], ["icaritin", "CHEMICAL", 17, 25], ["icaritin", "SIMPLE_CHEMICAL", 17, 25], ["icaritin", "SIMPLE_CHEMICAL", 54, 62], ["bone", "TISSUE", 97, 101], ["icaritin in the injected hydrogels", "TREATMENT", 17, 51], ["icaritin+Gel\"", "TREATMENT", 54, 67], ["the bone formation rate", "PROBLEM", 93, 116], ["blank repair", "TREATMENT", 136, 148], ["icaritin", "OBSERVATION", 17, 25], ["bone", "ANATOMY", 97, 101]]], ["The encapsulation of both exogenous MSCs and icaritin in the hydrogels (\"icaritin +MSC+Gel\") further enhanced bone formation in the defect site (Figure 5f\u2212i) .", [["MSCs", "ANATOMY", 36, 40], ["MSC", "ANATOMY", 83, 86], ["bone", "ANATOMY", 110, 114], ["defect site", "ANATOMY", 132, 143], ["icaritin", "CHEMICAL", 45, 53], ["icaritin", "CHEMICAL", 45, 53], ["MSCs", "CELL", 36, 40], ["icaritin", "SIMPLE_CHEMICAL", 45, 53], ["icaritin", "SIMPLE_CHEMICAL", 73, 81], ["bone", "TISSUE", 110, 114], ["MSCs", "CELL_TYPE", 36, 40], ["both exogenous MSCs and icaritin in the hydrogels", "PROBLEM", 21, 70], ["icaritin +MSC+Gel\"", "TREATMENT", 73, 91], ["further enhanced bone formation", "PROBLEM", 93, 124], ["the defect site", "PROBLEM", 128, 143], ["encapsulation", "OBSERVATION_MODIFIER", 4, 17], ["both", "OBSERVATION_MODIFIER", 21, 25], ["exogenous MSCs", "OBSERVATION", 26, 40], ["icaritin", "OBSERVATION_MODIFIER", 45, 53], ["hydrogels", "ANATOMY", 61, 70], ["MSC", "ANATOMY", 83, 86], ["bone", "ANATOMY", 110, 114], ["defect", "OBSERVATION", 132, 138]]], ["These data demonstrate that the Ci-I gelatin hydrogel is an excellent carrier of cells and hydrophobic drugs for promoting in situ bone regeneration and treating SAON.\u25a0 RESULTS AND DISCUSSIONDelivery of Icaritin by Ci-I Hydrogels Facilitates the Recruitment of Endogenous Cells To Expedite the Healing of SAON in Vivo.", [["cells", "ANATOMY", 81, 86], ["bone", "ANATOMY", 131, 135], ["Cells", "ANATOMY", 272, 277], ["SAON", "DISEASE", 162, 166], ["Icaritin", "CHEMICAL", 203, 211], ["Icaritin", "CHEMICAL", 203, 211], ["cells", "CELL", 81, 86], ["bone", "TISSUE", 131, 135], ["Icaritin", "SIMPLE_CHEMICAL", 203, 211], ["Ci-I Hydrogels", "SIMPLE_CHEMICAL", 215, 229], ["Cells", "CELL", 272, 277], ["These data", "TEST", 0, 10], ["the Ci-I gelatin hydrogel", "TREATMENT", 28, 53], ["hydrophobic drugs", "TREATMENT", 91, 108], ["promoting in situ bone regeneration", "TREATMENT", 113, 148], ["Icaritin", "TREATMENT", 203, 211], ["Ci-I Hydrogels", "TREATMENT", 215, 229], ["Endogenous Cells", "TREATMENT", 261, 277], ["SAON in Vivo", "TREATMENT", 305, 317], ["situ bone regeneration", "OBSERVATION", 126, 148], ["Endogenous Cells", "OBSERVATION", 261, 277], ["Healing", "OBSERVATION_MODIFIER", 294, 301]]], ["Our in vitro data have demonstrated that icaritin-laden Ci-I gelatin hydrogels can attract MSCs to infiltrate and migrate into hydrogels (Figure 2b) .", [["MSCs", "ANATOMY", 91, 95], ["icaritin", "CHEMICAL", 41, 49], ["icaritin", "CHEMICAL", 41, 49], ["icaritin", "SIMPLE_CHEMICAL", 41, 49], ["Ci-I gelatin hydrogels", "SIMPLE_CHEMICAL", 56, 78], ["MSCs", "CELL", 91, 95], ["MSCs", "CELL_TYPE", 91, 95], ["Our in vitro data", "TEST", 0, 17], ["icaritin-laden Ci-I gelatin hydrogels", "TREATMENT", 41, 78], ["MSCs", "PROBLEM", 91, 95], ["infiltrate", "PROBLEM", 99, 109], ["infiltrate", "OBSERVATION", 99, 109]]], ["To evaluate the cell recruitment in vivo, immediately after the core decompression surgery and treatment with hydrogel injections in the created tunnel, we injected SPIO-labeled MSCs (1 million cells in 100 \u03bcL of media) in the ipsilateral tibia of the same limb.", [["cell", "ANATOMY", 16, 20], ["MSCs", "ANATOMY", 178, 182], ["cells", "ANATOMY", 194, 199], ["ipsilateral tibia", "ANATOMY", 227, 244], ["limb", "ANATOMY", 257, 261], ["SPIO", "CHEMICAL", 165, 169], ["cell", "CELL", 16, 20], ["SPIO", "SIMPLE_CHEMICAL", 165, 169], ["MSCs", "CELL", 178, 182], ["cells", "CELL", 194, 199], ["ipsilateral tibia", "MULTI-TISSUE_STRUCTURE", 227, 244], ["limb", "ORGANISM_SUBDIVISION", 257, 261], ["SPIO-labeled MSCs", "CELL_LINE", 165, 182], ["the core decompression surgery", "TREATMENT", 60, 90], ["treatment", "TREATMENT", 95, 104], ["hydrogel injections", "TREATMENT", 110, 129], ["the created tunnel", "TREATMENT", 133, 151], ["cell recruitment", "OBSERVATION", 16, 32], ["decompression", "OBSERVATION", 69, 82], ["tunnel", "ANATOMY", 145, 151], ["ipsilateral", "ANATOMY_MODIFIER", 227, 238], ["tibia", "ANATOMY", 239, 244], ["same limb", "ANATOMY", 252, 261]]], ["Six weeks postsurgery, the SPIO-labeled MSCs were hardly found within and around the tunnels with no hydrogel implantation (\"Blank\") or with blank hydrogel implantation (\"Gel\") ( Figure 6 ).", [["MSCs", "ANATOMY", 40, 44], ["SPIO", "CHEMICAL", 27, 31], ["SPIO", "SIMPLE_CHEMICAL", 27, 31], ["MSCs", "CELL", 40, 44], ["MSCs", "CELL_TYPE", 40, 44], ["the SPIO-labeled MSCs", "TEST", 23, 44], ["hydrogel implantation", "TREATMENT", 101, 122], ["blank hydrogel implantation", "TREATMENT", 141, 168], ["no", "UNCERTAINTY", 98, 100], ["hydrogel implantation", "OBSERVATION", 101, 122]]], ["However, significantly more SPIO-labeled MSCs were found within and around the tunnels which were injected with hydrogels containing either icaritin alone (\"icaritin +Gel\") or both MSCs and icaritin (\"icaritin+MSC+Gel\") ( Figure 6 ).", [["MSCs", "ANATOMY", 41, 45], ["MSCs", "ANATOMY", 181, 185], ["MSC", "ANATOMY", 210, 213], ["SPIO", "CHEMICAL", 28, 32], ["icaritin", "CHEMICAL", 140, 148], ["icaritin", "CHEMICAL", 157, 165], ["icaritin", "CHEMICAL", 190, 198], ["icaritin", "CHEMICAL", 201, 209], ["icaritin", "CHEMICAL", 140, 148], ["icaritin", "CHEMICAL", 190, 198], ["SPIO", "SIMPLE_CHEMICAL", 28, 32], ["MSCs", "CELL", 41, 45], ["icaritin", "SIMPLE_CHEMICAL", 140, 148], ["icaritin", "SIMPLE_CHEMICAL", 157, 165], ["MSCs", "CELL", 181, 185], ["icaritin", "SIMPLE_CHEMICAL", 190, 198], ["icaritin", "SIMPLE_CHEMICAL", 201, 209], ["MSCs", "CELL_TYPE", 41, 45], ["MSCs", "CELL_TYPE", 181, 185], ["significantly more SPIO-labeled MSCs", "PROBLEM", 9, 45], ["hydrogels", "TREATMENT", 112, 121], ["icaritin", "TREATMENT", 140, 148], ["icaritin (\"icaritin", "TREATMENT", 190, 209]]], ["This is consistent with our previous finding that icaritin can directly promote the migration of MSCs by upregulating the expression of vascular cell adhesion molecule-1 (VCAM-1).", [["MSCs", "ANATOMY", 97, 101], ["icaritin", "CHEMICAL", 50, 58], ["icaritin", "CHEMICAL", 50, 58], ["icaritin", "SIMPLE_CHEMICAL", 50, 58], ["MSCs", "CELL", 97, 101], ["vascular cell adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 136, 169], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 171, 177], ["MSCs", "CELL_TYPE", 97, 101], ["vascular cell adhesion molecule-1", "PROTEIN", 136, 169], ["VCAM", "PROTEIN", 171, 175], ["icaritin", "TREATMENT", 50, 58], ["the migration of MSCs", "TREATMENT", 80, 101], ["vascular cell adhesion molecule", "TEST", 136, 167], ["VCAM", "TEST", 171, 175], ["consistent with", "UNCERTAINTY", 8, 23], ["migration", "OBSERVATION_MODIFIER", 84, 93], ["vascular", "ANATOMY", 136, 144], ["cell adhesion", "OBSERVATION", 145, 158]]], ["54 These data further demonstrated that the icaritin-laden Ci-I gelatin hydrogels can recruit endogenous MSCs from the surrounding tissues to migrate to the bone defects, thereby promoting new bone formation.\u25a0 CONCLUSIONSCollectively, we demonstrate a unique injectable hydrogel with desirable properties including ease of preparation, unscathed mechanical properties after injection, sustained delivery of small hydrophobic molecular drugs, and injection with encapsulated cells.", [["MSCs", "ANATOMY", 105, 109], ["tissues", "ANATOMY", 131, 138], ["bone", "ANATOMY", 157, 161], ["bone", "ANATOMY", 193, 197], ["cells", "ANATOMY", 474, 479], ["icaritin", "CHEMICAL", 44, 52], ["icaritin", "CHEMICAL", 44, 52], ["icaritin", "SIMPLE_CHEMICAL", 44, 52], ["Ci-I gelatin hydrogels", "SIMPLE_CHEMICAL", 59, 81], ["MSCs", "CELL", 105, 109], ["tissues", "TISSUE", 131, 138], ["bone", "TISSUE", 157, 161], ["bone", "TISSUE", 193, 197], ["cells", "CELL", 474, 479], ["endogenous MSCs", "CELL_TYPE", 94, 109], ["encapsulated cells", "CELL_TYPE", 461, 479], ["the icaritin-laden Ci-I gelatin hydrogels", "TREATMENT", 40, 81], ["endogenous MSCs", "PROBLEM", 94, 109], ["the bone defects", "PROBLEM", 153, 169], ["new bone formation", "PROBLEM", 189, 207], ["a unique injectable hydrogel", "TREATMENT", 250, 278], ["ease of preparation", "TREATMENT", 315, 334], ["unscathed mechanical properties", "TREATMENT", 336, 367], ["injection", "TREATMENT", 374, 383], ["small hydrophobic molecular drugs", "TREATMENT", 407, 440], ["injection with encapsulated cells", "TREATMENT", 446, 479], ["endogenous MSCs", "OBSERVATION", 94, 109], ["bone", "ANATOMY", 157, 161], ["defects", "OBSERVATION", 162, 169], ["new", "OBSERVATION_MODIFIER", 189, 192], ["bone formation", "OBSERVATION", 193, 207], ["small", "OBSERVATION_MODIFIER", 407, 412], ["hydrophobic molecular drugs", "OBSERVATION", 413, 440], ["encapsulated cells", "OBSERVATION", 461, 479]]], ["Furthermore, the dynamic physical cross-links in this hydrogel enable the infiltration and migration of cells from the surrounding environment to speed up the in situ bone regeneration in a SAON animal model.", [["cells", "ANATOMY", 104, 109], ["bone", "ANATOMY", 167, 171], ["cells", "CELL", 104, 109], ["bone", "TISSUE", 167, 171], ["this hydrogel", "TREATMENT", 49, 62], ["the infiltration", "PROBLEM", 70, 86], ["migration of cells", "TREATMENT", 91, 109], ["infiltration", "OBSERVATION", 74, 86], ["migration of cells", "OBSERVATION", 91, 109], ["situ", "ANATOMY_MODIFIER", 162, 166], ["bone", "ANATOMY", 167, 171], ["regeneration", "OBSERVATION", 172, 184]]], ["This injectable hydrogel can be easily customized to carry different portfolios of therapeutic drugs and cells for treating a wide array of clinical conditions via minimally invasive procedures in deep and enclosed anatomical locations.", [["cells", "ANATOMY", 105, 110], ["cells", "CELL", 105, 110], ["This injectable hydrogel", "TREATMENT", 0, 24], ["therapeutic drugs", "TREATMENT", 83, 100], ["minimally invasive procedures", "TREATMENT", 164, 193], ["deep", "ANATOMY_MODIFIER", 197, 201], ["anatomical locations", "OBSERVATION", 215, 235]]]], "5211a96115e408a2ac2eced159e533e8b57acaa4": [["the great plagues of the Middle Ages which emptied cities of their populations and caused urban civilization to regress (a third of the European population disappeared between the end of the fourteenth and the beginning of the fifteenth century [1] ).", [["great", "OBSERVATION_MODIFIER", 4, 9], ["plagues", "OBSERVATION", 10, 17], ["Middle", "ANATOMY_MODIFIER", 25, 31]]], ["The viruses imported into America by the Spaniards which decimated the local populations more surely than the fights.", [["viruses", "OBSERVATION", 4, 11]]], ["The Spanish flu which caused more deaths at the beginning of the twentieth century than the First World War.", [["flu", "DISEASE", 12, 15], ["deaths", "DISEASE", 34, 40]]], ["The Acquired Immunodeficiency Syndrome, better known under its acronym AIDS, which is still the most deadly infectious disease in the world, and which has claimed nearly 25 million victims since its appearance in 1981.", [["Acquired Immunodeficiency Syndrome", "DISEASE", 4, 38], ["AIDS", "DISEASE", 71, 75], ["The Acquired Immunodeficiency Syndrome", "PROBLEM", 0, 38], ["Immunodeficiency Syndrome", "OBSERVATION", 13, 38], ["most deadly", "OBSERVATION_MODIFIER", 96, 107], ["infectious", "OBSERVATION", 108, 118]]], ["We also think of the Coronavirus disease , which is now considered as a global pandemic.", [["Coronavirus disease", "DISEASE", 21, 40], ["the Coronavirus disease", "PROBLEM", 17, 40], ["a global pandemic", "PROBLEM", 70, 87], ["Coronavirus disease", "OBSERVATION", 21, 40], ["global", "OBSERVATION_MODIFIER", 72, 78], ["pandemic", "OBSERVATION", 79, 87]]]], "PMC7502810": [["RESEARCH HYPOTHESESWe hypothesize that the combined use of mCIMT and iCIMT with individuals with hemiparesis willRESEARCH HYPOTHESES(1) Improve functional use of the upper extremity and hand for higher and lower functioning participants.RESEARCH HYPOTHESES(2) Improve subjective report on the amount of use and quality of movement in the hemiparetic UE for daily activities for higher and lower functioning participants andRESEARCH HYPOTHESES(3) Improve ADL participation for higher and lower functioning participantsRESEARCH HYPOTHESESIn addition, we hypothesize thatRESEARCH HYPOTHESES(4) Internet sessions will have greater participant adherence compared to that of the once weekly in-person sessions.STUDY DESIGN ::: METHODSThis research employed a pre-experimental design with a 6-week intervention period.", [["upper extremity", "ANATOMY", 166, 181], ["hand", "ANATOMY", 186, 190], ["hemiparesis", "DISEASE", 97, 108], ["upper extremity", "ORGANISM_SUBDIVISION", 166, 181], ["hand", "ORGANISM_SUBDIVISION", 186, 190], ["participants", "SPECIES", 224, 236], ["participants", "SPECIES", 407, 419], ["participants", "SPECIES", 505, 517], ["mCIMT and iCIMT", "TREATMENT", 59, 74], ["hemiparesis", "PROBLEM", 97, 108], ["higher and lower functioning participants", "PROBLEM", 378, 419], ["a 6-week intervention period", "TREATMENT", 782, 810], ["upper extremity", "ANATOMY", 166, 181], ["hand", "ANATOMY", 186, 190]]], ["Group interventions took place in a lab space at our university once per week. iCIMT sessions occurred twice a week, using web conferencing technology in participants' homes.", [["participants", "SPECIES", 154, 166], ["Group interventions", "TREATMENT", 0, 19]]], ["Assessments were conducted twice, at baseline and six weeks later.", [["Assessments", "TEST", 0, 11]]], ["Both individual and group sessions required sign-in attendance to determine participant adherence to the program.PARTICIPANTS ::: METHODSThe sample size was determined using a power analysis based on a study by Page et al. (2008).", [["a power analysis", "TEST", 174, 190], ["a study", "TEST", 200, 207]]], ["The effect size was Cohen's d = 0.88.", [["size", "OBSERVATION_MODIFIER", 11, 15]]], ["With 20 participants we can achieve the power of .80, allowing 5% Type I error.", [["participants", "SPECIES", 8, 20]]], ["Anticipating 20% of attrition and considering this is a new approach, we recruited 32 participants using a convenience sampling method.", [["participants", "SPECIES", 86, 98], ["a convenience sampling method", "TREATMENT", 105, 134]]], ["Our data analysis included 28 participants.", [["participants", "SPECIES", 30, 42], ["Our data analysis", "TEST", 0, 17]]], ["Four participants did not complete the study; two decided to withdraw after pre-testing and two participants could not be assessed at posttest due to extenuating circumstances.", [["participants", "SPECIES", 5, 17], ["participants", "SPECIES", 96, 108], ["the study", "TEST", 35, 44]]], ["The 28 participants were divided into two groups based on their performance on the timed portion of the Wolf Motor Function Test (WMFT) at baseline.", [["participants", "ORGANISM", 7, 19], ["participants", "SPECIES", 7, 19]]], ["Since the WMFT timed portion measures functional ability ranging from gross to fine motor, it was determined that this was the best objective measurement to use to sort the participants into groups.", [["WMFT timed portion", "DNA", 10, 28], ["participants", "SPECIES", 173, 185]]], ["The cutoff point was 38, the mean score.", [["The cutoff point", "TEST", 0, 16]]], ["There were 15 higher functioning and 13 lower functioning participants.PARTICIPANTS ::: METHODSRecruitment methods included informational advertisement in local rehabilitation facilities, in-services to stroke support groups, distribution of flyers, phone calls, letters, and emails, to area clinicians.", [["stroke", "DISEASE", 203, 209], ["participants", "SPECIES", 58, 70]]], ["Inclusion criteria were (1) 18-75 years of age, (2) presence of consistent hemiparesis and impaired function, (3) ability to transfer self-independently, (4) at least six months post-stroke, (5) being able to follow two-step written and/or verbal directions, (6) having at least 15 degrees of active shoulder flexion and abduction, (7) having at least 5-10 degrees of active wrist flexion and 5-10 degrees of active wrist extension from neutral, (8) having at least 5-10 degrees of flexion in the thumb and/or digits, and (10) living in their own home with a device capable of video conferencing and Internet access.", [["shoulder", "ANATOMY", 300, 308], ["wrist", "ANATOMY", 375, 380], ["wrist", "ANATOMY", 416, 421], ["thumb", "ANATOMY", 497, 502], ["hemiparesis", "DISEASE", 75, 86], ["stroke", "DISEASE", 183, 189], ["shoulder", "ORGANISM_SUBDIVISION", 300, 308], ["flexion", "ORGANISM_SUBDIVISION", 309, 316], ["wrist", "ORGANISM_SUBDIVISION", 375, 380], ["flexion", "ORGANISM_SUBDIVISION", 381, 388], ["wrist", "ORGANISM_SUBDIVISION", 416, 421], ["flexion", "ORGANISM_SUBDIVISION", 482, 489], ["thumb", "ORGANISM_SUBDIVISION", 497, 502], ["consistent hemiparesis", "PROBLEM", 64, 86], ["impaired function", "PROBLEM", 91, 108], ["stroke", "PROBLEM", 183, 189], ["abduction", "TEST", 321, 330], ["active wrist flexion", "TEST", 368, 388], ["active wrist extension", "PROBLEM", 409, 431], ["flexion", "TEST", 482, 489], ["a device", "TREATMENT", 557, 565], ["consistent", "UNCERTAINTY", 64, 74], ["hemiparesis", "OBSERVATION", 75, 86], ["impaired function", "OBSERVATION", 91, 108], ["stroke", "OBSERVATION", 183, 189], ["shoulder flexion", "ANATOMY", 300, 316], ["abduction", "ANATOMY", 321, 330], ["wrist flexion", "ANATOMY", 375, 388], ["wrist", "ANATOMY", 416, 421], ["thumb", "ANATOMY", 497, 502], ["digits", "ANATOMY", 510, 516]]], ["Participants were excluded from the study if: (1) they were living in a nursing home, (2) they were receiving outside occupational therapy services, and/or (3) they did not understand and/or speak English at fifth grade level.PERFORMANCE MEASURES ::: METHODSUse of the hemiparetic upper extremity can be measured through functional use, motor ability, as well as the participant's perception of the use of their affected arm.", [["upper extremity", "ANATOMY", 281, 296], ["upper extremity", "ORGANISM_SUBDIVISION", 281, 296], ["arm", "ORGANISM_SUBDIVISION", 421, 424], ["Participants", "SPECIES", 0, 12], ["the study", "TEST", 32, 41], ["hemiparetic", "ANATOMY_MODIFIER", 269, 280], ["upper extremity", "ANATOMY", 281, 296]]], ["To assess the quality of movement and strength while performing different tasks, the Wolf Motor Function Test (WMFT) was implemented.", [["different tasks", "TEST", 64, 79], ["the Wolf Motor Function Test", "TEST", 81, 109]]], ["The WMFT is a standardized assessment that measures 17 gross and fine motor tasks in the affected UE.", [["WMFT", "DNA", 4, 8], ["a standardized assessment", "TEST", 12, 37], ["UE", "ANATOMY", 98, 100]]], ["The items include motions such as: forearm to the table, extended elbow, hand to the table, and lifting a basket, among others.", [["forearm", "ANATOMY", 35, 42], ["elbow", "ANATOMY", 66, 71], ["hand", "ANATOMY", 73, 77], ["forearm", "ORGANISM_SUBDIVISION", 35, 42], ["elbow", "ORGANISM_SUBDIVISION", 66, 71], ["hand", "ORGANISM_SUBDIVISION", 73, 77], ["forearm", "ANATOMY", 35, 42], ["elbow", "ANATOMY", 66, 71]]], ["Subtests progress from gross motor to complex fine motor movement targeting distal musculature.", [["distal musculature", "ANATOMY", 76, 94], ["distal musculature", "MULTI-TISSUE_STRUCTURE", 76, 94], ["motor movement", "OBSERVATION", 51, 65], ["distal", "ANATOMY_MODIFIER", 76, 82], ["musculature", "ANATOMY", 83, 94]]], ["In addition to timed subtests, raters score participants' functional ability preforming the subtests based on video recordings.", [["participants", "SPECIES", 44, 56], ["timed subtests", "TEST", 15, 29], ["the subtests", "TEST", 88, 100], ["video recordings", "TEST", 110, 126]]], ["A score of 0 indicates no use, while a score of 5 indicates \u201cnormal\u201d functional ability (Wolf et al., 2001).PERFORMANCE MEASURES ::: METHODSMorris et al. (2001) found the test-retest reliability was very high for both the Functional Ability Scale (r = 0.95) and timed subtests (r=0.90) of the WMFT.", [["A score", "TEST", 0, 7], ["a score", "TEST", 37, 44], ["the test", "TEST", 167, 175], ["retest reliability", "TEST", 176, 194], ["timed subtests", "TEST", 262, 276]]], ["Nijland et al. (2010) found that Spearman's rank correlation coefficients ranged from 0.70 to 0.86.", [["Spearman's rank correlation coefficients", "TEST", 33, 73]]], ["ICCs for inter-rater and intra-rater reliability ranged from 0.92 to 0.97.PERFORMANCE MEASURES ::: METHODSThe Motor Activity Log (MAL) assesses functional participation through a standardized structured interview; participants rate the Amount of Use (AOU) and Quality of Use (QOU) of the affected limb on a scale of 0 to 5.", [["limb", "ANATOMY", 297, 301], ["limb", "ORGANISM_SUBDIVISION", 297, 301], ["participants", "SPECIES", 214, 226], ["inter-rater", "TEST", 9, 20], ["intra-rater reliability", "TEST", 25, 48]]], ["A score of 5 indicates the affected limb performs at the same level as before the stroke (Uswatte et al., 2006).", [["limb", "ANATOMY", 36, 40], ["stroke", "DISEASE", 82, 88], ["limb", "ORGANISM_SUBDIVISION", 36, 40], ["A score", "TEST", 0, 7], ["the stroke", "PROBLEM", 78, 88], ["limb", "ANATOMY", 36, 40]]], ["The MAL's internal consistency was high (Cronbach's alpha = 0.94), and concurrent validity with the Action Reach Arm Test (ARAT) has been established (Uswatte et al., 2006).", [["MAL", "GENE_OR_GENE_PRODUCT", 4, 7], ["MAL", "PROTEIN", 4, 7], ["The MAL's internal consistency", "TEST", 0, 30], ["Cronbach's alpha", "TEST", 41, 57], ["Arm Test (ARAT)", "TEST", 113, 128], ["high", "OBSERVATION_MODIFIER", 35, 39]]], ["It has also excellent test-retest reliability (Van der Lee et al., 2004).PERFORMANCE MEASURES ::: METHODSThe Fugl-Meyer Assessment of the UE (FMA-UE) contains 33 standardized items that assess motor impairment in the upper extremity post-stroke.", [["upper extremity", "ANATOMY", 217, 232], ["motor impairment", "DISEASE", 193, 209], ["stroke", "DISEASE", 238, 244], ["upper extremity", "ORGANISM_SUBDIVISION", 217, 232], ["PERFORMANCE MEASURES", "TEST", 73, 93], ["METHODSThe", "TEST", 98, 108], ["Fugl", "TEST", 109, 113], ["motor impairment in the upper extremity", "PROBLEM", 193, 232], ["stroke", "PROBLEM", 238, 244], ["excellent", "OBSERVATION_MODIFIER", 12, 21], ["UE", "ANATOMY", 138, 140], ["UE", "ANATOMY", 146, 148], ["upper extremity", "ANATOMY", 217, 232], ["stroke", "OBSERVATION", 238, 244]]], ["FMA-UE items assess movement synergies, isolated movement, hand and wrist function, speed, dexterity, and reflexes, according to a 3-point scale.", [["hand", "ANATOMY", 59, 63], ["wrist", "ANATOMY", 68, 73], ["hand", "ORGANISM_SUBDIVISION", 59, 63], ["wrist", "ORGANISM_SUBDIVISION", 68, 73], ["FMA", "TEST", 0, 3], ["movement synergies", "TEST", 20, 38], ["hand and wrist function", "TEST", 59, 82], ["reflexes", "TEST", 106, 114], ["UE", "ANATOMY", 4, 6], ["wrist", "ANATOMY", 68, 73]]], ["A score of 0 indicates the individual cannot perform the item, a score of 1, partial performance, and a score of 2, full performance.", [["A score", "TEST", 0, 7], ["a score", "TEST", 63, 70], ["a score", "TEST", 102, 109]]], ["The FMA has high test-retest reliability (r= 0.834 to 0.972) (Kim et al., 2012).PERFORMANCE MEASURES ::: METHODSThe Functional Independence Measure (FIM) addresses performance in activities of daily living (ADL).", [["high test", "TEST", 12, 21], ["retest reliability", "TEST", 22, 40]]], ["A score of 7 indicates total independence in an ADL, a score of 1 is total dependence, and scores between 2 and 6 indicate the level of assistance needed to complete the task and/or need for adaptive equipment (Ottenbacher et al., 1996).", [["A score", "TEST", 0, 7], ["total dependence", "PROBLEM", 69, 85], ["scores", "TEST", 91, 97], ["adaptive equipment", "TREATMENT", 191, 209]]], ["Ottenbacher et al. (1996) reported reliability values across the 11 studies.", [["reliability values", "TEST", 35, 53]]], ["The results revealed a median interrater reliability for the total FIM of .95 and median test-retest and equivalence reliability values of .95 and .92, respectively.", [["the total FIM", "TEST", 57, 70], ["median test", "TEST", 82, 93]]], ["For the purposes of this study, we used the self-care section of the FIM that includes feeding, grooming, bathing, toileting, tub/shower transfers, and dressing.", [["this study", "TEST", 20, 30], ["the self-care section", "TREATMENT", 40, 61], ["the FIM", "TREATMENT", 65, 72], ["tub/shower transfers", "TREATMENT", 126, 146], ["dressing", "TREATMENT", 152, 160]]], ["We included the FIM in this study based on its ability to track the abilities of patients with chronic disease (Uniform Data System for Medical Rehabilitation, 2014).PROCEDURE ::: METHODSFirst, we acquired an IRB approval.", [["chronic disease", "DISEASE", 95, 110], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["this study", "TEST", 23, 33], ["chronic disease", "PROBLEM", 95, 110], ["Medical Rehabilitation", "TREATMENT", 136, 158], ["chronic", "OBSERVATION_MODIFIER", 95, 102], ["disease", "OBSERVATION", 103, 110]]], ["Then, we conducted telephone screenings to assess participants' eligibility.", [["participants", "SPECIES", 50, 62], ["telephone screenings", "TEST", 19, 39]]], ["Written consent was obtained during the pretest, which took place at the university lab site, followed by the administration of the WMFT, FMA, MAL, and FIM.", [["MAL", "PROTEIN", 143, 146], ["the WMFT", "TREATMENT", 128, 136]]], ["At the time of the home visit, a tool kit containing common objects for gross and fine motor movements was provided to each participant for use at home during the Internet-based sessions.", [["motor movements", "OBSERVATION", 87, 102]]], ["(See Figure 1).PROCEDURE ::: METHODSInternet session interventions occurred two times a week; one hour each session.", [["METHODSInternet session interventions", "TREATMENT", 29, 66]]], ["The participant and the therapist met, and the computer screens were adjusted allowing full view of the hemiplegic UE and hand in order to observe participants' engagement in tasks.", [["hand", "ANATOMY", 122, 126], ["hemiplegic", "DISEASE", 104, 114], ["hand", "ORGANISM_SUBDIVISION", 122, 126], ["participant", "SPECIES", 4, 15], ["participants", "SPECIES", 147, 159], ["the computer screens", "TEST", 43, 63]]], ["In-person sessions were conducted once a week in a group setting lasting 1 to 1.5 hours for a total of three sessions per week.", [["person", "SPECIES", 3, 9]]], ["For the in-person sessions, social interaction among participants were encouraged in addition to group activities that facilitated engagement in occupation-based tasks.", [["person", "SPECIES", 11, 17], ["participants", "SPECIES", 53, 65]]], ["Examples of group sessions included the following: food preparation, games, painting, crafts, seasonal activities, and various simulated instrumental ADL (IADL) tasks.PROCEDURE ::: METHODSBoth Internet and in-person sessions focused on completing a variety of gross and fine motor exercises to encourage transfer of tasks to participants' ADLs/IADLs.", [["person", "SPECIES", 209, 215], ["participants", "SPECIES", 325, 337], ["gross and fine motor exercises", "TREATMENT", 260, 290]]], ["In addition, participants were provided with a log to document adherence to the protocol and were requested to wear the mitt on the unaffected UE for about 4 hours per day.", [["participants", "SPECIES", 13, 25], ["the protocol", "TREATMENT", 76, 88]]], ["The in-person group session and the Internet sessions addressed daily activities that participants valued encouraging the transfer of motor abilities from therapy sessions to real-life situations.", [["person", "SPECIES", 7, 13], ["participants", "SPECIES", 86, 98], ["therapy sessions", "TREATMENT", 155, 171]]], ["The \u201ctransfer package\u201d that this study offered consisted of home skills assignments and discussion and demonstration on using the affected UE in daily activities (Taub, 2012).", [["this study", "TEST", 28, 38]]], ["Throughout the sessions, participants were encouraged to problem solve and improve their task performance though active participation and feedback; incorporating a motor relearning/task-oriented approach into the sessions (Chan et al., 2006).", [["participants", "SPECIES", 25, 37]]], ["Key components of the motor re-learning/task oriented approach were provided by structuring practice sessions, encouraging engagement in preferred tasks, fitting the task to the individual with just the right challenge, using strategies such as shaping to refine skills, and providing opportunities for intrinsic and extrinsic feedback (Almhdawi et al., 2014; Sabari et al., 2014).PROCEDURE ::: METHODSThese methods were used to measure adherence to the treatment program and to encourage participants to generalize the results found during treatment sessions to real-world environments.", [["participants", "SPECIES", 489, 501], ["METHODSThese methods", "TREATMENT", 395, 415], ["the treatment program", "TREATMENT", 450, 471], ["treatment sessions", "TREATMENT", 541, 559], ["right", "ANATOMY_MODIFIER", 203, 208]]], ["The WMFT, FMA, MAL, and FIM were administered at the end of the 6-week session to assess functional use of the affected UE and hand in daily activities.STATISTICAL ANALYSIS ::: METHODSWe used a two-tailed independent t-test to compare age and months post stroke, and chi-square for ethnicity, sex, marital status, and affected side for our pretest demographic characteristics.", [["hand", "ANATOMY", 127, 131], ["stroke", "DISEASE", 255, 261], ["hand", "ORGANISM_SUBDIVISION", 127, 131], ["MAL", "PROTEIN", 15, 18], ["The WMFT", "TEST", 0, 8], ["FIM", "TREATMENT", 24, 27], ["stroke", "PROBLEM", 255, 261], ["FMA", "ANATOMY", 10, 13]]], ["A one-tailed independent t-test compared pretest scores on functional outcome measures between group 1 (higher functioning group, n=15) and group 2 (lower functioning group, n=13).", [["pretest scores", "TEST", 41, 55]]], ["We anticipated that the higher functioning group's pre-test scores would be better than the lower functioning group.STATISTICAL ANALYSIS ::: METHODSTo address the first three research hypotheses, we used a one-tailed paired t-test for the total scores of the WMFT (timed and functional ability scales), FMA-UE, MAL and FIM, for Group 1 and Group 2, separately.", [["the higher functioning group's pre-test scores", "PROBLEM", 20, 66]]], ["In order to control Type I error in multiple measures of eight outcome variables, we used Benjamini-Hochberg method using the false discovery rate (FDR).", [["Type I error", "PROBLEM", 20, 32], ["Benjamini-Hochberg method", "TREATMENT", 90, 115]]], ["This method decreases the possibility of the false discovery rate; therefore, it can control the event that small p-values (<.05) happen by chance, leading to incorrectly rejecting the true null hypothesis (Benjamini & Hochberg, 1995).", [["small p-values", "PROBLEM", 108, 122], ["small", "OBSERVATION_MODIFIER", 108, 113]]], ["This method uses sequential modified Bonferroni correction for multiple hypothesis testing.", [["This method", "TREATMENT", 0, 11], ["sequential modified Bonferroni correction", "TREATMENT", 17, 58], ["multiple hypothesis testing", "TEST", 63, 90]]], ["Controlling the FDR instead of the Family Wise Error Rate in Bonferroni correction, Benjamini-Hochberg method is less stringent and increases the method's power (Benjamini & Hochberg, 2000; Benjamini & Yekutieli, 2001).", [["Error Rate in Bonferroni correction", "TREATMENT", 47, 82], ["Benjamini-Hochberg method", "TREATMENT", 84, 109]]], ["The smallest p-value is ranked one, next smallest is two, and the largest p-value has the rank of ten for ten tests, for example, then comparing each p-value to its Benjamni-Hochberg (BH) critical value.", [["ten tests", "TEST", 106, 115], ["smallest", "OBSERVATION_MODIFIER", 4, 12], ["p-value", "OBSERVATION", 13, 20], ["largest", "OBSERVATION_MODIFIER", 66, 73]]], ["This critical value is calculated using the formula, (i/m)Q, where i is the rank, m is the total number of tests, and Q is the false discovery rate.", [["tests", "TEST", 107, 112]]], ["The largest p-value, which is smaller than the BH critical value (p<(i/m)Q) are significant (Statistics How To, 2020).", [["largest", "OBSERVATION_MODIFIER", 4, 11], ["p-value", "OBSERVATION", 12, 19], ["smaller", "OBSERVATION_MODIFIER", 30, 37], ["significant", "OBSERVATION_MODIFIER", 80, 91]]], ["McDonald (2014) states that \u201call the p-values smaller that it are also significant, even the ones that are not less than their Benjamini-Hochberg critical value\u201d (pp. 254-260).STATISTICAL ANALYSIS ::: METHODSTo address the fourth research hypothesis, the percentages measuring participants' adherence for attending Internet and in person sessions were compared using proportion comparison for different total numbers using the formula,STATISTICAL ANALYSIS ::: METHODSwhere p1 is the proportion of attendance for group sessions,STATISTICAL ANALYSIS ::: METHODSp2 is the proportion of attendance for Internet sessions,STATISTICAL ANALYSIS ::: METHODSp is the proportion of attendance for total sessionsSTATISTICAL ANALYSIS ::: METHODSn1 and n2 are the number of total attendance for group and internet sessions, respectively.STATISTICAL ANALYSIS ::: METHODSAll statistical analyses used SPSS 26.0 and the significance level was set at .05.RESULTSThe results for demographic information included age, sex, ethnicity, marital status, affected side, and length of time since stroke are shown in Table 1.", [["stroke", "DISEASE", 1070, 1076], ["p1", "DNA", 473, 475], ["participants", "SPECIES", 277, 289], ["person", "SPECIES", 331, 337], ["total sessions", "TREATMENT", 686, 700], ["METHODSAll statistical analyses", "TEST", 848, 879], ["SPSS", "TEST", 885, 889], ["the significance level", "TEST", 899, 921], ["stroke", "PROBLEM", 1070, 1076], ["significant", "OBSERVATION_MODIFIER", 71, 82]]], ["The results show no significant differences between Group 1 (higher functioning) and Group 2 (lower functioning).", [["no", "UNCERTAINTY", 17, 19], ["significant", "OBSERVATION_MODIFIER", 20, 31]]], ["For months post stroke, both groups fit into the 24 to 36-month category post-stroke.RESULTSPretest comparison scores between Group 1 and Group 2 on functional outcome measures are detailed in Table 2.", [["stroke", "DISEASE", 16, 22], ["stroke", "DISEASE", 78, 84], ["stroke", "PROBLEM", 16, 22], ["stroke", "PROBLEM", 78, 84], ["functional outcome measures", "TREATMENT", 149, 176], ["stroke", "OBSERVATION", 16, 22], ["stroke", "OBSERVATION", 78, 84]]], ["Since there are eight tests, using Benjamini-Hochburg (BH) method, we used (i/8) * .05 to calculate the critical value, and the original p-value was compared with the BH critical value (The last column in Table 2).", [["eight tests", "TEST", 16, 27], ["Benjamini-Hochburg (BH) method", "TREATMENT", 35, 65]]], ["The results show that Group 1 had significantly better scores at pretest compared to those of Group 2 on all outcome measures except the FIM self-care portion.RESULTSTesting hypotheses 1-3, pre and posttest comparisons are shown in Table 3.", [["all outcome measures", "TREATMENT", 105, 125]]], ["Since we used 16 tests altogether, BH critical values were calculated using 16 tests (shown in the last column in Table 2).", [["16 tests", "TEST", 14, 22], ["BH critical values", "TEST", 35, 53], ["16 tests", "TEST", 76, 84]]], ["Both groups showed significant improvement for all outcome measures except for the timed WMFT and the grip strength sub-test of the WMFT for Group 1, and hand to box strength subtest for Group 2.RESULTSAdherence for Internet session and in-person group sessions are detailed in Table 4.", [["hand", "ANATOMY", 154, 158], ["hand", "ORGANISM_SUBDIVISION", 154, 158], ["all outcome measures", "TREATMENT", 47, 67], ["the timed WMFT", "TEST", 79, 93], ["the grip strength sub", "TEST", 98, 119], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["improvement", "OBSERVATION", 31, 42]]], ["The results show that the adherence for Internet sessions was higher, (84.5%) than in-person group session (75.3%).", [["person", "SPECIES", 86, 92]]], ["Z score for the proportion difference was 2.65 (p=.004), showing Internet session attendance was significantly higher than that for group sessions.DISCUSSIONThe addition of telehealth to a modified CIMT protocol is an innovative approach ensuring compliance, providing education for participants and families, and overcoming financial and transportation barriers.", [["participants", "SPECIES", 283, 295], ["Z score", "TEST", 0, 7], ["a modified CIMT protocol", "TREATMENT", 187, 211]]], ["Based on our findings, both high and low functioning participants demonstrated significant improvements across a variety of assessments that measured functional use and quality of use in the hemiparetic UE.", [["participants", "SPECIES", 53, 65], ["our findings", "TEST", 9, 21], ["high", "OBSERVATION_MODIFIER", 28, 32], ["significant", "OBSERVATION_MODIFIER", 79, 90], ["improvements", "OBSERVATION", 91, 103], ["hemiparetic UE", "ANATOMY", 191, 205]]], ["The protocol was adapted from the original design created by Taub et al. (1994), with an emphasis on retaining the three core components of CIMT including: intensive and graded use of affected limb, constraint of the unaffected limb, and the transfer package; use of the limb in daily activities.DISCUSSIONThe results showed significant improvements on both the amount of use and quality of use in functional participation measured by the Motor Activity Log (MAL) in a very similar manner for both higher and lower functioning groups.", [["limb", "ANATOMY", 193, 197], ["limb", "ANATOMY", 228, 232], ["limb", "ANATOMY", 271, 275], ["limb", "ORGANISM_SUBDIVISION", 193, 197], ["limb", "ORGANISM_SUBDIVISION", 228, 232], ["limb", "ORGANISM_SUBDIVISION", 271, 275], ["The protocol", "TREATMENT", 0, 12], ["affected limb", "PROBLEM", 184, 197], ["the transfer package", "TREATMENT", 238, 258], ["limb", "ANATOMY", 193, 197], ["limb", "ANATOMY", 228, 232], ["limb", "ANATOMY", 271, 275], ["significant", "OBSERVATION_MODIFIER", 325, 336], ["improvements", "OBSERVATION", 337, 349]]], ["There were no significant differences on the timed WMFT among the higher functioning group.", [["significant differences", "PROBLEM", 14, 37], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37]]], ["For the higher functioning group, it was observed during the posttest that they were more focused on the quality of their movements and their ability to achieve the desired actions on the WMFT as opposed to completing the functions with speed during the posttest sessions.DISCUSSIONFinally, for the strength sub-tests of the WMFT, Group 1 demonstrated a positive change in hand to box performance and Group 2 demonstrated a positive change in grip strength.", [["hand", "ANATOMY", 373, 377], ["hand", "ORGANISM_SUBDIVISION", 373, 377], ["grip", "ORGANISM_SUBDIVISION", 443, 447], ["the strength sub", "TEST", 295, 311], ["a positive change in hand to box performance", "PROBLEM", 352, 396], ["a positive change in grip strength", "PROBLEM", 422, 456], ["positive", "OBSERVATION", 354, 362], ["positive", "OBSERVATION_MODIFIER", 424, 432], ["change", "OBSERVATION", 433, 439], ["grip strength", "OBSERVATION", 443, 456]]], ["For the hand to box subtest, most of the participants in the higher functioning group demonstrated greater ability to raise the shoulder against resistance than the lower functioning group both at baseline and post intervention.DISCUSSIONResults for the WMFT and MAL in this study were similar to Page and Levine's (2007) MAL and WMFT scores except for the WMFT timed portion for Group 1.", [["hand", "ANATOMY", 8, 12], ["hand", "ORGANISM_SUBDIVISION", 8, 12], ["participants", "ORGANISM", 41, 53], ["shoulder", "ORGANISM_SUBDIVISION", 128, 136], ["MAL", "PROTEIN", 263, 266], ["participants", "SPECIES", 41, 53], ["intervention", "TREATMENT", 215, 227], ["this study", "TEST", 270, 280], ["WMFT scores", "TEST", 330, 341], ["the WMFT timed portion", "TREATMENT", 353, 375], ["shoulder", "ANATOMY", 128, 136]]], ["Page and Levine utilized a webcam and video-conferencing system to deliver a 10-week CIMT training program.", [["a 10-week CIMT training program", "TREATMENT", 75, 106]]], ["Additionally, the findings of this study were consistent in many areas with studies conducted by Taub et al. (2005), Lum et al. (2004), and Brennan et al. (2011).", [["this study", "TEST", 30, 40], ["studies", "TEST", 76, 83]]], ["These studies explored the efficacy of conducting telerehabilitation using platform technology that specifically monitored repetitive task performance and promoted motor re-learning through shaping.", [["These studies", "TEST", 0, 13], ["conducting telerehabilitation", "TREATMENT", 39, 68], ["platform technology", "TREATMENT", 75, 94], ["repetitive task performance", "TEST", 123, 150]]], ["Although our study did not have access to sophisticated technology platforms, the concepts of motor relearning and shaping were incorporated into the in-person and telehealth sessions.", [["our study", "TEST", 9, 18]]], ["The results suggest that the concepts of motor re-learning and shaping using telehealth resulted in similar functional improvements, regardless of the varying systems.DISCUSSIONIt is important to note the delineation of the data related to the months post-stroke for the participants.", [["stroke", "DISEASE", 256, 262], ["participants", "SPECIES", 271, 283], ["functional improvements", "OBSERVATION", 108, 131]]], ["The months post-stroke was in the 24-36-month range.", [["stroke", "DISEASE", 16, 22], ["stroke", "PROBLEM", 16, 22], ["stroke", "OBSERVATION", 16, 22]]], ["Significant gains were still made in the categories of WMFT (functional ability scale), the FMA-UE, the MAL (AOU, QOU), and FIM self-care, aligning with the results found by Wolf et al. (2008) who studied the effect of CIMT on hemiparesis 1-2 years after the onset of stroke.", [["CIMT", "DISEASE", 219, 223], ["hemiparesis", "DISEASE", 227, 238], ["stroke", "DISEASE", 268, 274], ["Significant gains", "PROBLEM", 0, 17], ["CIMT on hemiparesis", "PROBLEM", 219, 238], ["stroke", "PROBLEM", 268, 274], ["UE", "ANATOMY", 96, 98], ["hemiparesis", "OBSERVATION", 227, 238], ["stroke", "OBSERVATION", 268, 274]]], ["These findings are consistent with the premise that individuals with chronic stroke suppress the use of the affected UE resulting in \u201clearned non-use\u201d and intensive training in the use of the affected limb results in cortical reorganization and functional improvements (Page et al., 2004).DISCUSSIONBoth groups significantly improved in FIM scores for self-care tasks.DISCUSSIONIn our study, the lower functioning group reported at baseline that they relied on a caregiver to do the task if it was too difficult.", [["limb", "ANATOMY", 201, 205], ["cortical", "ANATOMY", 217, 225], ["chronic stroke", "DISEASE", 69, 83], ["UE", "DISEASE", 117, 119], ["limb", "ORGANISM_SUBDIVISION", 201, 205], ["cortical", "MULTI-TISSUE_STRUCTURE", 217, 225], ["chronic stroke", "PROBLEM", 69, 83], ["the affected UE", "PROBLEM", 104, 119], ["intensive training", "TREATMENT", 155, 173], ["cortical reorganization", "PROBLEM", 217, 240], ["our study", "TEST", 381, 390], ["consistent with", "UNCERTAINTY", 19, 34], ["chronic", "OBSERVATION_MODIFIER", 69, 76], ["stroke", "OBSERVATION", 77, 83], ["affected limb", "ANATOMY", 192, 205], ["cortical reorganization", "OBSERVATION", 217, 240]]], ["It is possible that they may have learned how to be more encouraging with their significant others and step back from \u201cdoing the task\u201d for their loved one.DISCUSSIONMany studies do not show significant improvement for ADLs since individuals tend to compensate using the unaffected to perform daily tasks (Ploughman & Corbett, 2004).", [["DISCUSSIONMany studies", "TEST", 155, 177], ["significant", "OBSERVATION_MODIFIER", 190, 201], ["improvement", "OBSERVATION", 202, 213]]], ["However, we speculate that in addition to caregiver education, our study participants became more actively engaged in ADLs because of the emphasis in our program on problem solving and learning new ways of performing tasks (Almhdawi et al., 2014; Chan et al., 2006; Sabari et al., 2014).", [["participants", "SPECIES", 73, 85], ["caregiver education", "TREATMENT", 42, 61], ["our study", "TEST", 63, 72]]], ["We do not know what instructions were discussed with study participants in other studies; however, we believe not only emphasizing repetition but also introducing a new mind-set should be part of CIMT training.", [["participants", "SPECIES", 59, 71], ["other studies", "TEST", 75, 88], ["CIMT training", "TREATMENT", 196, 209]]], ["A decline in ADL abilities has been associated with depression (Tomita et al., 2004), whereas; engagement in either telehealth or monitored home programs has been shown to decrease depression in individuals post stroke (Linder et al., 2015).DISCUSSIONFinally, although this study combined traditional in-person group therapy and home-based individual therapy utilizing the Internet, when we compared attendance rates, the Internet sessions were attended with greater consistency compared to the group sessions.", [["depression", "DISEASE", 52, 62], ["depression", "DISEASE", 181, 191], ["stroke", "DISEASE", 212, 218], ["A decline in ADL abilities", "PROBLEM", 0, 26], ["depression", "PROBLEM", 52, 62], ["depression", "PROBLEM", 181, 191], ["stroke", "PROBLEM", 212, 218], ["this study", "TEST", 269, 279], ["group therapy", "TREATMENT", 311, 324], ["home-based individual therapy", "TREATMENT", 329, 358], ["decline", "OBSERVATION_MODIFIER", 2, 9]]], ["The telehealth approach allowed for increased flexibility which facilitated adherence to the program.", [["The telehealth approach", "TREATMENT", 0, 23], ["increased flexibility", "PROBLEM", 36, 57]]], ["By implementing video-conferencing sessions, the participants were able to engage in therapy sessions from the comfort of their own homes.", [["participants", "SPECIES", 49, 61], ["therapy sessions", "TREATMENT", 85, 101]]], ["This largely eliminated the need to travel as frequently as traditional therapy requires, making this an accessible way to deliver services to individuals in the future.", [["traditional therapy", "TREATMENT", 60, 79]]], ["This was a benefit for our participants since this program was conducted during the winter months in a Northeastern city.", [["participants", "SPECIES", 27, 39]]], ["Participants were encouraged to engage in meaningful activities in their natural home environments.", [["Participants", "SPECIES", 0, 12]]], ["However, we do not conclude that in-person group therapy can be eliminated.DISCUSSIONTelehealth programs have limitations including the fact that therapists are unable to provide hands on guidance and must rely on verbal instruction and visual demonstration for the participant to understand the exercise or activity.", [["therapy", "TREATMENT", 49, 56], ["DISCUSSIONTelehealth programs", "TREATMENT", 75, 104]]], ["In-person group sessions once a week allowed the opportunity to assess participants' progress accurately, provide tactile guidance, and make appropriate recommendations for future sessions.", [["person", "SPECIES", 3, 9], ["participants", "SPECIES", 71, 83]]], ["The two Internet sessions per week lessened the burden on participants and caregivers for transportation; meanwhile, the once per week in-person sessions provided the hands-on therapeutic interaction between the therapists and participants.", [["participants", "SPECIES", 58, 70], ["participants", "SPECIES", 227, 239], ["hands", "ANATOMY", 167, 172]]], ["An additional component was the opportunity for participants to engage in social interaction, an important component in recovery.", [["participants", "SPECIES", 48, 60]]], ["This opportunity may have provided further encouragement for them to continue home-based telehealth sessions, providing a notion that they are not alone in doing it.", [["home-based telehealth sessions", "TREATMENT", 78, 108]]], ["Comparison of the effectiveness of this combined approach and the cost of delivery are encouraged for future studies.DISCUSSIONA major limitation for most CIMT studies pertains to the strict inclusion criteria, which is derived and modified from the traditional CIMT approach.", [["this combined approach", "TREATMENT", 35, 57], ["delivery", "TREATMENT", 74, 82], ["future studies", "TEST", 102, 116], ["most CIMT studies", "TEST", 150, 167], ["the traditional CIMT approach", "TREATMENT", 246, 275]]], ["The strict inclusion criteria result in difficulty with recruitment of participants, and it excludes willing participants who desire to regain function of their affected UE; however, studies have been conducted with participants who do not meet the criteria for hand function.", [["hand", "ANATOMY", 262, 266], ["hand", "ORGANISM_SUBDIVISION", 262, 266], ["participants", "SPECIES", 71, 83], ["participants", "SPECIES", 109, 121], ["participants", "SPECIES", 216, 228], ["The strict inclusion criteria", "TEST", 0, 29]]], ["Taub et al. (1999) report improvements in real world function for participants who are lower functioning.", [["participants", "SPECIES", 66, 78]]], ["This study included participants who did not meet the criteria for CIMT studies and improvements in UE function was achieved.DISCUSSIONThe American Occupational Therapy Association's (AOTA) position on telehealth sets guidelines for the delivery of occupational therapy services using telehealth to promote participation (AOTA, 2018).", [["participants", "SPECIES", 20, 32], ["This study", "TEST", 0, 10], ["CIMT studies", "TEST", 67, 79], ["UE function", "TEST", 100, 111], ["occupational therapy services", "TREATMENT", 249, 278]]], ["The occupational therapy practitioner must adhere to occupational therapy practice guidelines and ethical practice whether in-person or using web-based technologies to provide services.", [["The occupational therapy practitioner", "TREATMENT", 0, 37], ["occupational therapy", "TREATMENT", 53, 73]]], ["We found that many times family members were willing to assist participants and set them up with the technology and join in with them during the session.", [["participants", "SPECIES", 63, 75]]], ["We observed that spousal support was valuable, especially for our lower functioning group, and they benefitted from the interactions with their spouses/significant others throughout our sessions.", [["spousal support", "TREATMENT", 17, 32]]], ["Spouses and significant others were encouraged to provide thoughtful and creative problem-solving opportunities for the participants and to assist them with the technologies that were new to them or unfamiliar.", [["participants", "SPECIES", 120, 132]]], ["Therefore, we suggest that a family-centered approach is important for post stroke therapy and telehealth is an integral element for the approach.CONCLUSIONBy combining mCIMT with telehealth and traditional group rehabilitation, our study demonstrated statistically significant improvements in function as well as the participants' perceived use of hemiparetic upper extremity for both higher and lower functioning participants.", [["upper extremity", "ANATOMY", 361, 376], ["stroke", "DISEASE", 76, 82], ["hemiparetic", "ORGANISM_SUBDIVISION", 349, 360], ["upper extremity", "ORGANISM_SUBDIVISION", 361, 376], ["participants", "SPECIES", 318, 330], ["participants", "SPECIES", 415, 427], ["a family-centered approach", "TREATMENT", 27, 53], ["post stroke therapy", "TREATMENT", 71, 90], ["the approach", "TREATMENT", 133, 145], ["telehealth", "TREATMENT", 180, 190], ["traditional group rehabilitation", "TREATMENT", 195, 227], ["our study", "TEST", 229, 238], ["hemiparetic upper extremity", "TREATMENT", 349, 376], ["significant", "OBSERVATION_MODIFIER", 266, 277], ["improvements", "OBSERVATION", 278, 290], ["upper extremity", "ANATOMY", 361, 376], ["lower functioning", "OBSERVATION_MODIFIER", 397, 414]]], ["Future studies should utilize a larger sample size to improve generalizability and the addition of a control group for a higher level of evidence.", [["Future studies", "TEST", 0, 14], ["a larger sample size", "TREATMENT", 30, 50], ["a control group", "TREATMENT", 99, 114]]], ["In addition, follow up assessment after a three-month period would determine if the gains made in the program were sustained.", [["follow up assessment", "TEST", 13, 33]]], ["We further recommend that future researchers consider the use of group therapy telehealth sessions to improve participation, motivation, socialization, and group comradery.", [["group therapy telehealth sessions", "TREATMENT", 65, 98]]]], "1bd626c6e2bf333c14247fa3e4781bf8764caf3c": [["IntroductionThe COVID-19 pandemic has rapidly caused an enormous worldwide medical and socioeconomic impact since the first case emerged on November 16th 2019 [1] .", [["The COVID", "TREATMENT", 12, 21], ["enormous", "OBSERVATION_MODIFIER", 56, 64], ["worldwide", "OBSERVATION_MODIFIER", 65, 74]]], ["Although a self-limiting illness for most, the percentage of COVID-19 patients with hypoxaemic respiratory failure requiring ICU admission for mechanical ventilation translates into large numbers which may challenge healtcare provision.", [["respiratory", "ANATOMY", 95, 106], ["self-limiting illness", "DISEASE", 11, 32], ["respiratory failure", "DISEASE", 95, 114], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["a self-limiting illness", "PROBLEM", 9, 32], ["COVID", "TEST", 61, 66], ["hypoxaemic respiratory failure", "PROBLEM", 84, 114], ["mechanical ventilation", "TREATMENT", 143, 165], ["hypoxaemic", "OBSERVATION_MODIFIER", 84, 94], ["respiratory failure", "OBSERVATION", 95, 114], ["mechanical ventilation", "OBSERVATION", 143, 165]]], ["In Northern Italy, an exponential increase in COVID-19 admissions rapidly overwhelmed normal ICU capacity [2] and surge capacity had to be created quickly.", [["surge capacity", "PROBLEM", 114, 128], ["exponential", "OBSERVATION_MODIFIER", 22, 33], ["increase", "OBSERVATION_MODIFIER", 34, 42]]], ["The exact reason for the sudden need for ICU surge capacity in Italy, and whether this will generalise to other countries, is unclear, but both demographic factors and healthcare system structure are likely to be important.", [["likely to be", "UNCERTAINTY", 200, 212]]], ["Whilst standard acute wards may be re-purposed easily, creating ICU capacity is constrained by the need for complex equipment and the delivery of highly specialised medical and nursing care.", [["complex equipment", "TREATMENT", 108, 125], ["nursing care", "TREATMENT", 177, 189], ["acute", "OBSERVATION_MODIFIER", 16, 21]]], ["Nevertheless, there are mechanisms by which ICU capacity could be increased in an emergency, including facilitating ICU discharge of recovering patients through liberating downstream beds by reducing elective work, by stopping elective work likely to require ICU admission, or by changing referral policies.", [["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152]]], ["Furthermore, since ICUs in the UK typically undertake a high proportion of emergency work, much of which will continue despite the pandemic, and since occupancy is typically well above 80%, such strategies are likely to result in only a relatively modest increase in capacity.", [["the pandemic", "PROBLEM", 127, 139], ["a relatively modest increase in capacity", "PROBLEM", 235, 275], ["modest", "OBSERVATION_MODIFIER", 248, 254], ["increase", "OBSERVATION_MODIFIER", 255, 263]]], ["A greater increase in emergency physical capacity for mechanical ventilation could be achieved by opening new level 3 beds with additional equipment (e.g. operating theatre ventilators).", [["A greater increase in emergency physical capacity", "PROBLEM", 0, 49], ["mechanical ventilation", "TREATMENT", 54, 76], ["additional equipment", "TREATMENT", 128, 148], ["operating theatre ventilators", "TREATMENT", 155, 184], ["greater", "OBSERVATION_MODIFIER", 2, 9], ["increase", "OBSERVATION_MODIFIER", 10, 18]]], ["This requires significant changes to infrastructure, processes, or sta ng and is therefore logistically complex, expensive, and most importantly slow to implement.", [["significant", "OBSERVATION_MODIFIER", 14, 25]]], ["The explosion of cases seen in Italy means that an early warning of need for surge capacity is likely to be required in other countries including England.IntroductionEpidemiological simulation has previously been successful in predicting the need for surge H1N1 ICU capacity in 2009 [4, 5] .", [["surge capacity", "PROBLEM", 77, 91]]], ["In recent days, a similar simulation model for COVID-19 has been described [6] , which suggests an overwhelming demand for critical care, with a peak occurring between May and early June 2020 and lasting 2 to 3 months depending on non-pharmacological intervention (NPI) assumptions.", [["COVID", "TEST", 47, 52], ["non-pharmacological intervention", "TREATMENT", 231, 263], ["overwhelming", "OBSERVATION", 99, 111]]], ["Such projected timescales are unlikely to be reliable and are unsuitable for real-time surveillance and early warning.", [["unlikely to be", "UNCERTAINTY", 30, 44]]], ["In this paper we use published COVID-19 diagnosis data for England to generate the earliest possible estimates of additional ICU demand due to infections in the coming days, based on cautious epidemiological data from the literature and under the assumption that the current increase in cases represents the exponential phase of an outbreak rather than a change in ascertainment.", [["infections", "DISEASE", 143, 153], ["infections", "PROBLEM", 143, 153], ["infections", "OBSERVATION", 143, 153], ["exponential", "OBSERVATION_MODIFIER", 308, 319], ["phase", "OBSERVATION_MODIFIER", 320, 325]]], ["We started to extract this data feed on 13/03/20 to give daily case data.", [["this data feed", "TREATMENT", 22, 36]]], ["Figure 2: Regional demographics and expected critical care demand per case of COVID-19, stratified by region and compared to ICU bed capacity per 100,000 people.", [["people", "SPECIES", 154, 160], ["COVID", "TEST", 78, 83]]], ["The numerical data can be seen in Table 1 .MethodsWe assumed that the daily incidence of COVID-19 can be modelled as an exponential growth (in line with what was observed in Italy [2] ).", [["COVID-19", "CHEMICAL", 89, 97], ["COVID-19", "CHEMICAL", 89, 97], ["The numerical data", "TEST", 0, 18], ["COVID", "TEST", 89, 94], ["growth", "OBSERVATION_MODIFIER", 132, 138]]], ["Therefore, we forecast the likely distributions of new COVID-19 diagnoses over the next 14 days by using an ordinary least squares fit to linearly extrapolate from the logarithm of the cumulative cases.", [["COVID", "DNA", 55, 60], ["new COVID-19 diagnoses", "PROBLEM", 51, 73], ["new", "OBSERVATION_MODIFIER", 51, 54]]], ["We di\u21b5erentiated the cumulative model to obtain a daily incidence model i.e. we multiply by the exponent ( d dx \u21e5 Ae Bx \u21e4 = BAe Bx ), which stabilises the exponent fitting (B).MethodsUsing early data from Verity et al. 2020 [9] (reproduced in Table 1 ), we estimated the ICU admission rate by standardising to the local population in each NHS commissioning region in England (see Figure 2 , obtained from the Clinical Commissioning Group population estimates for mid-2018 [10] ).", [["Bx", "PROTEIN", 117, 119], ["BAe Bx", "PROTEIN", 124, 130], ["Ae Bx", "TEST", 114, 119], ["BAe Bx", "TEST", 124, 130]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not peer-reviewed)The copyright holder for this preprint . https://doi.org/10.1101/2020.03.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 184, 204], ["this preprint", "TREATMENT", 209, 222], ["med", "ANATOMY", 99, 102]]], ["19 Overall, Figure 4 shows predictions that will challenge ICU capacity in all areas, particularly in populous regions.", [["populous", "ANATOMY_MODIFIER", 102, 110]]], ["London and the Midlands will gain a number of COVID-19 patients equi-valent to 100% standard capacity within 14 days for slightly di\u21b5erent reasons.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["COVID", "TEST", 46, 51], ["slightly di\u21b5erent reasons", "PROBLEM", 121, 146]]], ["Whereas in the Midlands, due to an increased average age, a higher percentage of ICU admissions is predicted (see Table 1 ), which combined with a higher number of cases than other regions will lead to exhausted capacity.", [["exhausted capacity", "PROBLEM", 202, 220], ["increased", "OBSERVATION_MODIFIER", 35, 44], ["average", "OBSERVATION_MODIFIER", 45, 52]]], ["As normal occupancy is often above 80%, even the additional minimum capacity due to COVID-19 of 20% in other regions will prove to be di cult to 5 .", [["COVID", "TEST", 84, 89], ["di cult", "TEST", 134, 141], ["normal", "OBSERVATION", 3, 9]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not peer-reviewed)The copyright holder for this preprint . https://doi.org/10.1101/2020.03.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 184, 204], ["this preprint", "TREATMENT", 209, 222], ["med", "ANATOMY", 99, 102]]], ["The figure illustrates the large regional variation in projected ICU occupancy, with London and the Midlands reaching near 100% additional capacity due to COVID-19 within 14 days, whereas areas such as the South West and South East will only have approximately 20% of their beds occupied by COVID-19 patients.DiscussionIn this study we demonstrate how publicly available data can be rapidly combined to dynamic-6 .", [["patients", "ORGANISM", 300, 308], ["patients", "SPECIES", 300, 308], ["the large regional variation", "PROBLEM", 23, 51], ["COVID", "TEST", 155, 160], ["this study", "TEST", 322, 332], ["large", "OBSERVATION_MODIFIER", 27, 32], ["regional", "OBSERVATION_MODIFIER", 33, 41], ["variation", "OBSERVATION_MODIFIER", 42, 51], ["projected", "OBSERVATION_MODIFIER", 55, 64], ["ICU occupancy", "OBSERVATION", 65, 78]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not peer-reviewed)The copyright holder for this preprint . https://doi.org/10.1101/2020.03.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 184, 204], ["this preprint", "TREATMENT", 209, 222], ["med", "ANATOMY", 99, 102]]], ["19.20039057 doi: medRxiv preprint ally model short-term ICU requirements in light of the emerging COVID-19 pandemic.", [["pandemic", "PROBLEM", 107, 115]]], ["Our data suggests that traditional ICU capacity could be rapidly consumed over a period of approximately 14 days from the time of modelling/writing, such figures hide substantial regional heterogeneity, with London and the Midlands demonstrating the most rapid growth.", [["Our data", "TEST", 0, 8], ["traditional ICU capacity", "PROBLEM", 23, 47], ["substantial regional heterogeneity", "PROBLEM", 167, 201], ["substantial", "OBSERVATION_MODIFIER", 167, 178], ["regional", "OBSERVATION_MODIFIER", 179, 187], ["heterogeneity", "OBSERVATION", 188, 201]]], ["Within the current acute stage of this pandemic, we hope our findings provide a framework to facilitate the rapid development and deployment of additional ICU surge capacity as was required within days of the Italian pandemic [2] .(which was not peer-reviewed)In the future, we feel that our methodological approach (use of emerging epidemic curve data, Monte Carlo simulation, and population standardisation), as well as our simultaneous deployment of an interactive and dynamically updated web-tool have merit in modelling and communicating any future dynamically emerging event.(which was not peer-reviewed)However, we do recognise that as with all models our is subject to significant assumptions and limitations.", [["additional ICU surge capacity", "TREATMENT", 144, 173], ["epidemic curve data", "TEST", 333, 352], ["acute", "OBSERVATION_MODIFIER", 19, 24]]], ["Both model and parameter uncertainties are inevitable, particularly when predicting the behaviour of a novel virus in a new population, and this may radically a\u21b5ect our forecasts.(which was not peer-reviewed)Nevertheless, we set out to provide the earliest possible data-driven forecast and therefore explicitly accept the limitations of the data that were available to us at the time.", [["a novel virus", "PROBLEM", 101, 114], ["the data", "TEST", 338, 346], ["parameter uncertainties", "OBSERVATION", 15, 38]]], ["With the small amount of available data, there are some specific limitations which need to be discussed.", [["small", "OBSERVATION_MODIFIER", 9, 14], ["amount", "OBSERVATION_MODIFIER", 15, 21]]], ["Our use of an updated, online resource we hope is a novel way of allowing interested parties to interact with the mathematical assumptions and formulate their own opinions.(which was not peer-reviewed)We have used PHE published data for case ascertainment.", [["PHE", "CHEMICAL", 214, 217]]], ["However, being as our explicit aim is to model the most severe cases, the e\u21b5ect of any ascertainment bias on our findings should be minimised due to the roll-out of routine testing for all critical care patients as part of the \"COVID Hospitalisation in England Surveillance System-CHESS\" [18] .", [["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 203, 211], ["any ascertainment bias", "PROBLEM", 83, 105], ["routine testing", "TEST", 165, 180]]], ["Specifically, at the time of writing, test capacity for COVID-19(which was not peer-reviewed)in the UK has led to stringent requirements for testing with only cases requiring hospitalisation being routinely tested [16] .", [["test capacity", "TEST", 38, 51], ["COVID", "TEST", 56, 61], ["testing", "TEST", 141, 148]]], ["By incorporating a 'delay to ICU' parameter within our model, that can take on negative values (thus indicating a diagnosis after ICU admission), we hope to have replicated the anecdotal experience of clinicians in these early phases of the pandemic; that a substantial proportion of patients are being con- forecast numbers as these data inform our standardised estimates of ICU cases from within each population [9] .", [["patients", "ORGANISM", 284, 292], ["patients", "SPECIES", 284, 292]]], ["If the upturn in COVID-19 cases seen at the time of writing is largely driven by increased or altered ascertainment rather than a true rise in cases, 7 .", [["COVID", "TEST", 17, 22], ["a true rise in cases", "PROBLEM", 128, 148]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not peer-reviewed)The copyright holder for this preprint .(which was not peer-reviewed)then this would render our model overly pessimistic.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 184, 204], ["med", "ANATOMY", 99, 102]]], ["Nevertheless, this will always be a limitation of any early modelling [9] .(which was not peer-reviewed)Although we have resolved ICU admissions to the level of a commissioning region, this assumes that each region behaves as a homogeneously allocated 'pool' of ICU beds, which is not necessarily true because inter-hospital ICU-to-ICU transfers may not be feasible for both operational and clinical reasons.", [["ICU beds", "TREATMENT", 262, 270], ["not necessarily", "UNCERTAINTY", 281, 296]]], ["In this sense our predictions represent a 'best case' scenario and cannot be used for decision making at the level of an individual unit.(which was not peer-reviewed)Building on this theme, we forecast the percentage of COVID-19 bed requirements in isolation, figures which do not reflect competing ICU burden.", [["COVID-19 bed requirements", "TREATMENT", 220, 245]]], ["Since UK bed occupancy is typically greater than 80% and may frequently exceed 100% [7] , clearly not all beds can simply be re-allocated for COVID-19 patients.", [["UK", "GENE_OR_GENE_PRODUCT", 6, 8], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["greater", "OBSERVATION_MODIFIER", 36, 43]]], ["This may be especially true for specialist ICUs (e.g. neuroscience or cardiac) which may not be able to entirely reconfigure, or high-dependency beds which may not be able to provide mechanical ventilation routinely.", [["cardiac", "ANATOMY", 70, 77], ["cardiac", "ORGAN", 70, 77], ["high-dependency beds", "PROBLEM", 129, 149], ["mechanical ventilation", "TREATMENT", 183, 205]]], ["Furthermore, we assumed that all adult critical care bed spaces can be used for mechanically ventilated ICU patients, which operationally may not be possible for a variety of reasons including equipment and sta\u21b5 availability.", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116]]], ["Thus, the precise percentage of additional COVID-19 patients that will actually exhaust routine capacity will vary from unit to unit, particularly in ICUs with a substantial postoperative elective surgical workload.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["a substantial postoperative elective surgical workload", "TREATMENT", 160, 214]]], ["Finally, front-line clinicians reviewing our results in these early days of the pandemic will highlight the disconnect between our estimated 'confirmed' cases and the substantial operational workload that is being created by treating all suspicious cases of respiratory failure as COVID-19 until proven otherwise.(which was not peer-reviewed)At the time of writing, the potential challenge that faces the health system (including intensive care) is essentially without precedent and has resulted in social and political interventions that have never been seen in peacetime.", [["respiratory", "ANATOMY", 258, 269], ["respiratory failure", "DISEASE", 258, 277], ["respiratory failure", "PROBLEM", 258, 277], ["COVID", "TEST", 281, 286], ["political interventions", "TREATMENT", 510, 533], ["respiratory failure", "OBSERVATION", 258, 277]]], ["We hope that regardless of the assumptions inherent within our model (which we feel are based on best available data) that the overarching message of the need for urgent surge capacity is timely.", [["urgent surge capacity", "TREATMENT", 163, 184]]], ["Finally, we hope that our transparency in releasing our code, model assumptions, and results in a dynamic web format embodies a new paradigm in rapidly developed and reviewed science that persists beyond the current pandemic.ConclusionsEarly warning of an impending need for ICU surge capacity is crucial if there is to be sufficient time to re-configure services.", [["ICU surge capacity", "TREATMENT", 275, 293], ["new", "OBSERVATION_MODIFIER", 128, 131]]], ["There remains a significant degree of uncertainty in the predictions due both to limitations of the reporting data and modelling assumptions.", [["the reporting data", "TEST", 96, 114], ["modelling assumptions", "TEST", 119, 140], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["degree", "OBSERVATION_MODIFIER", 28, 34], ["uncertainty", "OBSERVATION", 38, 49]]], ["This emphasises the need for the collection of real-time patient-facing local data by initiatives such as CHESS [18] and a dynamic approach to improving models as new data becomes available.ConclusionsDeclarations of interest statement None declared.Conclusions.", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["a dynamic approach", "TREATMENT", 121, 139]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Conclusions(which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.03.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 196, 216], ["this preprint", "TREATMENT", 221, 234], ["med", "ANATOMY", 99, 102]]]], "PMC3294738": [["Nosocomial TB in IndiaIndia has more TB patients than any other country (20) and accounts for one fifth of the world's incident TB cases (21); the reported incidence in 2003 was 168 per 100,000 (20).", [["TB", "DISEASE", 11, 13], ["IndiaIndia", "CHEMICAL", 17, 27], ["TB", "DISEASE", 37, 39], ["TB", "DISEASE", 128, 130], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["Nosocomial TB", "PROBLEM", 0, 13], ["TB cases", "TEST", 128, 136], ["TB", "OBSERVATION", 11, 13]]], ["Every year, TB develops in nearly 2 million persons in India, and nearly 1 million cases are smear positive; an estimated 40% of the Indian population is latently infected with M. tuberculosis (21).", [["TB", "DISEASE", 12, 14], ["M. tuberculosis", "DISEASE", 177, 192], ["M. tuberculosis", "ORGANISM", 177, 192], ["persons", "SPECIES", 44, 51], ["M. tuberculosis", "SPECIES", 177, 192], ["M. tuberculosis", "SPECIES", 177, 192], ["TB", "PROBLEM", 12, 14], ["smear positive", "PROBLEM", 93, 107], ["M. tuberculosis", "PROBLEM", 177, 192], ["latently", "OBSERVATION_MODIFIER", 154, 162], ["infected", "OBSERVATION_MODIFIER", 163, 171], ["tuberculosis", "OBSERVATION", 180, 192]]], ["India's Revised National TB Control Programme (RNTCP) now provides access to DOTS for >85% of the population (21).", [["TB", "DISEASE", 25, 27]]], ["This program is the fastest expanding DOTS program in the world and the largest in the world in terms of patients receiving initial treatment (21).", [["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["initial treatment", "TREATMENT", 124, 141], ["largest", "OBSERVATION_MODIFIER", 72, 79]]], ["Outside of the RNTCP, India has a large private health sector that is actively involved in providing TB care (23,24); almost half of patients with TB in India initially seek care from the private sector (22).", [["TB", "DISEASE", 101, 103], ["TB", "DISEASE", 147, 149], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["TB", "PROBLEM", 147, 149], ["large", "OBSERVATION_MODIFIER", 34, 39]]], ["Thus, because Indian healthcare workers see large numbers of TB patients and because large numbers of TB patients are hospitalized (25), the risk for nosocomial exposure is substantial.Nosocomial TB in IndiaDespite the prevalence of TB in India and the expected high probability of nosocomial transmission, little is known about nosocomial TB.", [["TB", "DISEASE", 61, 63], ["TB", "DISEASE", 102, 104], ["TB", "DISEASE", 196, 198], ["TB", "DISEASE", 233, 235], ["nosocomial transmission", "DISEASE", 282, 305], ["TB", "DISEASE", 340, 342], ["patients", "ORGANISM", 64, 72], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 105, 113], ["nosocomial exposure", "PROBLEM", 150, 169], ["Nosocomial TB", "PROBLEM", 185, 198], ["TB", "PROBLEM", 233, 235], ["nosocomial transmission", "PROBLEM", 282, 305], ["nosocomial TB", "PROBLEM", 329, 342], ["large", "OBSERVATION_MODIFIER", 44, 49], ["large", "OBSERVATION_MODIFIER", 85, 90], ["numbers", "OBSERVATION_MODIFIER", 91, 98], ["nosocomial exposure", "OBSERVATION", 150, 169], ["substantial", "OBSERVATION_MODIFIER", 173, 184], ["TB", "OBSERVATION", 196, 198], ["TB", "OBSERVATION", 233, 235], ["high", "OBSERVATION_MODIFIER", 262, 266], ["nosocomial", "OBSERVATION", 282, 292]]], ["In fact, until 2004, no studies on nosocomial TB in India had been published.", [["TB", "DISEASE", 46, 48], ["nosocomial TB", "PROBLEM", 35, 48]]], ["Table 1 summarizes the results of recent studies on TB among healthcare workers from 3 large tertiary hospitals (26\u201330).", [["TB", "DISEASE", 52, 54], ["recent studies", "TEST", 34, 48]]], ["These studies provide some data on the incidence of active TB (28,29), prevalence of latent TB infection (26), risk factors for active TB (30), and annual risk for latent TB infection among healthcare workers (27).", [["TB", "DISEASE", 59, 61], ["latent TB infection", "DISEASE", 85, 104], ["TB", "DISEASE", 135, 137], ["TB infection", "DISEASE", 171, 183], ["These studies", "TEST", 0, 13], ["active TB", "PROBLEM", 52, 61], ["latent TB infection", "PROBLEM", 85, 104], ["active TB", "PROBLEM", 128, 137], ["latent TB infection", "PROBLEM", 164, 183], ["active", "OBSERVATION_MODIFIER", 52, 58], ["TB", "OBSERVATION", 59, 61], ["latent", "OBSERVATION_MODIFIER", 85, 91], ["TB", "OBSERVATION_MODIFIER", 92, 94], ["infection", "OBSERVATION", 95, 104], ["latent", "OBSERVATION_MODIFIER", 164, 170], ["TB", "OBSERVATION", 171, 173]]], ["In addition, another recent study documented person-to-person transmission of TB among hospitalized patients (31).Nosocomial TB in IndiaAt a rural medical school hospital in Sevagram, Pai et al. performed the tuberculin skin test (TST) and a whole-blood interferon-\u03b3 release assay (IGRA) for 726 healthcare workers (26); 50% were positive by either TST or IGRA.", [["skin", "ANATOMY", 220, 224], ["blood", "ANATOMY", 248, 253], ["TB", "DISEASE", 78, 80], ["TB", "DISEASE", 125, 127], ["patients", "ORGANISM", 100, 108], ["skin", "ORGAN", 220, 224], ["blood", "ORGANISM_SUBSTANCE", 248, 253], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 254, 266], ["interferon", "PROTEIN", 254, 264], ["\u03b3", "PROTEIN", 265, 266], ["IGRA", "PROTEIN", 356, 360], ["person", "SPECIES", 45, 51], ["person", "SPECIES", 55, 61], ["patients", "SPECIES", 100, 108], ["another recent study", "TEST", 13, 33], ["Nosocomial TB", "PROBLEM", 114, 127], ["the tuberculin skin test", "TEST", 205, 229], ["TST", "TEST", 231, 234], ["a whole-blood interferon", "TREATMENT", 240, 264], ["IGRA", "TEST", 356, 360], ["TB", "OBSERVATION", 125, 127], ["skin", "ANATOMY", 220, 224]]], ["Nearly 70% of the participants reported direct contact with sputum smear\u2013positive TB patients.", [["TB", "DISEASE", 82, 84], ["participants", "ORGANISM", 18, 30], ["patients", "ORGANISM", 85, 93], ["participants", "SPECIES", 18, 30], ["patients", "SPECIES", 85, 93]]], ["Increasing age and duration of employment were risk factors for latent TB infection.", [["TB infection", "DISEASE", 71, 83], ["risk factors", "PROBLEM", 47, 59], ["latent TB infection", "PROBLEM", 64, 83], ["TB", "OBSERVATION_MODIFIER", 71, 73], ["infection", "OBSERVATION", 74, 83]]], ["Nurses, nursing students, orderlies, and laboratory staff had higher prevalence of latent infection (26).", [["infection", "DISEASE", 90, 99], ["latent infection", "PROBLEM", 83, 99], ["latent", "OBSERVATION_MODIFIER", 83, 89], ["infection", "OBSERVATION", 90, 99]]], ["A repeat survey of 216 medical and nursing students in this cohort enabled estimation of the annual risk for latent infection by using TST and IGRA (27).", [["infection", "DISEASE", 116, 125], ["A repeat survey", "TEST", 0, 15], ["latent infection", "PROBLEM", 109, 125], ["TST", "TEST", 135, 138], ["IGRA", "TEST", 143, 147], ["latent", "OBSERVATION_MODIFIER", 109, 115], ["infection", "OBSERVATION", 116, 125]]], ["When both tests were used, the annual risk for latent TB infection was estimated to be 5% (27).", [["TB infection", "DISEASE", 54, 66], ["both tests", "TEST", 5, 15], ["latent TB infection", "PROBLEM", 47, 66], ["latent", "OBSERVATION_MODIFIER", 47, 53], ["TB", "OBSERVATION_MODIFIER", 54, 56], ["infection", "OBSERVATION", 57, 66]]], ["The estimated community-based annual risk for infection in India is 1.5% (32), so the excess risk of 3.5% may be attributable to nosocomial exposure.Nosocomial TB in IndiaAt a tertiary care hospital in Chandigarh, Rao et al. estimated the incidence of active TB among resident physicians (28).", [["infection", "DISEASE", 46, 55], ["TB", "DISEASE", 160, 162], ["TB", "DISEASE", 259, 261], ["infection", "PROBLEM", 46, 55], ["nosocomial exposure", "PROBLEM", 129, 148], ["Nosocomial TB", "PROBLEM", 149, 162], ["community", "OBSERVATION_MODIFIER", 14, 23], ["infection", "OBSERVATION", 46, 55], ["may be attributable to", "UNCERTAINTY", 106, 128], ["nosocomial exposure", "OBSERVATION", 129, 148], ["TB", "OBSERVATION", 160, 162], ["active", "OBSERVATION_MODIFIER", 252, 258], ["TB", "OBSERVATION", 259, 261]]], ["Among residents already working in the hospital, TB developed in 9 (2%) of 470, for an incidence of 11.2 new cases per 1,000 person-years of exposure.", [["TB", "DISEASE", 49, 51], ["TB", "PROBLEM", 49, 51]]], ["Extrapulmonary disease developed in two thirds of the residents.", [["Extrapulmonary", "ANATOMY", 0, 14], ["Extrapulmonary disease", "DISEASE", 0, 22], ["Extrapulmonary disease", "PROBLEM", 0, 22], ["disease", "OBSERVATION", 15, 22]]], ["Overall, this study showed a high rate of TB (predominantly extrapulmonary) among those who worked in medical subspecialties.", [["TB", "DISEASE", 42, 44], ["this study", "TEST", 9, 19], ["TB", "PROBLEM", 42, 44], ["TB", "OBSERVATION", 42, 44], ["extrapulmonary", "ANATOMY", 60, 74]]], ["However, most cases were identified by using clinical criteria, and few were bacteriologically confirmed.Nosocomial TB in IndiaIn a retrospective review of healthcare workers who underwent anti-TB treatment in a tertiary care hospital in Vellore, Gopinath et al. identified 125 healthcare workers who had been treated for active TB between 1992 and 2001 (29).", [["TB", "DISEASE", 116, 118], ["TB", "DISEASE", 329, 331], ["Nosocomial TB", "PROBLEM", 105, 118], ["anti-TB treatment", "TREATMENT", 189, 206], ["active TB", "PROBLEM", 322, 331]]], ["The annual incidence of pulmonary TB was 0.35\u20131.80 per 1,000 persons during this period.", [["pulmonary", "ANATOMY", 24, 33], ["pulmonary TB", "DISEASE", 24, 36], ["pulmonary", "ORGAN", 24, 33], ["persons", "SPECIES", 61, 68], ["pulmonary TB", "PROBLEM", 24, 36], ["pulmonary", "ANATOMY", 24, 33], ["TB", "OBSERVATION", 34, 36]]], ["The annual incidence of extrapulmonary TB was 0.34\u20131.57 per 1,000.", [["extrapulmonary TB", "DISEASE", 24, 41], ["extrapulmonary TB", "TEST", 24, 41], ["extrapulmonary", "ANATOMY", 24, 38], ["TB", "OBSERVATION", 39, 41]]], ["These rates may have been underestimated because only healthcare workers who underwent TB treatment were counted.", [["TB", "DISEASE", 87, 89], ["TB treatment", "TREATMENT", 87, 99]]], ["In this hospital, a case-control study showed that low body mass index and employment in medical wards were risk factors for TB disease among healthcare workers (30).Nosocomial TB in IndiaIn a molecular epidemiologic study at a TB hospital in Delhi, Bhanu et al. performed DNA fingerprinting on 83 M. tuberculosis isolates from patients in 2 adjacent wards (31).", [["body", "ANATOMY", 55, 59], ["TB", "DISEASE", 125, 127], ["TB", "DISEASE", 177, 179], ["TB", "DISEASE", 228, 230], ["body", "ORGANISM_SUBDIVISION", 55, 59], ["DNA", "CELLULAR_COMPONENT", 273, 276], ["M. tuberculosis", "ORGANISM", 298, 313], ["patients", "ORGANISM", 328, 336], ["M. tuberculosis", "SPECIES", 298, 313], ["patients", "SPECIES", 328, 336], ["M. tuberculosis", "SPECIES", 298, 313], ["a case-control study", "TEST", 18, 38], ["low body mass index", "PROBLEM", 51, 70], ["TB disease", "PROBLEM", 125, 135], ["Nosocomial TB", "PROBLEM", 166, 179], ["DNA fingerprinting", "TEST", 273, 291], ["TB", "OBSERVATION", 177, 179]]], ["Of these 83 isolates, 8 strains were grouped into 3 clusters (identical fingerprints) by using IS6110 restriction fragment length polymorphism and spoligotyping analyses.", [["IS6110 restriction fragment length polymorphism", "DNA", 95, 142], ["8 strains", "PROBLEM", 22, 31], ["IS6110 restriction fragment length polymorphism", "PROBLEM", 95, 142], ["spoligotyping analyses", "TEST", 147, 169], ["fragment", "OBSERVATION_MODIFIER", 114, 122], ["length", "OBSERVATION_MODIFIER", 123, 129]]], ["Within each cluster, epidemiologic data showed overlapping hospitalization periods, which raises the possibility of nosocomial transmission (31).Nosocomial TB in IndiaIn summary, these studies suggest that nosocomial transmission of TB is a problem in India.", [["TB", "DISEASE", 156, 158], ["nosocomial transmission", "DISEASE", 206, 229], ["TB", "DISEASE", 233, 235], ["epidemiologic data", "TEST", 21, 39], ["nosocomial transmission", "PROBLEM", 116, 139], ["Nosocomial TB", "PROBLEM", 145, 158], ["these studies", "TEST", 179, 192], ["nosocomial transmission of TB", "PROBLEM", 206, 235], ["raises the possibility of", "UNCERTAINTY", 90, 115], ["nosocomial", "OBSERVATION", 206, 216], ["TB", "OBSERVATION", 233, 235]]], ["The prevalence of latent TB infection and annual risk for TB infection appears to be high even among young healthcare workers.", [["latent TB infection", "DISEASE", 18, 37], ["TB infection", "DISEASE", 58, 70], ["latent TB infection", "PROBLEM", 18, 37], ["TB infection", "PROBLEM", 58, 70], ["latent", "OBSERVATION_MODIFIER", 18, 24], ["TB", "OBSERVATION_MODIFIER", 25, 27], ["infection", "OBSERVATION", 28, 37]]], ["For example, in a hypothetical Indian hospital with 1,000 workers, \u2248500 (50%) will likely have latent infection, and \u224825 (5%) of uninfected workers will be newly infected each year.", [["infection", "DISEASE", 102, 111], ["workers", "ORGANISM", 140, 147], ["latent infection", "PROBLEM", 95, 111], ["uninfected workers", "TREATMENT", 129, 147], ["latent", "OBSERVATION_MODIFIER", 95, 101], ["infection", "OBSERVATION", 102, 111]]], ["The rate of active disease appears to be exceedingly high in subgroups such as interns, residents, and nurses.", [["active disease", "PROBLEM", 12, 26], ["active", "OBSERVATION_MODIFIER", 12, 18], ["disease", "OBSERVATION", 19, 26], ["appears to be", "UNCERTAINTY", 27, 40], ["exceedingly", "OBSERVATION_MODIFIER", 41, 52], ["high", "OBSERVATION", 53, 57]]], ["The incidences of TB disease and infection are higher than the national averages, which suggests an increased risk for acquiring TB in the hospital setting.", [["TB", "DISEASE", 18, 20], ["infection", "DISEASE", 33, 42], ["TB", "DISEASE", 129, 131], ["TB disease", "PROBLEM", 18, 28], ["infection", "PROBLEM", 33, 42], ["an increased risk", "PROBLEM", 97, 114], ["TB disease", "OBSERVATION", 18, 28], ["infection", "OBSERVATION", 33, 42], ["higher", "OBSERVATION_MODIFIER", 47, 53], ["increased", "OBSERVATION_MODIFIER", 100, 109]]], ["For example, the estimated incidence of TB among residents was 10-fold higher than the incidence for the country (28).Nosocomial TB in IndiaThe predominance of extrapulmonary (mostly pleural) disease among healthcare workers may indicate progression to disease from newly acquired primary infection rather than reactivation of latent TB.", [["extrapulmonary", "ANATOMY", 160, 174], ["pleural", "ANATOMY", 183, 190], ["TB", "DISEASE", 40, 42], ["TB", "DISEASE", 129, 131], ["extrapulmonary (mostly pleural) disease", "DISEASE", 160, 199], ["primary infection", "DISEASE", 281, 298], ["TB", "DISEASE", 334, 336], ["pleural", "ORGAN", 183, 190], ["TB", "PROBLEM", 40, 42], ["Nosocomial TB", "PROBLEM", 118, 131], ["extrapulmonary (mostly pleural) disease", "PROBLEM", 160, 199], ["disease", "PROBLEM", 253, 260], ["newly acquired primary infection", "PROBLEM", 266, 298], ["latent TB", "PROBLEM", 327, 336], ["TB", "OBSERVATION", 40, 42], ["TB", "OBSERVATION", 129, 131], ["predominance", "OBSERVATION_MODIFIER", 144, 156], ["extrapulmonary", "ANATOMY", 160, 174], ["mostly", "OBSERVATION_MODIFIER", 176, 182], ["pleural", "ANATOMY", 183, 190], ["disease", "OBSERVATION", 192, 199], ["primary", "OBSERVATION_MODIFIER", 281, 288], ["infection", "OBSERVATION", 289, 298], ["latent", "OBSERVATION_MODIFIER", 327, 333], ["TB", "OBSERVATION", 334, 336]]], ["Molecular epidemiologic studies suggest that pleural TB is different from other forms of extrapulmonary TB and is associated with the highest fingerprint clustering rate of all forms of TB, which suggests that pleural TB may be an early manifestation of recent infection (33).", [["pleural", "ANATOMY", 45, 52], ["pleural", "ANATOMY", 210, 217], ["pleural TB", "DISEASE", 45, 55], ["extrapulmonary TB", "DISEASE", 89, 106], ["TB", "DISEASE", 186, 188], ["pleural TB", "DISEASE", 210, 220], ["infection", "DISEASE", 261, 270], ["pleural", "ORGAN", 45, 52], ["pleural TB", "CANCER", 210, 220], ["Molecular epidemiologic studies", "TEST", 0, 31], ["pleural TB", "PROBLEM", 45, 55], ["extrapulmonary TB", "PROBLEM", 89, 106], ["TB", "PROBLEM", 186, 188], ["pleural TB", "PROBLEM", 210, 220], ["recent infection", "PROBLEM", 254, 270], ["pleural", "ANATOMY", 45, 52], ["TB", "OBSERVATION", 53, 55], ["different", "OBSERVATION_MODIFIER", 59, 68], ["extrapulmonary", "ANATOMY", 89, 103], ["TB", "OBSERVATION", 104, 106], ["highest", "OBSERVATION_MODIFIER", 134, 141], ["fingerprint", "OBSERVATION_MODIFIER", 142, 153], ["clustering", "OBSERVATION_MODIFIER", 154, 164], ["rate", "OBSERVATION_MODIFIER", 165, 169], ["all forms", "OBSERVATION_MODIFIER", 173, 182], ["TB", "OBSERVATION", 186, 188], ["pleural", "ANATOMY", 210, 217], ["TB", "OBSERVATION", 218, 220], ["early", "OBSERVATION_MODIFIER", 231, 236], ["infection", "OBSERVATION", 261, 270]]], ["Lastly, although this assumption is based on limited data, nosocomial transmission of TB among hospitalized patients may occur in urban hospitals.Factors That May Facilitate Nosocomial TransmissionSeveral factors may facilitate nosocomial transmission in Indian hospitals, although their relative importance in facilitating transmission is unknown (Table 2).", [["TB", "DISEASE", 86, 88], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["TB", "PROBLEM", 86, 88], ["Nosocomial TransmissionSeveral factors", "TREATMENT", 174, 212]]], ["The overwhelming number of TB patients and repeated exposures to smear-positive TB patients are likely to be critical factors.", [["TB", "DISEASE", 27, 29], ["TB", "DISEASE", 80, 82], ["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 83, 91], ["smear", "TEST", 65, 70], ["overwhelming", "OBSERVATION_MODIFIER", 4, 16], ["number", "OBSERVATION_MODIFIER", 17, 23], ["TB", "OBSERVATION_MODIFIER", 27, 29], ["likely to be", "UNCERTAINTY", 96, 108]]], ["The RNTCP alone starts treatment for >100,000 patients every month (21), and thousands more are managed in the private sector (19,22\u201324).", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["The RNTCP", "TREATMENT", 0, 9], ["treatment", "TREATMENT", 23, 32]]], ["Repeated exposure of trainees is particularly worrisome, given the lack of TB infection control measures at most healthcare facilities.", [["infection", "DISEASE", 78, 87], ["TB infection control measures", "TREATMENT", 75, 104], ["TB", "OBSERVATION_MODIFIER", 75, 77], ["infection", "OBSERVATION", 78, 87]]], ["During this phase of their training, stress is placed on physical examination.", [["their training", "TREATMENT", 21, 35], ["physical examination", "TEST", 57, 77]]], ["Evaluation of the respiratory system, for example, is invariably included in licensure examinations.", [["respiratory system", "ANATOMY", 18, 36], ["Evaluation of the respiratory system", "TEST", 0, 36], ["licensure examinations", "TEST", 77, 99], ["respiratory system", "ANATOMY", 18, 36]]], ["Because patients with cavitary TB are likely to exhibit signs during a lung exam, TB patients are considered excellent teaching material.", [["lung", "ANATOMY", 71, 75], ["cavitary TB", "DISEASE", 22, 33], ["TB", "DISEASE", 82, 84], ["patients", "ORGANISM", 8, 16], ["lung", "ORGAN", 71, 75], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 8, 16], ["patients", "SPECIES", 85, 93], ["cavitary TB", "PROBLEM", 22, 33], ["a lung exam", "TEST", 69, 80], ["cavitary", "OBSERVATION_MODIFIER", 22, 30], ["TB", "OBSERVATION", 31, 33], ["likely to exhibit", "UNCERTAINTY", 38, 55], ["lung", "ANATOMY", 71, 75]]], ["Trainees spend considerable time eliciting physical signs in such patients, which results in repeated exposure to patients with infectious TB during trainees' first clinical rotations.", [["TB", "DISEASE", 139, 141], ["patients", "ORGANISM", 66, 74], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 114, 122], ["infectious TB", "PROBLEM", 128, 141]]], ["This fact may explain the high incidence of infection among them (27).Factors That May Facilitate Nosocomial TransmissionDelays in diagnosis and initiation of treatment and failure to separate or isolate patients with smear-positive TB from other patients also contribute to transmission risk.", [["infection", "DISEASE", 44, 53], ["TransmissionDelays", "DISEASE", 109, 127], ["TB", "DISEASE", 233, 235], ["patients", "ORGANISM", 204, 212], ["patients", "ORGANISM", 247, 255], ["patients", "SPECIES", 204, 212], ["patients", "SPECIES", 247, 255], ["infection", "PROBLEM", 44, 53], ["Nosocomial TransmissionDelays", "TREATMENT", 98, 127], ["treatment", "TREATMENT", 159, 168], ["failure to separate", "PROBLEM", 173, 192], ["smear", "TEST", 218, 223], ["positive TB", "PROBLEM", 224, 235], ["transmission risk", "PROBLEM", 275, 292], ["may explain", "UNCERTAINTY", 10, 21], ["high", "OBSERVATION_MODIFIER", 26, 30], ["infection", "OBSERVATION", 44, 53]]], ["Previous studies in India have shown that diagnostic delays are common, and private practitioners, in particular, tend to underuse sputum microscopy, thereby increasing the probability of missing infectious TB patients (17,19,34).", [["TB", "DISEASE", 207, 209], ["patients", "ORGANISM", 210, 218], ["patients", "SPECIES", 210, 218], ["Previous studies", "TEST", 0, 16], ["sputum microscopy", "TEST", 131, 148], ["missing infectious TB patients", "PROBLEM", 188, 218], ["infectious", "OBSERVATION_MODIFIER", 196, 206]]], ["Unnecessary or prolonged hospitalization of TB patients who could have been treated on an ambulatory basis might also contribute to high exposure levels in hospitals.", [["TB", "DISEASE", 44, 46], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["high exposure levels", "PROBLEM", 132, 152], ["prolonged", "OBSERVATION_MODIFIER", 15, 24]]], ["A survey of TB hospitals in India showed that nearly 1 million patients sought treatment in 1999.", [["TB", "DISEASE", 12, 14], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71]]], ["Approximately 77% of these patients were reported to have undergone sputum examination, and one third of all patients had a diagnosis of TB (25).", [["sputum", "ANATOMY", 68, 74], ["TB", "DISEASE", 137, 139], ["patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 109, 117], ["sputum examination", "TEST", 68, 86], ["TB", "PROBLEM", 137, 139], ["sputum", "OBSERVATION", 68, 74], ["TB", "OBSERVATION", 137, 139]]], ["Approximately one third of the hospitals admitted every sputum smear\u2013positive TB patient encountered at their institution.Factors That May Facilitate Nosocomial TransmissionSeveral factors might prolong infectiousness of TB patients and thereby facilitate nosocomial transmission.", [["TB", "DISEASE", 78, 80], ["TB", "DISEASE", 221, 223], ["patient", "ORGANISM", 81, 88], ["patients", "ORGANISM", 224, 232], ["patient", "SPECIES", 81, 88], ["patients", "SPECIES", 224, 232], ["Nosocomial TransmissionSeveral factors", "TREATMENT", 150, 188], ["nosocomial", "OBSERVATION", 256, 266]]], ["Poor adherence to treatment, lack of continuous drug supply, use of suboptimal treatment regimens, lack of adequate treatment support (e.g., direct observation of therapy [DOT]), and insufficient treatment duration have been reported, particularly in the private sector (18,19,24,25,35,36).Factors That May Facilitate Nosocomial TransmissionFew hospitals in India have established infection control procedures.", [["infection", "DISEASE", 381, 390], ["treatment", "TREATMENT", 18, 27], ["continuous drug supply", "TREATMENT", 37, 59], ["suboptimal treatment regimens", "TREATMENT", 68, 97], ["adequate treatment support", "TREATMENT", 107, 133], ["therapy [DOT])", "TREATMENT", 163, 177], ["infection control procedures", "TREATMENT", 381, 409], ["infection", "OBSERVATION", 381, 390]]], ["Hospitals, especially publicly owned facilities, tend to be crowded, poorly ventilated, and have limited or no facilities for respiratory isolation.", [["respiratory", "ANATOMY", 126, 137], ["respiratory isolation", "TREATMENT", 126, 147]]], ["Most respiratory care procedures (including sputum collection) are routinely carried out in a general ward setting, rather than in respiratory isolation rooms.", [["respiratory", "ANATOMY", 5, 16], ["sputum collection", "TEST", 44, 61]]], ["Further, few of these hospitals offer routine screening programs to detect and treat TB among healthcare workers.Factors That May Facilitate Nosocomial TransmissionPrevious surveys have identified gaps in knowledge and awareness about TB in healthcare workers in India (18,19,24,36,37).", [["TB", "DISEASE", 85, 87], ["TB", "DISEASE", 235, 237], ["routine screening programs", "TREATMENT", 38, 64]]], ["A survey of 213 nurses in 2 hospitals in Delhi showed that only 67% reported M. tuberculosis as the causative organism, and only 22% reported sputum microscopy as the most appropriate way to diagnose TB (37).", [["tuberculosis", "DISEASE", 80, 92], ["TB", "DISEASE", 200, 202], ["M. tuberculosis", "ORGANISM", 77, 92], ["M. tuberculosis", "SPECIES", 77, 92], ["M. tuberculosis", "SPECIES", 77, 92], ["M. tuberculosis", "PROBLEM", 77, 92], ["the causative organism", "PROBLEM", 96, 118], ["sputum microscopy", "TEST", 142, 159], ["tuberculosis", "OBSERVATION", 80, 92]]], ["In another survey, only 12% of 204 private practitioners in Delhi reported ordering sputum smears for a patient with suspected TB.", [["TB", "DISEASE", 127, 129], ["patient", "ORGANISM", 104, 111], ["patient", "SPECIES", 104, 111], ["ordering sputum smears", "TEST", 75, 97], ["TB", "PROBLEM", 127, 129], ["TB", "OBSERVATION", 127, 129]]], ["For treating TB, 187 physicians used 102 different regimens (18).", [["TB", "DISEASE", 13, 15], ["TB", "PROBLEM", 13, 15]]], ["Other surveys have reported similar findings in India (17,19,24,35,36).", [["similar", "OBSERVATION_MODIFIER", 28, 35], ["findings", "OBSERVATION", 36, 44]]], ["Finally, healthcare workers may believe that that they cannot avoid nosocomial infection, which results in resigned acceptance on their part.", [["nosocomial infection", "DISEASE", 68, 88], ["nosocomial infection", "PROBLEM", 68, 88], ["infection", "OBSERVATION", 79, 88]]], ["Since nearly half the Indian population is infected, healthcare workers do not view latent TB infection as a problem.", [["TB infection", "DISEASE", 91, 103], ["latent TB infection", "PROBLEM", 84, 103], ["infected", "OBSERVATION", 43, 51], ["TB", "OBSERVATION_MODIFIER", 91, 93], ["infection", "OBSERVATION", 94, 103]]], ["Hence, latent infection is rarely treated, even in high-risk groups such as household contacts and HIV-infected patients (38,39).Implementing TB Infection Control in IndiaEffective TB infection control in healthcare settings depends on early identification, isolating infected persons, and rapidly and effectively treating persons with TB (2,4,5).", [["latent infection", "DISEASE", 7, 23], ["HIV-infected", "DISEASE", 99, 111], ["TB", "DISEASE", 142, 144], ["IndiaEffective TB infection", "DISEASE", 166, 193], ["TB", "DISEASE", 336, 338], ["patients", "ORGANISM", 112, 120], ["persons", "ORGANISM", 277, 284], ["persons", "ORGANISM", 323, 330], ["HIV", "SPECIES", 99, 102], ["patients", "SPECIES", 112, 120], ["persons", "SPECIES", 277, 284], ["persons", "SPECIES", 323, 330], ["HIV", "SPECIES", 99, 102], ["latent infection", "PROBLEM", 7, 23], ["HIV", "PROBLEM", 99, 102], ["TB Infection Control", "TREATMENT", 142, 162], ["IndiaEffective TB infection control", "TREATMENT", 166, 201], ["TB", "PROBLEM", 336, 338], ["latent", "OBSERVATION_MODIFIER", 7, 13], ["infection", "OBSERVATION", 14, 23], ["TB", "OBSERVATION_MODIFIER", 142, 144], ["Infection", "OBSERVATION", 145, 154], ["TB", "OBSERVATION_MODIFIER", 181, 183], ["infection", "OBSERVATION", 184, 193]]], ["In all healthcare settings, a basic TB infection control program should be implemented, as recommended by WHO and other agencies (2\u20135,7).", [["infection", "DISEASE", 39, 48], ["a basic TB infection control program", "TREATMENT", 28, 64], ["TB", "OBSERVATION_MODIFIER", 36, 38], ["infection", "OBSERVATION", 39, 48]]], ["WHO also recommends developing an infection control plan, educating healthcare workers and patients, improving sputum collection practices, performing triage and evaluation of suspected TB patients in outpatient settings, and reducing exposure in the laboratory (7).", [["sputum", "ANATOMY", 111, 117], ["infection", "DISEASE", 34, 43], ["TB", "DISEASE", 186, 188], ["patients", "ORGANISM", 91, 99], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 189, 197], ["an infection control plan", "TREATMENT", 31, 56], ["triage", "TEST", 151, 157], ["evaluation", "TEST", 162, 172], ["infection", "OBSERVATION", 34, 43]]], ["In the United States, administrative controls (early detection, isolation, and treatment of patients with TB) have been the most effective components of TB infection control programs (9).Implementing TB Infection Control in IndiaIn India, of all the recommended interventions, implementing administrative controls is likely to be the most feasible and effective strategy.", [["TB", "DISEASE", 106, 108], ["infection", "DISEASE", 156, 165], ["TB", "DISEASE", 200, 202], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["isolation", "TREATMENT", 64, 73], ["treatment", "TREATMENT", 79, 88], ["TB", "PROBLEM", 106, 108], ["TB infection control programs", "TREATMENT", 153, 182], ["interventions", "TREATMENT", 262, 275], ["implementing administrative controls", "TREATMENT", 277, 313], ["most effective", "OBSERVATION_MODIFIER", 124, 138], ["TB", "OBSERVATION_MODIFIER", 153, 155], ["infection", "OBSERVATION", 156, 165], ["TB", "OBSERVATION_MODIFIER", 200, 202], ["Infection", "OBSERVATION", 203, 212]]], ["Controls include early detection of patients with infectious TB, isolating or at least segregating those with infectious pulmonary TB from other patients, and rapidly initiating anti-TB treatment, supported by measures to improve adherence (e.g., DOT).Implementing TB Infection Control in IndiaImplementing many of the recommended engineering controls is not feasible in most healthcare facilities because of the high costs of such measures (e.g., negative-pressure isolation rooms).", [["pulmonary", "ANATOMY", 121, 130], ["TB", "DISEASE", 61, 63], ["infectious pulmonary TB", "DISEASE", 110, 133], ["TB", "DISEASE", 265, 267], ["patients", "ORGANISM", 36, 44], ["pulmonary", "ORGAN", 121, 130], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 145, 153], ["infectious TB", "PROBLEM", 50, 63], ["infectious pulmonary TB", "PROBLEM", 110, 133], ["anti-TB treatment", "TREATMENT", 178, 195], ["TB Infection Control", "TREATMENT", 265, 285], ["such measures", "TREATMENT", 427, 440], ["infectious", "OBSERVATION_MODIFIER", 50, 60], ["infectious", "OBSERVATION_MODIFIER", 110, 120], ["pulmonary", "ANATOMY", 121, 130], ["TB", "OBSERVATION", 131, 133], ["TB", "OBSERVATION_MODIFIER", 265, 267], ["Infection", "OBSERVATION", 268, 277]]], ["However, separation or segregation of smear-positive TB patients in private or semiprivate rooms or wards with simple mechanical exhaust ventilation (e.g., window fans) could be feasible in some settings, particularly in the private sector and well-funded public hospitals.", [["TB", "DISEASE", 53, 55], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["smear", "TEST", 38, 43], ["simple mechanical exhaust ventilation", "TREATMENT", 111, 148], ["positive", "OBSERVATION_MODIFIER", 44, 52], ["TB", "OBSERVATION_MODIFIER", 53, 55], ["exhaust ventilation", "OBSERVATION", 129, 148]]], ["These measures have been shown to be useful in terminating an outbreak of nosocomial tuberculosis (9).", [["nosocomial tuberculosis", "DISEASE", 74, 97], ["nosocomial tuberculosis", "PROBLEM", 74, 97], ["shown to be", "UNCERTAINTY", 25, 36], ["outbreak", "OBSERVATION_MODIFIER", 62, 70], ["nosocomial", "OBSERVATION_MODIFIER", 74, 84], ["tuberculosis", "OBSERVATION", 85, 97]]], ["This intervention is particularly necessary at centers that manage patients with MDRTB; at such centers, patients with infectious TB must not be admitted to the same wards as patients with HIV infection.Implementing TB Infection Control in IndiaPersonal respiratory protection measures (e.g., N95 respirators) are probably not feasible because of the high cost.", [["respiratory", "ANATOMY", 254, 265], ["MDRTB", "DISEASE", 81, 86], ["TB", "DISEASE", 130, 132], ["HIV infection", "DISEASE", 189, 202], ["TB", "DISEASE", 216, 218], ["patients", "ORGANISM", 67, 75], ["patients", "ORGANISM", 105, 113], ["patients", "ORGANISM", 175, 183], ["HIV", "ORGANISM", 189, 192], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 105, 113], ["patients", "SPECIES", 175, 183], ["HIV", "SPECIES", 189, 192], ["HIV", "SPECIES", 189, 192], ["This intervention", "TREATMENT", 0, 17], ["MDRTB", "TREATMENT", 81, 86], ["infectious TB", "PROBLEM", 119, 132], ["HIV infection", "PROBLEM", 189, 202], ["TB Infection Control", "TREATMENT", 216, 236], ["IndiaPersonal respiratory protection measures", "TREATMENT", 240, 285], ["N95 respirators", "TREATMENT", 293, 308], ["the high cost", "PROBLEM", 347, 360], ["infection", "OBSERVATION", 193, 202], ["TB", "OBSERVATION_MODIFIER", 216, 218], ["Infection", "OBSERVATION", 219, 228], ["respiratory protection", "OBSERVATION", 254, 276], ["probably not", "UNCERTAINTY", 314, 326], ["high", "OBSERVATION_MODIFIER", 351, 355], ["cost", "OBSERVATION", 356, 360]]], ["The use of respirators may have a role in hospitals that manage MDRTB, but more successful and affordable measures include improving natural ventilation through open windows and sunlight.", [["MDRTB", "DISEASE", 64, 69], ["MDRTB", "TREATMENT", 64, 69], ["affordable measures", "TREATMENT", 95, 114], ["improving natural ventilation", "TREATMENT", 123, 152], ["open windows", "TREATMENT", 161, 173]]], ["The efficacy of UV germicidal lights is being evaluated in other low-income countries, and results of such studies are needed to determine their value in reducing nosocomial transmission.", [["UV germicidal lights", "TREATMENT", 16, 36], ["such studies", "TEST", 102, 114], ["UV", "OBSERVATION", 16, 18], ["germicidal lights", "OBSERVATION", 19, 36], ["nosocomial", "OBSERVATION", 163, 173]]], ["In developing TB infection control programs, crucial issues are educating healthcare workers about nosocomial TB and measures that can help prevent such transmission, educating patients on cough procedures, and using simple surgical masks on patients with infectious TB (especially if they are not segregated) who are coughing.Implementing TB Infection Control in IndiaPeriodic testing of healthcare workers for latent TB and treating those with latent infections who are at high risk for progression to active TB might be feasible in selected settings, particularly among trainees and junior staff (who seem to be disproportionately affected).", [["TB infection", "DISEASE", 14, 26], ["TB", "DISEASE", 110, 112], ["TB", "DISEASE", 267, 269], ["TB", "DISEASE", 340, 342], ["TB", "DISEASE", 419, 421], ["infections", "DISEASE", 453, 463], ["TB", "DISEASE", 511, 513], ["patients", "ORGANISM", 177, 185], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 177, 185], ["patients", "SPECIES", 242, 250], ["TB infection control programs", "TREATMENT", 14, 43], ["nosocomial TB", "TREATMENT", 99, 112], ["cough procedures", "TREATMENT", 189, 205], ["simple surgical masks", "TREATMENT", 217, 238], ["infectious TB", "PROBLEM", 256, 269], ["coughing", "PROBLEM", 318, 326], ["latent TB", "PROBLEM", 412, 421], ["latent infections", "PROBLEM", 446, 463], ["active TB", "PROBLEM", 504, 513], ["TB", "OBSERVATION_MODIFIER", 14, 16], ["infection", "OBSERVATION", 17, 26], ["TB", "OBSERVATION_MODIFIER", 340, 342], ["Infection", "OBSERVATION", 343, 352], ["active", "OBSERVATION_MODIFIER", 504, 510], ["TB", "OBSERVATION", 511, 513]]], ["Screening for latent TB infection with newer, blood-based IGRAs may not be feasible in most settings at this time.", [["blood", "ANATOMY", 46, 51], ["TB infection", "DISEASE", 21, 33], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["Screening", "TEST", 0, 9], ["latent TB infection", "PROBLEM", 14, 33], ["blood-based IGRAs", "TREATMENT", 46, 63], ["TB", "OBSERVATION_MODIFIER", 21, 23], ["infection", "OBSERVATION", 24, 33]]], ["Although IGRAs have some advantages over TST, including increased specificity and the ability to discriminate between infection with M. tuberculosis and M. bovis BCG, they have limited applicability in many resource-limited settings because of the high costs and the need for laboratory infrastructure (26,41).", [["infection", "DISEASE", 118, 127], ["M. tuberculosis", "DISEASE", 133, 148], ["M. tuberculosis", "ORGANISM", 133, 148], ["M. bovis", "ORGANISM", 153, 161], ["BCG", "ORGANISM", 162, 165], ["IGRAs", "PROTEIN", 9, 14], ["M. tuberculosis", "SPECIES", 133, 148], ["M. bovis", "SPECIES", 153, 161], ["BCG", "SPECIES", 162, 165], ["M. tuberculosis", "SPECIES", 133, 148], ["M. bovis", "SPECIES", 153, 161], ["IGRAs", "TEST", 9, 14], ["TST", "TEST", 41, 44], ["increased specificity", "PROBLEM", 56, 77], ["infection", "PROBLEM", 118, 127], ["M. tuberculosis", "PROBLEM", 133, 148], ["M. bovis BCG", "TREATMENT", 153, 165], ["the high costs", "PROBLEM", 244, 258], ["laboratory infrastructure", "TEST", 276, 301]]], ["However, new data suggest that IGRAs hold promise for serial testing of healthcare workers and can overcome some of the limitations of serial tuberculin testing (27).", [["IGRAs", "PROTEIN", 31, 36], ["IGRAs", "TEST", 31, 36], ["serial testing", "TEST", 54, 68], ["serial tuberculin testing", "TEST", 135, 160]]], ["A recent study from India showed that in a setting with intensive nosocomial exposure, healthcare workers had strong interferon-\u03b3 responses that persistently stayed elevated even after treatment for latent infection (42).", [["infection", "DISEASE", 206, 215], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 117, 129], ["interferon", "PROTEIN", 117, 127], ["A recent study", "TEST", 0, 14], ["treatment", "TREATMENT", 185, 194], ["latent infection", "PROBLEM", 199, 215], ["infection", "OBSERVATION", 206, 215]]], ["Persistence of infection or reexposure might account for this phenomenon.Implementing TB Infection Control in IndiaEvaluation of symptomatic healthcare workers for active TB is feasible and should be implemented routinely.", [["infection", "DISEASE", 15, 24], ["TB", "DISEASE", 86, 88], ["TB", "DISEASE", 171, 173], ["infection", "PROBLEM", 15, 24], ["reexposure", "PROBLEM", 28, 38], ["this phenomenon", "PROBLEM", 57, 72], ["TB Infection Control", "TREATMENT", 86, 106], ["active TB", "PROBLEM", 164, 173], ["infection", "OBSERVATION", 15, 24], ["might account for", "UNCERTAINTY", 39, 56], ["TB", "OBSERVATION_MODIFIER", 86, 88], ["Infection", "OBSERVATION", 89, 98]]], ["In addition to the above measures, hospitals should make every effort to treat TB patients on an ambulatory basis (25).", [["TB", "DISEASE", 79, 81], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["the above measures", "TREATMENT", 15, 33], ["TB", "PROBLEM", 79, 81], ["an ambulatory basis", "TEST", 94, 113]]], ["If hospitalization is required, every effort should be made to segregate potentially infectious patients from immunocompromised patients, rapidly diagnose and initiate treatment, and discharge patients promptly with DOT on an outpatient basis.Implementing TB Infection Control in IndiaLastly, efforts should be made to improve the quality of TB care in the private sector through better coordination between the RNTCP and the private sector (22).", [["TB", "DISEASE", 256, 258], ["TB", "DISEASE", 342, 344], ["patients", "ORGANISM", 96, 104], ["patients", "ORGANISM", 128, 136], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 128, 136], ["patients", "SPECIES", 193, 201], ["treatment", "TREATMENT", 168, 177], ["TB Infection Control", "TREATMENT", 256, 276], ["TB care", "TREATMENT", 342, 349], ["TB", "OBSERVATION_MODIFIER", 256, 258], ["Infection", "OBSERVATION", 259, 268]]], ["By improving TB diagnosis and treatment practices, smear-positive TB patients are more likely to receive rapid diagnosis and treatment, thereby directly and indirectly reducing the overall transmission in the community and in the nosocomial setting.", [["TB", "DISEASE", 13, 15], ["TB", "DISEASE", 66, 68], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["treatment practices", "TREATMENT", 30, 49], ["smear", "TEST", 51, 56], ["treatment", "TREATMENT", 125, 134], ["improving", "OBSERVATION_MODIFIER", 3, 12], ["TB", "OBSERVATION", 13, 15], ["nosocomial", "OBSERVATION", 230, 240]]], ["Such public-private partnerships are currently ongoing in India (22), and these programs could address the issue of nosocomial TB.Implementing TB Infection Control in IndiaWho should design and implement TB infection control programs in India?", [["TB", "DISEASE", 127, 129], ["TB", "DISEASE", 143, 145], ["infection", "DISEASE", 207, 216], ["nosocomial TB", "PROBLEM", 116, 129], ["TB Infection Control", "TREATMENT", 143, 163], ["TB infection control programs", "TREATMENT", 204, 233], ["nosocomial TB", "OBSERVATION", 116, 129], ["TB", "OBSERVATION_MODIFIER", 143, 145], ["Infection", "OBSERVATION", 146, 155]]], ["Further, the private sector in India is dominant, diverse, and largely unregulated (22).", [["dominant", "OBSERVATION", 40, 48], ["diverse", "OBSERVATION_MODIFIER", 50, 57]]], ["Although a few hospitals have received quality certifications (e.g., ISO 9000), no pressure is on healthcare facilities to get accredited; in fact, India has no national accrediting body.", [["body", "ANATOMY", 182, 186], ["body", "ORGANISM_SUBDIVISION", 182, 186], ["few", "OBSERVATION_MODIFIER", 11, 14]]], ["Also, a large proportion of Indians pay for health care with personal funds rather than health insurance.Implementing TB Infection Control in IndiaGiven these problems, we cannot envision a simple approach to implementing infection control programs in India.", [["TB", "DISEASE", 118, 120], ["infection", "DISEASE", 222, 231], ["TB Infection Control", "TREATMENT", 118, 138], ["a simple approach", "TREATMENT", 188, 205], ["infection control programs", "TREATMENT", 222, 248], ["large", "OBSERVATION_MODIFIER", 8, 13], ["TB", "OBSERVATION_MODIFIER", 118, 120], ["Infection", "OBSERVATION", 121, 130], ["infection", "OBSERVATION", 222, 231]]], ["While technical guidance should come from international agencies such as WHO and the International Union Against Tuberculosis and Lung Disease, these guidelines need to be adapted to the Indian context by RNTCP.", [["Lung", "ANATOMY", 130, 134], ["Tuberculosis", "DISEASE", 113, 125], ["Lung Disease", "DISEASE", 130, 142], ["Lung", "ORGAN", 130, 134], ["Tuberculosis", "PROBLEM", 113, 125], ["Lung Disease", "PROBLEM", 130, 142], ["Tuberculosis", "OBSERVATION", 113, 125], ["Lung", "ANATOMY", 130, 134], ["Disease", "OBSERVATION", 135, 142]]], ["Ultimately, implementing adequate infection control measures is the responsibility of each healthcare facility.", [["infection", "DISEASE", 34, 43], ["adequate infection control measures", "TREATMENT", 25, 60], ["adequate", "OBSERVATION_MODIFIER", 25, 33], ["infection", "OBSERVATION", 34, 43]]], ["RNTCP may not have the regulatory authority to enforce implementation; however, by partnering with the private sector, RNTCP can improve the quality of case detection and treatment provided in the private sector, which can, by itself, improve infection control.Call for Research and ActionDespite India's long and distinguished history of TB research, nosocomial TB has in large part not been addressed by researchers, at least until recently.", [["infection", "DISEASE", 243, 252], ["TB", "DISEASE", 339, 341], ["TB", "DISEASE", 363, 365], ["RNTCP", "TREATMENT", 119, 124], ["treatment", "TREATMENT", 171, 180], ["infection control", "TREATMENT", 243, 260], ["nosocomial TB", "PROBLEM", 352, 365], ["infection", "OBSERVATION", 243, 252]]], ["Although a few studies have been published (26\u201331), many more are needed, as summarized in Table 3.", [["a few studies", "TEST", 9, 22]]], ["A first step is to determine the prevalence of TB among healthcare workers and to evaluate risk factors for nosocomial transmission.", [["TB", "DISEASE", 47, 49], ["nosocomial transmission", "PROBLEM", 108, 131]]], ["In addition, we must assess the availability of resources in India to implement TB infection control measures and to assess what additional resources are needed in areas that have little or no TB infection control programs.", [["infection", "DISEASE", 83, 92], ["infection", "DISEASE", 196, 205], ["TB infection control measures", "TREATMENT", 80, 109], ["TB infection control programs", "PROBLEM", 193, 222], ["no", "UNCERTAINTY", 190, 192], ["TB", "OBSERVATION_MODIFIER", 193, 195], ["infection", "OBSERVATION", 196, 205]]], ["India is a vast country with substantial regional variability in resources and expertise.", [["substantial", "OBSERVATION_MODIFIER", 29, 40], ["regional variability", "OBSERVATION", 41, 61]]], ["Some healthcare facilities (e.g., private hospitals and medical schools) may have implemented control measures or may have the resources and skills needed to establish effective infection control programs.Call for Research and ActionAfter assessing the disease prevalence, risk factors, and resources, India must implement effective strategies to reduce nosocomial transmission.", [["infection", "DISEASE", 178, 187], ["effective infection control programs", "TREATMENT", 168, 204], ["effective strategies", "TREATMENT", 323, 343], ["nosocomial transmission", "PROBLEM", 354, 377]]], ["Trials are therefore needed to evaluate relatively simple, feasible interventions and their effectiveness in reducing nosocomial risk.", [["feasible interventions", "TREATMENT", 59, 81], ["reducing nosocomial risk", "PROBLEM", 109, 133]]], ["The lessons learned in such trials will be applicable in other resource-limited settings.Call for Research and ActionIn conclusion, healthcare workers are essential in the fight against TB, and their health needs to be protected.", [["TB", "DISEASE", 186, 188], ["TB", "PROBLEM", 186, 188]]], ["India, with its vast human and intellectual capital, nearly countrywide DOTS coverage, and a large, well-funded, successful national TB control program, is well placed to tackle this problem and set an example for other high-prevalence countries.", [["human", "ORGANISM", 21, 26], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 21, 26], ["nearly countrywide DOTS coverage", "TREATMENT", 53, 85], ["successful national TB control program", "TREATMENT", 113, 151], ["large", "OBSERVATION_MODIFIER", 93, 98]]]], "d7080c93cbea57445c4845ae12ed6e4502fe1ef5": [["BackgroundThe available scientific evidence and previous clinical experiences with SARS -CoV, MERS -CoV and even HIV have urged physicians to consider the use of an array of potential therapies like chloroquine and hydroxychloroquine, remdesivir, lopinavir/ritonavir, interferon beta, monoclonal antibodies, convalescent plasma, hyper immune globulin, antibody-rich blood products either alone or combined with supportive care (e.g., oxygenation, ventilation, fluid management) under several regulatory approaches that healthcare authorities made available.", [["plasma", "ANATOMY", 321, 327], ["blood", "ANATOMY", 366, 371], ["SARS -CoV", "DISEASE", 83, 92], ["chloroquine", "CHEMICAL", 199, 210], ["hydroxychloroquine", "CHEMICAL", 215, 233], ["remdesivir", "CHEMICAL", 235, 245], ["lopinavir/ritonavir", "CHEMICAL", 247, 266], ["chloroquine", "CHEMICAL", 199, 210], ["hydroxychloroquine", "CHEMICAL", 215, 233], ["remdesivir", "CHEMICAL", 235, 245], ["lopinavir", "CHEMICAL", 247, 256], ["ritonavir", "CHEMICAL", 257, 266], ["SARS -CoV", "ORGANISM", 83, 92], ["MERS -CoV", "ORGANISM", 94, 103], ["chloroquine", "SIMPLE_CHEMICAL", 199, 210], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 215, 233], ["remdesivir", "SIMPLE_CHEMICAL", 235, 245], ["lopinavir", "SIMPLE_CHEMICAL", 247, 256], ["ritonavir", "SIMPLE_CHEMICAL", 257, 266], ["interferon beta", "GENE_OR_GENE_PRODUCT", 268, 283], ["convalescent", "ORGANISM", 308, 320], ["plasma", "ORGANISM_SUBSTANCE", 321, 327], ["hyper immune globulin", "SIMPLE_CHEMICAL", 329, 350], ["blood", "ORGANISM_SUBSTANCE", 366, 371], ["interferon beta", "PROTEIN", 268, 283], ["monoclonal antibodies", "PROTEIN", 285, 306], ["hyper immune globulin", "PROTEIN", 329, 350], ["antibody", "PROTEIN", 352, 360], ["HIV", "SPECIES", 113, 116], ["SARS -CoV", "SPECIES", 83, 92], ["MERS -CoV", "SPECIES", 94, 103], ["HIV", "SPECIES", 113, 116], ["SARS", "PROBLEM", 83, 87], ["potential therapies", "TREATMENT", 174, 193], ["chloroquine", "TREATMENT", 199, 210], ["hydroxychloroquine", "TREATMENT", 215, 233], ["remdesivir", "TREATMENT", 235, 245], ["lopinavir", "TREATMENT", 247, 256], ["ritonavir", "TREATMENT", 257, 266], ["interferon beta", "TREATMENT", 268, 283], ["monoclonal antibodies", "TEST", 285, 306], ["convalescent plasma", "TEST", 308, 327], ["hyper immune globulin", "TREATMENT", 329, 350], ["antibody", "TEST", 352, 360], ["rich blood products", "TREATMENT", 361, 380], ["supportive care", "TREATMENT", 411, 426], ["oxygenation", "TREATMENT", 434, 445], ["ventilation", "TREATMENT", 447, 458], ["fluid management", "TREATMENT", 460, 476]]], ["Nevertheless, the use of potential therapies in COVID-19 represents a critical responsibility, considering that these therapies are not approved by competent regulatory authorities to treat this disease, and respectively their safety and efficacy profile is under investigation [1] .Regulatory landscape for accessing COVID-19 therapies in the EU and USThere are several regulatory approaches for accessing potential therapies in COVID-19 and they can be classified as clinical trials, compassionate use, emergency use and off-label use (Table 1) [1] [2] [3] .Regulatory landscape for accessing COVID-19 therapies in the EU and USThe European Medicines Agency (EMA), even in this pandemic crisis, remained neutral by leaving within the remit of national regulatory authorities to launch their pragmatic regulatory pathways.", [["COVID-19", "CHEMICAL", 48, 56], ["COVID-19", "CHEMICAL", 48, 56], ["COVID-19", "CELL", 48, 56], ["Table 1) [1] [2] [3]", "SIMPLE_CHEMICAL", 538, 558], ["potential therapies", "TREATMENT", 25, 44], ["these therapies", "TREATMENT", 112, 127], ["this disease", "PROBLEM", 190, 202], ["accessing COVID", "TREATMENT", 308, 323], ["therapies", "TREATMENT", 327, 336], ["accessing potential therapies", "TREATMENT", 397, 426], ["COVID", "TEST", 430, 435], ["accessing COVID", "TREATMENT", 585, 600], ["therapies", "TREATMENT", 604, 613], ["this pandemic crisis", "PROBLEM", 675, 695]]], ["Even though the EMA provided scientific advice for national regulatory agencies and manufacturers [3] , many countries in Europe launched different regulatory approaches and protocols for accessing potential medicines [4] [5] [6] [7] .", [["[4] [5] [6] [7]", "SIMPLE_CHEMICAL", 218, 233], ["accessing potential medicines", "TREATMENT", 188, 217]]], ["Moreover, the dosing regimen in the protocols even for off-label use is not the same between countries, not to mention other programs.", [["the dosing regimen", "TREATMENT", 10, 28], ["the protocols", "TREATMENT", 32, 45]]], ["Under ideal conditions, the off-label program would constitute in the creation of a target patient population, informed consent and track and follow-up reports [8, 9] .", [["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 91, 98]]], ["Still, prescribing an already approved medicine either for an indication, a dose or a way that is not approved for COVID-19 seems to be very challenging for clinicians.", [["COVID-19", "CHEMICAL", 115, 123]]], ["Therefore, under the COVID-19 emergency conditions, it is hard to believe that the off-label use would result to be the best approach for accessing potential medicines, considering the ongoing regulatory debates and the difficulties in assessing riskbenefit for each patient due to the pressurized and stressful situation [8, 9] .Regulatory landscape for accessing COVID-19 therapies in the EU and USUnlike EMA and some European countries, the Food and Drug Administration (FDA) was not very keen toward off-label use, by initiating the approval of the compassionate use, followed by the approval of emergency use for particular treatments and clinical trials [10] .", [["patient", "ORGANISM", 267, 274], ["patient", "SPECIES", 267, 274], ["accessing potential medicines", "TREATMENT", 138, 167], ["accessing COVID", "TREATMENT", 355, 370], ["therapies", "TREATMENT", 374, 383], ["Drug Administration", "TREATMENT", 453, 472], ["particular treatments", "TREATMENT", 618, 639]]], ["Although terminology and modalities may not be identical, compassionate use programs demanding regulatory approval, informed consent and follow-up information are established in most countries [11, 12] , and can be used to facilitate the access of seriously ill COVID-19 patients that cannot have access in clinical studies.", [["patients", "ORGANISM", 271, 279], ["patients", "SPECIES", 271, 279], ["seriously ill COVID", "TREATMENT", 248, 267], ["clinical studies", "TEST", 307, 323]]], ["Moreover, compassionate use might be seen as a treatment option for small countries which rarely have access to international clinical studies.", [["a treatment option", "TREATMENT", 45, 63], ["international clinical studies", "TEST", 112, 142]]], ["In the past, during the interval of 5 years (1984) (1985) (1986) (1987) (1988) (1989) , the unapproved Ganciclovir was prescribed under the compassionate use for treatment of pneumonia Cytomegalovirus (CMV), retinitis CMV and colitis CMV for seriously ill immune-compromised patients and even today after 30 years it remains the preferred therapy for the treatment of CMV [13] .Regulatory landscape for accessing COVID-19 therapies in the EU and USOn the other hand, the idea for approving the emergency use relies not just in the emergency circumstances but also in providing legal protection for healthcare professionals and manufacturers for eventual adverse events and medication errors that the potential medicine may cause, as well as prescribing and dispensing a donated medicine free of charge within the framework of the hospital, and not obtaining informed consent for patients while tracking and reporting the treatment's outcomes [14, 15] .", [["Ganciclovir", "CHEMICAL", 103, 114], ["pneumonia Cytomegalovirus (CMV), retinitis CMV and colitis", "DISEASE", 175, 233], ["ill immune-compromised", "DISEASE", 252, 274], ["Ganciclovir", "CHEMICAL", 103, 114], ["Cytomegalovirus", "ORGANISM", 185, 200], ["CMV", "ORGANISM", 202, 205], ["CMV", "ORGANISM", 218, 221], ["colitis", "PATHOLOGICAL_FORMATION", 226, 233], ["CMV", "ORGANISM", 234, 237], ["patients", "ORGANISM", 275, 283], ["CMV", "ORGANISM", 368, 371], ["patients", "ORGANISM", 879, 887], ["patients", "SPECIES", 275, 283], ["patients", "SPECIES", 879, 887], ["CMV", "SPECIES", 202, 205], ["CMV", "SPECIES", 234, 237], ["CMV", "SPECIES", 368, 371], ["the unapproved Ganciclovir", "TREATMENT", 88, 114], ["pneumonia Cytomegalovirus (CMV)", "PROBLEM", 175, 206], ["retinitis CMV", "PROBLEM", 208, 221], ["colitis CMV", "PROBLEM", 226, 237], ["the treatment of CMV", "TREATMENT", 351, 371], ["accessing COVID", "TREATMENT", 403, 418], ["therapies", "TREATMENT", 422, 431], ["eventual adverse events", "PROBLEM", 645, 668], ["medication errors", "PROBLEM", 673, 690], ["pneumonia", "OBSERVATION", 175, 184], ["retinitis CMV", "OBSERVATION", 208, 221], ["colitis", "OBSERVATION", 226, 233]]], ["Having regard to the fact that the manufacturer Gilead was called from the licensed clinicians to provide Remdesivir to hospitalized COVID-19 patients under the compassionate use, since 25th January 2020, and based on the methodological issues found at Grein et al.'s paper [16] , it remains doubtful whether Gilead or regulatory authorities were not vulnerable toward this program.", [["Remdesivir", "CHEMICAL", 106, 116], ["COVID", "DISEASE", 133, 138], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["the methodological issues", "PROBLEM", 218, 243]]], ["Even though the regulatory authorities usually approve most of the compassionate use requests when meeting the criteria, the key player in this program is the manufacturer, who is not legally obliged to provide the medicine to patients and is usually reluctant due to several factors (1) the outcomes of the compassionate program are not considered as an evidence for approval; (2) they may have limited quantities of the potential medicine already involved in clinical trials; (3) they may think they will be prejudiced if the medicine is proven to be ineffective and unsafe; (4) they want to bypass the regulatory requirements to provide followup information; (5) and the reimbursements issues in some countries [17] [18] [19] .", [["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 227, 235]]], ["According to regulatory authorities, the golden criterion for accessing and investigating potential medicines are clinical trials.", [["potential medicines", "TREATMENT", 90, 109], ["clinical trials", "TREATMENT", 114, 129]]], ["The speed and volume of various clinical trials like Discovery, Recovery, Anger, Solidarity, New York Trial, characterized with different study designs, experimental arms, outcome measures, eligibility criteria and hypothesis emphasize the urge to produce significant safety and efficacy data in the middle of this pandemic crisis [20, 21] .", [["experimental arms, outcome measures", "TREATMENT", 153, 188], ["eligibility criteria", "TEST", 190, 210], ["efficacy data", "TEST", 279, 292]]], ["The golden criterion for the elucidation of the safety and efficacy profile of the potential therapies in COVID-19 does not rely just on the pursuit of randomized clinical studies under an ideal sample size and power, but one should analyze carefully and considerate the other aspects of the study design (e.g. study duration and masking), eligibility criteria (enrolling participants with similar characteristics) and clinically meaningful endpoints.", [["COVID-19", "CHEMICAL", 106, 114], ["participants", "SPECIES", 372, 384], ["the potential therapies", "TREATMENT", 79, 102], ["COVID", "TEST", 106, 111], ["clinical studies", "TEST", 163, 179], ["the study", "TEST", 288, 297], ["golden", "OBSERVATION", 4, 10]]], ["This table used unified regulatory characteristics of the EU and the US.", [["the US", "TEST", 65, 71]]], ["Also, when a unified criteria was not met we used the not applicable (N/A) choiceConclusionHaving regard to the diverse clinical presentation, course and progression of COVID-19 and the limited medical supply, regulatory authorities should establish robust regulatory programs that minimize clinical dilemmas in choosing the best therapy for COVID-19 patients.", [["COVID", "DISEASE", 169, 174], ["patients", "ORGANISM", 351, 359], ["patients", "SPECIES", 351, 359], ["COVID", "TEST", 169, 174], ["robust regulatory programs", "TREATMENT", 250, 276], ["COVID", "TEST", 342, 347]]], ["While clinicians should continue to inform COVID-19 patients or their legal representatives for the potential outcomes of therapies, obtaining informed consent from them is crucial for facilitating the clinical decision.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["therapies", "TREATMENT", 122, 131]]], ["Based on the available data, we believe that in COVID-19, no golden criterion is met in clinical research, not to mention clinical practice.", [["COVID", "TEST", 48, 53], ["golden criterion", "PROBLEM", 61, 77]]], ["Therefore, compassionate use program's mechanism with no control group might be shifted from \"outside of clinical studies\" to \"parallel with clinical studies\" to permit clinical studies to be implemented within their rigorous and narrow framework.", [["clinical studies", "TEST", 105, 121], ["clinical studies", "TEST", 141, 157], ["clinical studies", "TEST", 169, 185]]]], "49ef14fbeee682057ed14674f623ca36c6d954cc": [["IntroductionReal-time (rt) PCR and reverse transcription (RT) PCR techniques are rapid and versatile diagnostic procedures broadly used in clinical virology where there are mostly considered as diagnostic ''gold standards'' [1] .", [["IntroductionReal-time (rt) PCR", "TREATMENT", 0, 30], ["reverse transcription (RT) PCR techniques", "TREATMENT", 35, 76]]], ["Monitoring rt-PCR and rt-RT-PCR assays and validation of the results rely on the use of relevant external or internal controls (ECs or ICs) [1, 2] and commercial kits including such control systems are being increasingly improved for the molecular diagnosis of a number of pathogens such as HIV, hepatitis viruses, influenza viruses etc..", [["ECs", "ANATOMY", 128, 131], ["HIV, hepatitis viruses", "DISEASE", 291, 313], ["influenza viruses", "DISEASE", 315, 332], ["ECs", "CELL", 128, 131], ["HIV", "ORGANISM", 291, 294], ["hepatitis viruses", "ORGANISM", 296, 313], ["influenza viruses", "ORGANISM", 315, 332], ["ECs", "CELL_TYPE", 128, 131], ["ICs", "CELL_TYPE", 135, 138], ["HIV", "SPECIES", 291, 294], ["HIV", "SPECIES", 291, 294], ["hepatitis viruses", "SPECIES", 296, 313], ["Monitoring rt-PCR", "TEST", 0, 17], ["rt-RT-PCR assays", "TEST", 22, 38], ["internal controls (ECs", "TREATMENT", 109, 131], ["commercial kits", "TREATMENT", 151, 166], ["such control systems", "TREATMENT", 177, 197], ["pathogens", "PROBLEM", 273, 282], ["HIV", "PROBLEM", 291, 294], ["hepatitis viruses", "PROBLEM", 296, 313], ["influenza viruses etc", "PROBLEM", 315, 336], ["pathogens", "OBSERVATION", 273, 282]]], ["However, one of the main strengths of rt-PCR is versatility, which provides the opportunity to set-up ''in-house'' protocols for specific pathogens.", [["specific pathogens", "PROBLEM", 129, 147]]], ["The scientific literature now includes an impressive number of 'home made'' assays for various viral agents.", [["various viral agents", "TREATMENT", 87, 107]]], ["Whilst most commercial kits include both ICs and ECs allowing accurate validation of the results [3] , ''home made tests'' are frequently performed in the absence of ICs and therefore without any possible individual monitoring of each diagnostic reaction.", [["ECs", "ANATOMY", 49, 52], ["ICs", "CELL", 41, 44], ["ECs", "CELL", 49, 52], ["ICs", "CELL_TYPE", 41, 44], ["ECs", "CELL_TYPE", 49, 52], ["tests", "TEST", 115, 120], ["individual monitoring", "TEST", 205, 226], ["each diagnostic reaction", "PROBLEM", 230, 254]]], ["For example, the detection of technical errors or PCR amplification inhibitors is intrinsically impossible if only ECs are used.", [["ECs", "ANATOMY", 115, 118], ["ECs", "CELL", 115, 118], ["ECs", "CELL_TYPE", 115, 118], ["technical errors", "PROBLEM", 30, 46], ["PCR amplification inhibitors", "TREATMENT", 50, 78]]], ["In addition, ECs are usually undistinguishable from the native genome.IntroductionHere, our objective was to develop and test on a large number of clinical samples a bacteriophage-based IC system suitable for a standard laboratory of medical virology.", [["ECs", "ANATOMY", 13, 16], ["ECs", "CELL", 13, 16], ["genome", "CELLULAR_COMPONENT", 63, 69], ["ECs", "CELL_TYPE", 13, 16], ["native genome", "DNA", 56, 69], ["a bacteriophage", "TREATMENT", 164, 179], ["native genome", "OBSERVATION", 56, 69]]], ["We present results obtained by using T4 and MS2 bacteriophages as ICs in a routine-based evaluation includingExternal controls (ECs)Important criteria for the design of ECs include (i) the possibility to use quantified or semi quantified controls (in order to manage the detection level of the diagnostic test used), (ii) the possibility to distinguish amplicons obtained from ECs from those obtained from the detected pathogen (in order to detect false positives due to accidental amplification of EC) and (iii) the use of relevant nucleic acids (ie, RNA and DNA molecules for RNA and DNA viruses, respectively).External controls (ECs)Simple protocols for preparing plasmid DNA or synthetic RNA quantified controls are described in Supporting Information S1 and schematised in figure 1.", [["ECs", "ANATOMY", 128, 131], ["ECs", "ANATOMY", 169, 172], ["ECs", "ANATOMY", 377, 380], ["EC", "ANATOMY", 499, 501], ["ECs", "ANATOMY", 632, 635], ["nucleic acids", "CHEMICAL", 533, 546], ["T4", "SIMPLE_CHEMICAL", 37, 39], ["ECs", "CELL", 128, 131], ["ECs", "CELL", 169, 172], ["ECs", "CELL", 377, 380], ["EC", "CELL", 499, 501], ["nucleic acids", "SIMPLE_CHEMICAL", 533, 546], ["DNA", "CELLULAR_COMPONENT", 560, 563], ["DNA", "CELLULAR_COMPONENT", 586, 589], ["ECs", "CELL", 632, 635], ["DNA", "CELLULAR_COMPONENT", 675, 678], ["ECs", "CELL_TYPE", 128, 131], ["ECs", "CELL_TYPE", 169, 172], ["ECs", "CELL_TYPE", 377, 380], ["EC", "CELL_TYPE", 499, 501], ["DNA molecules", "PROTEIN", 560, 573], ["ECs", "CELL_TYPE", 632, 635], ["plasmid DNA", "DNA", 667, 678], ["T4 and MS2 bacteriophages", "TREATMENT", 37, 62], ["a routine-based evaluation", "TEST", 73, 99], ["External controls (ECs", "TREATMENT", 109, 131], ["the diagnostic test", "TEST", 290, 309], ["amplicons", "PROBLEM", 353, 362], ["false positives", "PROBLEM", 448, 463], ["relevant nucleic acids", "TREATMENT", 524, 546], ["RNA and DNA molecules", "TREATMENT", 552, 573], ["RNA and DNA viruses", "PROBLEM", 578, 597], ["External controls (ECs", "TREATMENT", 613, 635], ["Simple protocols", "TREATMENT", 636, 652], ["preparing plasmid DNA", "TREATMENT", 657, 678], ["synthetic RNA quantified controls", "TREATMENT", 682, 715]]], ["Such controls include specific sequences for the hybridisation of detection primers and probe, but also an exogenic ''Not I'' sequence (detectable by a specific probe or cleavable by the Not I restriction enzyme).Internal controls (ICs)2a. rt-PCR assays for the detection of T4 and MS2 bacteriophages.", [["T4", "GENE_OR_GENE_PRODUCT", 275, 277], ["exogenic ''Not I'' sequence", "DNA", 107, 134], ["Not I restriction enzyme", "PROTEIN", 187, 211], ["T4", "SPECIES", 275, 277], ["specific sequences", "TEST", 22, 40], ["detection primers", "TEST", 66, 83], ["Internal controls (ICs)", "TREATMENT", 213, 236], ["a. rt-PCR assays", "TEST", 237, 253], ["the detection", "TEST", 258, 271], ["T4 and MS2 bacteriophages", "PROBLEM", 275, 300], ["T4", "ANATOMY", 275, 277], ["MS2 bacteriophages", "OBSERVATION", 282, 300]]], ["The criteria to be addresses regarding ICs were: (i) to monitor all steps of the diagnostic procedure (extraction, RT, PCR); (ii) to be amenable for DNA and RNA viruses ; (iii) to rely on a detection system specific of the phage(s) to avoid complex molecular constructs; (iv) to be usable in either simplex or multiplex format, and in one-step or two-step RT-PCR reactions.Internal controls (ICs)We used freeze-dried E. coli Enterobacteria phage T4 (T4) and Enterobacteria phage MS2 (MS2) obtained from the American Type Culture Collection (ATCC ref.", [["DNA", "CELLULAR_COMPONENT", 149, 152], ["E. coli", "ORGANISM", 417, 424], ["Enterobacteria phage T4", "ORGANISM", 425, 448], ["T4", "CANCER", 450, 452], ["Enterobacteria phage MS2", "ORGANISM", 458, 482], ["E. coli", "SPECIES", 417, 424], ["E. coli", "SPECIES", 417, 424], ["the diagnostic procedure", "TREATMENT", 77, 101], ["extraction", "TREATMENT", 103, 113], ["RT, PCR", "TEST", 115, 122], ["DNA and RNA viruses", "PROBLEM", 149, 168], ["a detection system", "TEST", 188, 206], ["complex molecular constructs", "PROBLEM", 241, 269], ["PCR reactions", "PROBLEM", 359, 372], ["Internal controls (ICs", "TREATMENT", 373, 395], ["freeze", "TEST", 404, 410], ["dried E. coli Enterobacteria phage", "TEST", 411, 445], ["Enterobacteria phage MS2", "PROBLEM", 458, 482]]], ["11303-B4 & 15597-B1, respectively).", [["11303-B4 & 15597-B1", "CHEMICAL", 0, 19]]], ["Protocols for real time PCR detection of phages TA and MS2 were elaborated in various formats and are described in Supporting Information S2.", [["real time PCR", "TEST", 14, 27], ["phages TA", "TEST", 41, 50], ["MS2", "TEST", 55, 58]]], ["Briefly, primers and probes targeting T4 phage (T4F CCATCCATAGAGAAAATATCAGAACGA, T4R TAAATAATTCCTCTTTTCCCAGCG, T4probe VIC-AACCAGTAATTTCATCTGCTTCTGATGTGAGGC-TAM-RA) and MS2 phage (MS2F CTCTGAGAGCGGCTCTATTGGT, MS2R GTTCCCTACAACGAGCCTAAATTC, MS2probe VIC-TCAGACACGCGGTCCGCTATAACGA-TAMRA) were designed from genomic sequences.", [["T4 phage", "DNA", 38, 46], ["MS2 phage", "DNA", 169, 178], ["genomic sequences", "DNA", 305, 322], ["T4 phage", "TEST", 38, 46], ["T4F", "TEST", 48, 51], ["CCATCCATAGAGAAAATATCAGAACGA", "TEST", 52, 79], ["TAAATAATTCCTCTTTTCCCAGCG", "TEST", 85, 109], ["AACCAGTAATTTCATCTGCTTCTGATGTGAGGC", "TEST", 123, 156], ["MS2 phage", "TREATMENT", 169, 178], ["CTCTGAGAGCGGCTCTATTGGT", "TEST", 185, 207]]], ["Optimised oligonucleotide concentrations were 10pmol for primers and 4pmol for probes for both T4 and MS2 detection assays.Internal controls (ICs)2b.", [["oligonucleotide concentrations", "TEST", 10, 40], ["primers", "PROBLEM", 57, 64], ["probes", "TEST", 79, 85], ["both T4 and MS2 detection assays", "TEST", 90, 122], ["Internal controls (ICs)", "TREATMENT", 123, 146]]], ["Spiking and validation procedures.", [["validation procedures", "TREATMENT", 12, 33]]], ["A suspension of T4 and MS2 phages was used for spiking clinical samples.", [["samples", "ANATOMY", 64, 71], ["T4", "SIMPLE_CHEMICAL", 16, 18], ["A suspension of T4 and MS2 phages", "TREATMENT", 0, 33], ["suspension", "OBSERVATION_MODIFIER", 2, 12], ["T4", "ANATOMY", 16, 18], ["MS2 phages", "OBSERVATION", 23, 33]]], ["Both phages were diluted to provide a similar level of detection by rt-PCR.Internal controls (ICs)The following format was used: Similarly, the influence of spiking on the sensitivity of rt-PCR detection was evaluated by comparing detection of enterovirus (EV) and CMV in serial dilutions of cell culture supernatant media and a series of positive clinical samples spiked with T4-MS2 mix in either Two-step or One-step rt-PCR format (see Supporting Information S4).", [["cell", "ANATOMY", 292, 296], ["samples", "ANATOMY", 357, 364], ["enterovirus", "ORGANISM", 244, 255], ["EV", "ORGANISM", 257, 259], ["CMV", "ORGANISM", 265, 268], ["cell", "CELL", 292, 296], ["T4", "SIMPLE_CHEMICAL", 377, 379], ["EV", "SPECIES", 257, 259], ["CMV", "SPECIES", 265, 268], ["rt-PCR", "TEST", 68, 74], ["Internal controls (ICs)", "TREATMENT", 75, 98], ["rt-PCR detection", "TEST", 187, 203], ["enterovirus", "PROBLEM", 244, 255], ["CMV", "TEST", 265, 268], ["cell culture supernatant media", "TEST", 292, 322], ["positive clinical samples", "PROBLEM", 339, 364], ["T4-MS2 mix", "TREATMENT", 377, 387]]], ["Table 1 were included in the study.Routine applicationThe approval of the relevant Ethics Committee (IFR48, Marseilles, France) was obtained for investigating the benefit of using phage spiking, but individual consent from patients was not required since French national regulations under the term of Biomedical Research (Loi Huriet-S\u00e9rusclat (loi 881138)) indicate that the signature at the hospital entrance office warrants that all samples taken during hospitalization for diagnostic purposes are accessible for research (excluding human genetic research) without the specific consent of the patient.Routine application2b.", [["samples", "ANATOMY", 435, 442], ["patients", "ORGANISM", 223, 231], ["human", "ORGANISM", 535, 540], ["patient", "ORGANISM", 595, 602], ["application2b", "PROTEIN", 611, 624], ["patients", "SPECIES", 223, 231], ["human", "SPECIES", 535, 540], ["patient", "SPECIES", 595, 602], ["human", "SPECIES", 535, 540], ["the study", "TEST", 25, 34], ["Routine application", "TREATMENT", 35, 54], ["phage spiking", "PROBLEM", 180, 193], ["diagnostic purposes", "TEST", 476, 495], ["Routine application2b", "TREATMENT", 603, 624]]], ["Spiking and rt-PCR assays.", [["Spiking and rt-PCR assays", "PROBLEM", 0, 25]]], ["A 200ml volume of each 8,950 clinical specimens was spiked (according to the procedure described above) before extraction which was performed onto the MagNA Pure LC instrument (Roche) using the High Pure Viral Nucleic Acid Kit (DNA extraction) or the MagNA Pure LC RNA isolation High Performance kit (RNA extraction) according to manufacturer's recommendations.", [["specimens", "ANATOMY", 38, 47], ["DNA", "CELLULAR_COMPONENT", 228, 231], ["clinical specimens", "TEST", 29, 47], ["the procedure", "TREATMENT", 73, 86], ["extraction", "TREATMENT", 111, 121], ["the High Pure Viral Nucleic Acid Kit (DNA extraction", "TREATMENT", 190, 242], ["the MagNA Pure LC RNA isolation", "TREATMENT", 247, 278], ["High Performance kit (RNA extraction", "TREATMENT", 279, 315]]], ["CSF, amniotic fluids, biopsy tissues, effusions and aqueous humor were processed for DNA+RNA extraction using the BioRobot EZ1 with the Virus Mini Kit v2.0 (both from Qiagen).", [["amniotic fluids", "ANATOMY", 5, 20], ["biopsy tissues", "ANATOMY", 22, 36], ["effusions", "ANATOMY", 38, 47], ["aqueous humor", "ANATOMY", 52, 65], ["effusions", "DISEASE", 38, 47], ["CSF", "ORGANISM_SUBSTANCE", 0, 3], ["amniotic fluids", "ORGANISM_SUBSTANCE", 5, 20], ["biopsy tissues", "TISSUE", 22, 36], ["aqueous humor", "ORGANISM_SUBSTANCE", 52, 65], ["DNA", "CELLULAR_COMPONENT", 85, 88], ["BioRobot EZ1", "PROTEIN", 114, 126], ["CSF, amniotic fluids", "TEST", 0, 20], ["biopsy tissues", "TEST", 22, 36], ["effusions", "PROBLEM", 38, 47], ["aqueous humor", "PROBLEM", 52, 65], ["DNA", "PROBLEM", 85, 88], ["RNA extraction", "TREATMENT", 89, 103], ["the BioRobot EZ1", "TREATMENT", 110, 126], ["amniotic fluids", "OBSERVATION", 5, 20], ["effusions", "OBSERVATION", 38, 47]]], ["Reverse transcription was performed for RNA viruses using the TaqMan Reverse Transcription Reagents kit (Roche) and random hexanucleotides as per manufacturer's instructions.", [["hexanucleotides", "CHEMICAL", 123, 138], ["Reverse transcription", "TREATMENT", 0, 21], ["RNA viruses", "PROBLEM", 40, 51], ["the TaqMan", "TREATMENT", 58, 68], ["random hexanucleotides", "TREATMENT", 116, 138]]], ["For each specimen: (i) rt-PCR reactions were carried out according to medical prescription (Table 1) , and (ii) distinct rt-PCR reactions for detection of T4 or MS2 were performed under a 15 mL reaction format (7,5 mL of mastermix, 3 pmol of each primer and 1,2 pmol of probe) and a standard cycling protocol (50uC for 2 min, 95uC for 10 min and 45 cycles 95uC for 15 sec, 60uC for 1 min).", [["specimen", "ANATOMY", 9, 17], ["T4", "SIMPLE_CHEMICAL", 155, 157], ["rt-PCR reactions", "PROBLEM", 23, 39], ["distinct rt-PCR reactions", "TEST", 112, 137], ["T4 or MS2", "PROBLEM", 155, 164], ["mastermix", "TREATMENT", 221, 230], ["each primer", "TREATMENT", 242, 253], ["a standard cycling protocol", "TREATMENT", 281, 308], ["T4", "ANATOMY", 155, 157]]], ["For each series of T4 and MS2 rt-PCR, the mean Ct value and the standard deviation within the series were calculated.", [["T4", "TEST", 19, 21], ["MS2 rt-PCR", "TEST", 26, 36], ["Ct value", "TEST", 47, 55], ["the standard deviation within the series", "TEST", 60, 100]]], ["Each individual reaction was subsequently analysed as follows:Routine application(i) If the Ct value was equal to or lower than the mean Ct value of the series +1SD, it was recorded as ''correct detection of the phage'' (CDP), and associated with the absence of detectable inhibitor or technical problem while processing the corresponding sample. (ii) If the Ct value was higher than the mean Ct value of the series +1SD (or undetectable), it was recorded as ''inefficient detection of the phage'' (IDP), and associated with the presence of amplification inhibitor(s) or technical problem while processing the corresponding sample.Routine applicationN When IDP was associated with a positive PCR (detection of a pathogen), this result was validated despite the presence of inhibitors (this would not apply to the case in which quantification of viral load is necessary).Routine applicationN When IDP was associated with negative PCR detection results, a new assay was performed using a tenfold dilution of the nucleic acid extract.", [["nucleic acid", "CHEMICAL", 1010, 1022], ["Each individual reaction", "PROBLEM", 0, 24], ["the Ct value", "TEST", 88, 100], ["Ct value", "TEST", 137, 145], ["detectable inhibitor or technical problem", "PROBLEM", 262, 303], ["the Ct value", "TEST", 355, 367], ["the mean Ct value", "TEST", 384, 401], ["amplification inhibitor", "TREATMENT", 541, 564], ["technical problem", "PROBLEM", 571, 588], ["Routine applicationN", "TREATMENT", 631, 651], ["a positive PCR", "PROBLEM", 681, 695], ["a pathogen", "PROBLEM", 710, 720], ["inhibitors", "TREATMENT", 773, 783], ["viral load", "PROBLEM", 845, 855], ["Routine applicationN", "TREATMENT", 870, 890], ["a new assay", "TEST", 952, 963], ["a tenfold dilution", "TREATMENT", 984, 1002], ["the nucleic acid extract", "TREATMENT", 1006, 1030]]], ["Positive results were validated.Optimization and validation of proceduresThe detection of EV and CMV in serial dilutions of supernatant cell culture media or in series of positive clinical samples spiked with T4-MS2 mix was performed and the comparison of the Ct values showed that neither the addition of the phage mix itself (Wilcoxon test, p = 0.18 for CMV and 0.45 for EV), nor the presence of phage-specific primers and probe in the reaction mix (Wilcoxon test, p = 0.77 for CMV and 0.18 for EV) did interfere with the Ct value associated with viral detection in Two-step (Table 2 and 3) and One-step rt-PCR.Phage spiking in routine rt-PCR virological diagnosisDuring the period of study, 8,950 clinical samples were spiked with phages and tested: 7,397 for the presence of DNA viruses only, 337 for the presence of RNA viruses only and 1,216 for both, corresponding to a total of 45,530 results transmitted to the prescribers (see details in Figure 2 ).Phage spiking in routine rt-PCR virological diagnosisInhibitors could be detected for all types of samples, but with highly variable rates (analysis performed for series including a minimum of 10 samples): less than 10% in the case of pleural effusions and sputum samples, genital and pharynx swabs, lymph nodes and placentas; 10% to 30% for EDTA whole blood, white blood cells, sera, biopsies, pericardial and peritoneal effusions, bronchial aspiration, CSF, amniotic fluids, others swabs, urine, aqueous humor and culture cells; 30% to 50% for plasma, BAL and stools; more than 50% for heparinized plasma and bone marrow.Phage spiking in routine rt-PCR virological diagnosisIDPs were significantly more frequently detected for MS2 (RNA) than T4 (DNA) in plasma, BAL and CSF samples (p,0.05, Khi2 test, Yates corrected).", [["supernatant cell", "ANATOMY", 124, 140], ["samples", "ANATOMY", 189, 196], ["samples", "ANATOMY", 709, 716], ["samples", "ANATOMY", 1058, 1065], ["pleural effusions", "ANATOMY", 1194, 1211], ["sputum samples", "ANATOMY", 1216, 1230], ["genital", "ANATOMY", 1232, 1239], ["pharynx swabs", "ANATOMY", 1244, 1257], ["lymph nodes", "ANATOMY", 1259, 1270], ["placentas", "ANATOMY", 1275, 1284], ["whole blood", "ANATOMY", 1306, 1317], ["white blood cells", "ANATOMY", 1319, 1336], ["sera", "ANATOMY", 1338, 1342], ["biopsies", "ANATOMY", 1344, 1352], ["pericardial", "ANATOMY", 1354, 1365], ["peritoneal effusions", "ANATOMY", 1370, 1390], ["bronchial", "ANATOMY", 1392, 1401], ["amniotic fluids", "ANATOMY", 1419, 1434], ["swabs", "ANATOMY", 1443, 1448], ["urine", "ANATOMY", 1450, 1455], ["aqueous humor", "ANATOMY", 1457, 1470], ["culture cells", "ANATOMY", 1475, 1488], ["plasma", "ANATOMY", 1505, 1511], ["BAL", "ANATOMY", 1513, 1516], ["stools", "ANATOMY", 1521, 1527], ["plasma", "ANATOMY", 1559, 1565], ["bone marrow", "ANATOMY", 1570, 1581], ["plasma", "ANATOMY", 1715, 1721], ["BAL", "ANATOMY", 1723, 1726], ["CSF samples", "ANATOMY", 1731, 1742], ["pleural effusions", "DISEASE", 1194, 1211], ["pericardial and peritoneal effusions", "DISEASE", 1354, 1390], ["EDTA", "CHEMICAL", 1301, 1305], ["CMV", "ORGANISM", 97, 100], ["cell", "CELL", 136, 140], ["T4", "SIMPLE_CHEMICAL", 209, 211], ["CMV", "ORGANISM", 356, 359], ["CMV", "ORGANISM", 480, 483], ["samples", "CANCER", 709, 716], ["DNA", "CELLULAR_COMPONENT", 779, 782], ["samples", "CANCER", 1058, 1065], ["samples", "CANCER", 1155, 1162], ["pleural effusions", "PATHOLOGICAL_FORMATION", 1194, 1211], ["sputum samples", "CANCER", 1216, 1230], ["genital", "ORGANISM_SUBDIVISION", 1232, 1239], ["pharynx swabs", "MULTI-TISSUE_STRUCTURE", 1244, 1257], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 1259, 1270], ["placentas", "MULTI-TISSUE_STRUCTURE", 1275, 1284], ["EDTA", "SIMPLE_CHEMICAL", 1301, 1305], ["blood", "ORGANISM_SUBSTANCE", 1312, 1317], ["white blood cells", "CELL", 1319, 1336], ["sera", "ORGANISM_SUBSTANCE", 1338, 1342], ["biopsies", "TISSUE", 1344, 1352], ["pericardial", "MULTI-TISSUE_STRUCTURE", 1354, 1365], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 1370, 1380], ["CSF", "ORGANISM_SUBSTANCE", 1414, 1417], ["amniotic fluids", "ORGANISM_SUBSTANCE", 1419, 1434], ["urine", "ORGANISM_SUBSTANCE", 1450, 1455], ["aqueous humor", "ORGANISM_SUBSTANCE", 1457, 1470], ["culture cells", "CELL", 1475, 1488], ["plasma", "ORGANISM_SUBSTANCE", 1505, 1511], ["BAL", "ORGANISM_SUBSTANCE", 1513, 1516], ["stools", "ORGANISM_SUBSTANCE", 1521, 1527], ["plasma", "ORGANISM_SUBSTANCE", 1559, 1565], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 1570, 1581], ["DNA", "CELLULAR_COMPONENT", 1707, 1710], ["plasma", "ORGANISM_SUBSTANCE", 1715, 1721], ["BAL", "ORGANISM_SUBSTANCE", 1723, 1726], ["CSF samples", "ORGANISM_SUBSTANCE", 1731, 1742], ["white blood cells", "CELL_TYPE", 1319, 1336], ["EV", "SPECIES", 90, 92], ["CMV", "SPECIES", 97, 100], ["procedures", "TREATMENT", 63, 73], ["The detection", "TEST", 73, 86], ["EV", "TEST", 90, 92], ["CMV", "PROBLEM", 97, 100], ["serial dilutions", "TEST", 104, 120], ["supernatant cell culture media", "TEST", 124, 154], ["positive clinical samples", "PROBLEM", 171, 196], ["T4-MS2 mix", "TEST", 209, 219], ["the Ct values", "TEST", 256, 269], ["Wilcoxon test", "TEST", 328, 341], ["p", "TEST", 343, 344], ["CMV", "TEST", 356, 359], ["Wilcoxon test", "TEST", 452, 465], ["p", "TEST", 467, 468], ["CMV", "TEST", 480, 483], ["the Ct value", "TEST", 520, 532], ["viral detection", "TEST", 549, 564], ["One-step rt-PCR", "TEST", 597, 612], ["routine rt-PCR", "TEST", 630, 644], ["study", "TEST", 687, 692], ["clinical samples", "TEST", 700, 716], ["DNA viruses", "PROBLEM", 779, 790], ["RNA viruses", "PROBLEM", 821, 832], ["routine rt-PCR virological diagnosisInhibitors", "TREATMENT", 976, 1022], ["series", "TEST", 1122, 1128], ["pleural effusions", "PROBLEM", 1194, 1211], ["sputum samples", "TEST", 1216, 1230], ["genital and pharynx swabs", "TEST", 1232, 1257], ["lymph nodes", "TEST", 1259, 1270], ["placentas", "TEST", 1275, 1284], ["EDTA whole blood", "TEST", 1301, 1317], ["white blood cells", "TEST", 1319, 1336], ["sera", "TEST", 1338, 1342], ["biopsies", "TEST", 1344, 1352], ["pericardial and peritoneal effusions", "PROBLEM", 1354, 1390], ["bronchial aspiration", "PROBLEM", 1392, 1412], ["CSF, amniotic fluids", "TEST", 1414, 1434], ["others swabs", "TEST", 1436, 1448], ["urine", "TEST", 1450, 1455], ["aqueous humor", "TEST", 1457, 1470], ["culture cells", "TEST", 1475, 1488], ["plasma, BAL", "TEST", 1505, 1516], ["stools", "TEST", 1521, 1527], ["heparinized plasma and bone marrow", "TEST", 1547, 1581], ["routine rt-PCR virological diagnosisIDPs", "TEST", 1599, 1639], ["MS2 (RNA", "TEST", 1688, 1696], ["T4 (DNA) in plasma, BAL", "TEST", 1703, 1726], ["CSF samples", "TEST", 1731, 1742], ["p", "TEST", 1744, 1745], ["Khi2 test", "TEST", 1752, 1761], ["CMV", "OBSERVATION", 97, 100], ["supernatant cell", "OBSERVATION", 124, 140], ["RNA viruses", "OBSERVATION", 821, 832], ["pleural", "ANATOMY", 1194, 1201], ["effusions", "OBSERVATION", 1202, 1211], ["genital", "ANATOMY", 1232, 1239], ["pharynx", "ANATOMY", 1244, 1251], ["lymph nodes", "OBSERVATION", 1259, 1270], ["pericardial", "ANATOMY", 1354, 1365], ["peritoneal", "ANATOMY", 1370, 1380], ["effusions", "OBSERVATION", 1381, 1390], ["bronchial", "ANATOMY", 1392, 1401], ["aspiration", "OBSERVATION", 1402, 1412], ["stools", "OBSERVATION", 1521, 1527], ["bone marrow", "ANATOMY", 1570, 1581]]], ["Conversely, IDPs were significantly more frequently detected for T4 than MS2 in stools (p,0.05, Khi2 test, Yates corrected).Phage spiking in routine rt-PCR virological diagnosisFinally, it was noted that clinical samples stored at 280uC prior extraction exhibited an IDP rate lower than 30%.DiscussionRt-PCR and rt-RT-PCR techniques are now widely used for the molecular diagnosis of viral infections.", [["samples", "ANATOMY", 213, 220], ["viral infections", "DISEASE", 384, 400], ["IDPs", "GENE_OR_GENE_PRODUCT", 12, 16], ["T4", "SIMPLE_CHEMICAL", 65, 67], ["stools", "ORGANISM_SUBSTANCE", 80, 86], ["IDPs", "PROTEIN", 12, 16], ["Khi2 test", "TEST", 96, 105], ["routine rt-PCR virological diagnosis", "TEST", 141, 177], ["clinical samples", "TEST", 204, 220], ["prior extraction", "TREATMENT", 237, 253], ["an IDP rate", "TEST", 264, 275], ["DiscussionRt", "TEST", 291, 303], ["PCR", "TEST", 304, 307], ["rt-RT-PCR techniques", "TREATMENT", 312, 332], ["viral infections", "PROBLEM", 384, 400], ["viral", "OBSERVATION_MODIFIER", 384, 389], ["infections", "OBSERVATION", 390, 400]]], ["Our study was focused on the importance of quality controls for such diagnostic assays.", [["Our study", "TEST", 0, 9], ["such diagnostic assays", "TEST", 64, 86]]], ["We proposed a simple protocol for synthesizing specific external controls which combines standard techniques for obtaining quantified DNA or RNA positive controls.", [["DNA", "CELLULAR_COMPONENT", 134, 137], ["a simple protocol", "TREATMENT", 12, 29], ["synthesizing specific external controls", "TREATMENT", 34, 73], ["quantified DNA", "PROBLEM", 123, 137], ["RNA positive controls", "PROBLEM", 141, 162]]], ["Importantly, these controls were designed to include an extrinsic sequence that contains a (very rare) cutting site for the NotI restriction enzyme.", [["NotI", "GENE_OR_GENE_PRODUCT", 124, 128], ["NotI restriction enzyme", "PROTEIN", 124, 147], ["an extrinsic sequence", "TEST", 53, 74], ["a (very rare) cutting site", "PROBLEM", 89, 115], ["the NotI restriction enzyme", "TEST", 120, 147]]], ["This provides a simple tool for using adapted and reproducible amounts of positive controls, and also for identifying PCR contamination due to carry over of the positive control.", [["PCR contamination", "PROBLEM", 118, 135], ["the positive control", "TREATMENT", 157, 177]]], ["This detection can be performed by real time amplification using the specific Not I probe (Figure 1 [4, 5, 6, 7] .", [["Not I probe", "DNA", 78, 89], ["This detection", "TEST", 0, 14]]], ["Our study confirms that the performance of 'home made' tests can be significantly improved by the used of phage-based internal controls, but, most importantly, shows that such controls can be used for routine virological diagnosis and usable for a variety of clinical samples.", [["samples", "ANATOMY", 268, 275], ["samples", "CANCER", 268, 275], ["Our study", "TEST", 0, 9], ["' tests", "TEST", 53, 60], ["phage", "TREATMENT", 106, 111], ["routine virological diagnosis", "TEST", 201, 230], ["clinical samples", "TEST", 259, 275]]], ["Here, clinical samples were spiked with both T4 and MS2 phages, allowing the detection of inhibitors for both DNA and RNA viruses.", [["samples", "ANATOMY", 15, 22], ["samples", "CANCER", 15, 22], ["T4", "SIMPLE_CHEMICAL", 45, 47], ["DNA", "CELLULAR_COMPONENT", 110, 113], ["clinical samples", "TEST", 6, 22], ["both T4 and MS2 phages", "PROBLEM", 40, 62], ["inhibitors", "TREATMENT", 90, 100], ["both DNA", "PROBLEM", 105, 113], ["RNA viruses", "PROBLEM", 118, 129], ["RNA viruses", "OBSERVATION", 118, 129]]], ["Thirty-six different types of clinical samples were tested (including various blood samples, cerebrospi- nal fluids, stools, respiratory samples, swabs, biopsies or effusion fluids) and a large number of samples were tested in the context of an hospital routine molecular virology laboratory.", [["samples", "ANATOMY", 39, 46], ["blood samples", "ANATOMY", 78, 91], ["stools", "ANATOMY", 117, 123], ["respiratory samples", "ANATOMY", 125, 144], ["swabs", "ANATOMY", 146, 151], ["biopsies", "ANATOMY", 153, 161], ["effusion fluids", "ANATOMY", 165, 180], ["samples", "ANATOMY", 204, 211], ["samples", "CANCER", 39, 46], ["blood samples", "ORGANISM_SUBSTANCE", 78, 91], ["stools", "ORGANISM_SUBDIVISION", 117, 123], ["biopsies", "TISSUE", 153, 161], ["samples", "CANCER", 204, 211], ["clinical samples", "TEST", 30, 46], ["various blood samples", "TEST", 70, 91], ["cerebrospi- nal fluids", "TREATMENT", 93, 115], ["stools", "PROBLEM", 117, 123], ["respiratory samples", "TEST", 125, 144], ["swabs", "TEST", 146, 151], ["biopsies", "TEST", 153, 161], ["effusion fluids", "PROBLEM", 165, 180], ["effusion", "OBSERVATION", 165, 173], ["large", "OBSERVATION_MODIFIER", 188, 193]]], ["The use of phages as internal controls proved to be extremely versatile and could be adapted to a broad range of methods and pathogens.", [["phages", "TREATMENT", 11, 17], ["pathogens", "PROBLEM", 125, 134]]], ["It was validated for both PCR and RT-PCR real time techniques, in simplex or multiplex format and, in the case of RT-PCR assays, one-step or two-step amplification formats.", [["simplex", "ORGANISM", 66, 73], ["both PCR", "TEST", 21, 29], ["RT-PCR", "TEST", 34, 40], ["RT-PCR assays", "TEST", 114, 127]]], ["This is important and suggests that a strategy including phage-based internal controls can be implemented in diagnostic laboratories irrespective of the technical characteristics of the amplification methods used for routine tests.", [["a strategy including phage-based internal controls", "TREATMENT", 36, 86], ["the amplification methods", "TREATMENT", 182, 207], ["routine tests", "TEST", 217, 230]]], ["In our experience, the simplex format strategy (i.e. based on testing phages and viral pathogens in distinct amplification reactions) proved to be the most simple and costeffective for routine molecular diagnosis since it does not require the specific development of multiplex reactions and relies on a unique control reaction for DNA viruses and another for RNA viruses.DiscussionOur study identified different frequencies of inhibitors according to the nature of the clinical samples.", [["samples", "ANATOMY", 478, 485], ["DNA", "CELLULAR_COMPONENT", 331, 334], ["the simplex format strategy", "TREATMENT", 19, 46], ["testing phages", "TREATMENT", 62, 76], ["viral pathogens", "PROBLEM", 81, 96], ["distinct amplification reactions", "PROBLEM", 100, 132], ["multiplex reactions", "PROBLEM", 267, 286], ["a unique control reaction", "TREATMENT", 301, 326], ["DNA viruses", "PROBLEM", 331, 342], ["RNA viruses", "PROBLEM", 359, 370], ["DiscussionOur study", "TEST", 371, 390], ["different frequencies of inhibitors", "TREATMENT", 402, 437], ["the clinical samples", "TEST", 465, 485]]], ["In samples such as CSF, sera or pharynx swabs, inhibitors were identified in ,10% and ,15-20% for DNA and RNA virus detection, respectively.", [["samples", "ANATOMY", 3, 10], ["sera", "ANATOMY", 24, 28], ["pharynx swabs", "ANATOMY", 32, 45], ["CSF", "GENE_OR_GENE_PRODUCT", 19, 22], ["sera", "ORGANISM_SUBSTANCE", 24, 28], ["pharynx swabs", "MULTI-TISSUE_STRUCTURE", 32, 45], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["CSF, sera or pharynx swabs", "TEST", 19, 45], ["inhibitors", "TREATMENT", 47, 57], ["DNA", "PROBLEM", 98, 101], ["RNA virus detection", "TEST", 106, 125], ["pharynx", "ANATOMY", 32, 39]]], ["These values are unexpectedly high, and imply that a significant number of samples with results believed to be ''negative'' in the absence of an internal control should be considered ''unresolved''.", [["samples", "CANCER", 75, 82], ["These values", "TEST", 0, 12], ["an internal control", "TREATMENT", 142, 161], ["high", "OBSERVATION_MODIFIER", 30, 34], ["significant", "OBSERVATION_MODIFIER", 53, 64]]], ["Specific samples such as heparinized blood (72,9% of inhibitors for DNA virus detection), bone marrow (73.8% of inhibitors for DNA virus detection) and stools (36.6% and 20.8% of inhibitors for DNA and RNA viruses detection, respectively) may also benefit from the detection of inhibitors and the identification of ''unresolved'' tests.DiscussionIt should be noted that the frequency of amplification inhibition not only relates to the nature of the sample tested, but is also intrinsically linked with the technical protocols used for the extraction and amplification of nucleic acids.", [["samples", "ANATOMY", 9, 16], ["heparinized blood", "ANATOMY", 25, 42], ["bone marrow", "ANATOMY", 90, 101], ["nucleic acids", "CHEMICAL", 572, 585], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["DNA", "CELLULAR_COMPONENT", 68, 71], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 90, 101], ["DNA", "CELLULAR_COMPONENT", 127, 130], ["DNA", "CELLULAR_COMPONENT", 194, 197], ["nucleic acids", "SIMPLE_CHEMICAL", 572, 585], ["Specific samples", "TEST", 0, 16], ["heparinized blood", "TREATMENT", 25, 42], ["inhibitors", "TREATMENT", 53, 63], ["DNA virus detection", "TEST", 68, 87], ["bone marrow", "TEST", 90, 101], ["inhibitors", "TREATMENT", 112, 122], ["DNA virus detection", "TEST", 127, 146], ["stools", "TEST", 152, 158], ["inhibitors", "TREATMENT", 179, 189], ["DNA", "PROBLEM", 194, 197], ["RNA viruses detection", "TEST", 202, 223], ["inhibitors", "TREATMENT", 278, 288], ["amplification inhibition", "PROBLEM", 387, 411], ["the technical protocols", "TREATMENT", 503, 526], ["the extraction", "TREATMENT", 536, 550], ["nucleic acids", "TREATMENT", 572, 585], ["bone marrow", "ANATOMY", 90, 101]]], ["In our experience, no major differences were observed when different silica column-or magnetic beads-based extraction techniques, or different commercialized PCR or RT-PCR kits, were tested (data not shown).", [["silica", "CHEMICAL", 69, 75], ["silica", "CHEMICAL", 69, 75], ["different silica column", "TEST", 59, 82], ["magnetic beads", "TREATMENT", 86, 100], ["based extraction techniques", "TREATMENT", 101, 128], ["different commercialized PCR", "TEST", 133, 161], ["RT-PCR kits", "TEST", 165, 176]]], ["However, a detailed analysis may reveal that specific techniques give better results when used for testing specific samples.", [["samples", "ANATOMY", 116, 123], ["a detailed analysis", "TEST", 9, 28], ["testing specific samples", "TEST", 99, 123]]], ["We suggest that, in the future, phage-based internal controls may constitute cost-effective tools with which to measure the frequency of amplification inhibition in specific samples.", [["samples", "ANATOMY", 174, 181], ["phage", "TREATMENT", 32, 37], ["amplification inhibition in specific samples", "PROBLEM", 137, 181]]], ["Estimation of this parameter may become a major criterion for the evaluation of extraction (and to a lesser extent amplification) techniques.DiscussionFinally, in the context of diagnostic virology laboratories, our study shows that standard extraction and amplification techniques used for the molecular diagnosis of human pathogens led to a significant proportion of 'unresolved' results, which cannot be identified if an internal control is not used.", [["human", "ORGANISM", 318, 323], ["human", "SPECIES", 318, 323], ["human", "SPECIES", 318, 323], ["the evaluation", "TEST", 62, 76], ["extraction", "TREATMENT", 80, 90], ["a lesser extent amplification) techniques", "TREATMENT", 99, 140], ["our study", "TEST", 212, 221], ["standard extraction", "TREATMENT", 233, 252], ["amplification techniques", "TREATMENT", 257, 281], ["human pathogens", "PROBLEM", 318, 333]]], ["In the absence of an internal control, such samples are commonly identified as 'negative', which is with hindsight incorrect: in our hands, detecting amplification inhibition using phages as internal controls, and testing tenfold dilutions of the nucleic acid extracts demonstrated that some of these samples were actually positives.", [["samples", "ANATOMY", 44, 51], ["extracts", "ANATOMY", 260, 268], ["samples", "ANATOMY", 301, 308], ["nucleic acid", "CHEMICAL", 247, 259], ["samples", "CANCER", 44, 51], ["samples", "CANCER", 301, 308], ["phages", "TREATMENT", 181, 187], ["internal controls", "TEST", 191, 208], ["testing tenfold dilutions", "TEST", 214, 239], ["the nucleic acid extracts", "TEST", 243, 268], ["these samples", "TEST", 295, 308], ["internal control", "OBSERVATION", 21, 37]]], ["This cost-effective and convenient strategy can therefore be used for enhancing the quality of routine molecular diagnosis, but it may also be adapted in other contexts such as testing of large numbers of animal or environmental samples.Supporting InformationSupporting Information S1 Preparation of DNA and RNA synthetic ECs.", [["samples", "ANATOMY", 229, 236], ["ECs", "ANATOMY", 322, 325], ["DNA", "CELLULAR_COMPONENT", 300, 303], ["ECs", "CELL", 322, 325], ["ECs", "CELL_TYPE", 322, 325], ["routine molecular diagnosis", "TEST", 95, 122], ["large", "OBSERVATION_MODIFIER", 188, 193]]]], "PMC7413178": [["BackgroundCardiovascular disease (CVD) is the number-one cause of death globally [1], with over three-quarters of deaths associated with CVD occurring in low- and middle-income countries (LMICs) [2].", [["BackgroundCardiovascular disease", "DISEASE", 0, 32], ["CVD", "DISEASE", 34, 37], ["death", "DISEASE", 66, 71], ["deaths", "DISEASE", 114, 120], ["CVD", "DISEASE", 137, 140], ["BackgroundCardiovascular disease (CVD", "PROBLEM", 0, 37], ["death", "PROBLEM", 66, 71], ["CVD", "PROBLEM", 137, 140], ["middle", "ANATOMY_MODIFIER", 163, 169]]], ["In Uganda, CVD accounts for 10% of all deaths, making it the most common noncommunicable cause of death in the country [3].", [["CVD", "DISEASE", 11, 14], ["deaths", "DISEASE", 39, 45], ["death", "DISEASE", 98, 103], ["death", "PROBLEM", 98, 103]]], ["The burden of CVD in Uganda also appears to be increasing, with the number of deaths attributed to ischemic heart disease increasing by 13.4% between 2007 and 2017 [4].BackgroundThe rising burden of CVD in LMICs has led to an increased prevalence of heart failure (HF) [56] \u2013 a common end result of CVD where the heart is unable to meet bodily demands for blood and oxygen [7].", [["heart", "ANATOMY", 108, 113], ["heart", "ANATOMY", 250, 255], ["heart", "ANATOMY", 313, 318], ["blood", "ANATOMY", 356, 361], ["CVD", "DISEASE", 14, 17], ["deaths", "DISEASE", 78, 84], ["ischemic heart disease", "DISEASE", 99, 121], ["CVD", "DISEASE", 199, 202], ["heart failure", "DISEASE", 250, 263], ["HF", "DISEASE", 265, 267], ["CVD", "DISEASE", 299, 302], ["oxygen", "CHEMICAL", 366, 372], ["oxygen", "CHEMICAL", 366, 372], ["heart", "ORGAN", 108, 113], ["heart", "ORGAN", 250, 255], ["heart", "ORGAN", 313, 318], ["blood", "ORGANISM_SUBSTANCE", 356, 361], ["oxygen", "SIMPLE_CHEMICAL", 366, 372], ["CVD", "PROBLEM", 14, 17], ["ischemic heart disease", "PROBLEM", 99, 121], ["CVD", "PROBLEM", 199, 202], ["heart failure", "PROBLEM", 250, 263], ["CVD", "PROBLEM", 299, 302], ["burden", "OBSERVATION_MODIFIER", 4, 10], ["CVD", "OBSERVATION", 14, 17], ["appears to be", "UNCERTAINTY", 33, 46], ["increasing", "OBSERVATION_MODIFIER", 47, 57], ["ischemic", "OBSERVATION_MODIFIER", 99, 107], ["heart", "ANATOMY", 108, 113], ["disease", "OBSERVATION", 114, 121], ["rising", "OBSERVATION_MODIFIER", 182, 188], ["burden", "OBSERVATION_MODIFIER", 189, 195], ["increased", "OBSERVATION_MODIFIER", 226, 235], ["heart", "ANATOMY", 250, 255], ["failure", "OBSERVATION", 256, 263], ["CVD", "OBSERVATION", 299, 302], ["heart", "ANATOMY", 313, 318]]], ["Although there is currently no cure for HF, proper lifestyle changes, symptom management, and medical therapy can allow individuals diagnosed with this condition to enjoy an improved quality of life [89].", [["HF", "DISEASE", 40, 42], ["HF", "PROBLEM", 40, 42], ["symptom management", "TREATMENT", 70, 88], ["medical therapy", "TREATMENT", 94, 109]]], ["Accordingly, digital health interventions have recently been developed to simplify the process of managing and tracking the symptoms of HF [10111213141516171819].", [["HF", "DISEASE", 136, 138], ["10111213141516171819", "CHEMICAL", 140, 160], ["digital health interventions", "TREATMENT", 13, 41], ["the symptoms", "PROBLEM", 120, 132], ["HF", "PROBLEM", 136, 138]]], ["One such intervention, which was developed alongside HF patients and clinicians living in Canada, has been shown to improve patient self-care and quality of life amongst Canadian HF patients [1920].BackgroundBased on the success of digital health interventions in high-income countries, digital health presents a potential means of mitigating the growing burden of HF in LMICs.", [["HF", "DISEASE", 179, 181], ["HF", "DISEASE", 365, 367], ["patients", "ORGANISM", 56, 64], ["patient", "ORGANISM", 124, 131], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 56, 64], ["patient", "SPECIES", 124, 131], ["patients", "SPECIES", 182, 190], ["digital health interventions", "TREATMENT", 232, 260], ["HF", "PROBLEM", 365, 367], ["HF", "OBSERVATION", 365, 367]]], ["Due to the increasing degree of mobile phone penetration in LMICs [21], a digital health intervention could serve as a low-cost, scalable, and effective means of tracking, managing, and detecting the symptoms of patients living with HF.", [["HF", "DISEASE", 233, 235], ["patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 212, 220], ["a digital health intervention", "TREATMENT", 72, 101], ["the symptoms", "PROBLEM", 196, 208], ["HF", "PROBLEM", 233, 235]]], ["That said, various interventions previously deployed in LMICs have been unsuccessful due to a lack of local patient and clinician engagement in the design process [22].", [["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115]]], ["With the goal of informing a future digital health intervention for use in Uganda, we engaged Ugandan HF patients and clinicians regarding their experiences with HF management and mobile phone technology.Ethics Approval and Consent to Participate ::: MethodsEthics approval was obtained from the Uganda National Council of Science and Technology (HS 2364), the Makerere University School of Medicine Research and Ethics Committee (REF 2017\u2013076), and the University Health Network Research Ethics Board (ID# 14-7510).", [["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["a future digital health intervention", "TREATMENT", 27, 63], ["HF management", "TREATMENT", 162, 175]]], ["All study participants were given a standardized explanation of the study protocol, including potential risks and benefits, and subsequently consented to participate by either signing or providing a fingerprint on a consent form.Study Population ::: MethodsPatients and clinicians were recruited from UHI.", [["participants", "SPECIES", 10, 22], ["the study protocol", "TEST", 64, 82]]], ["Patient participants were considered eligible if they had previously been diagnosed with HF by a physician at UHI.", [["HF", "DISEASE", 89, 91], ["Patient", "SPECIES", 0, 7], ["participants", "SPECIES", 8, 20], ["HF", "PROBLEM", 89, 91]]], ["A second eligibility criterion was that the patient spoke either English or Luganda, or that they had an accompanying caregiver that could interpret dialogue from a third language into English.", [["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51]]], ["Patients unable to participate due to the severity of their illness were asked whether their caregiver could speak on their behalf.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Clinician participants were considered eligible if they were a physician or nurse with direct experience caring for HF patients at UHI.Data Collection ::: MethodsA survey was deployed amongst HF patients at UHI.", [["HF", "DISEASE", 116, 118], ["HF", "DISEASE", 192, 194], ["patients", "ORGANISM", 119, 127], ["patients", "ORGANISM", 195, 203], ["participants", "SPECIES", 10, 22], ["patients", "SPECIES", 119, 127], ["patients", "SPECIES", 195, 203], ["HF", "PROBLEM", 116, 118]]], ["The survey contained three sections: Patient Information, Patient Opinion, and Medical Information.", [["Patient", "SPECIES", 37, 44]]], ["The first two sections were completed by patients, whereas the final section was filled in by a consulting physician.", [["sections", "ANATOMY", 14, 22], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49]]], ["The patient-filled portion of the survey included demographic information, self-reported health status, HF self-care behaviours, access to technology, and comfort with different communication channels.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["For the opinion-based items, which were loosely based on a previous questionnaire deployed in Canada [25], patients were asked to rate their level of agreement on a five-point Likert scale.", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115]]], ["The elicited medical information included time since HF diagnosis, number of annual visits to a HF clinic, New York Heart Association class, left ventricular ejection fraction, primary cause of HF, and comorbidities.Data Collection ::: MethodsSemi-structured interviews were completed with a separate set of HF patients, caregivers, physicians, and nurses at UHI.", [["left ventricular", "ANATOMY", 141, 157], ["HF", "DISEASE", 96, 98], ["HF", "DISEASE", 194, 196], ["ventricular", "MULTI-TISSUE_STRUCTURE", 146, 157], ["patients", "ORGANISM", 311, 319], ["patients", "SPECIES", 311, 319], ["left ventricular ejection fraction", "TEST", 141, 175], ["HF", "PROBLEM", 194, 196], ["comorbidities", "PROBLEM", 202, 215], ["left ventricular", "ANATOMY", 141, 157], ["ejection fraction", "OBSERVATION", 158, 175], ["HF", "OBSERVATION", 194, 196]]], ["Participants were asked about their experiences with the healthcare system, HF management, and technology.", [["Participants", "SPECIES", 0, 12], ["HF management", "TREATMENT", 76, 89]]], ["The line of questioning was guided by a series of open-ended prompts (see Supplementary Materials 1 and 2), allowing for focused yet natural discussions regarding the three main topics.", [["line", "OBSERVATION_MODIFIER", 4, 8]]], ["A research assistant was present for each patient interview and offered interpretation services for patients that felt more comfortable speaking in Luganda.", [["patient", "ORGANISM", 42, 49], ["patients", "ORGANISM", 100, 108], ["patient", "SPECIES", 42, 49], ["patients", "SPECIES", 100, 108]]], ["For participants that did not speak either English or Luganda, interviews were completed with the patient\u2019s caregiver providing English interpretations of the patient\u2019s dialogue.", [["patient", "ORGANISM", 98, 105], ["patient", "ORGANISM", 159, 166], ["participants", "SPECIES", 4, 16], ["patient", "SPECIES", 98, 105], ["patient", "SPECIES", 159, 166]]], ["The interviews typically lasted between 15 and 45 minutes, and each interview was recorded for post hoc analysis.Quantitative Analysis ::: MethodsSurvey data were inputted into Microsoft Excel v16.36 (Microsoft, Redmond).", [["post hoc analysis", "TEST", 95, 112], ["MethodsSurvey data", "TEST", 139, 157]]], ["Categorical data were summarized using count and percentage.", [["Categorical data", "TEST", 0, 16], ["percentage", "TEST", 49, 59]]], ["Numerical data were represented using mean and standard deviation.", [["Numerical data", "TEST", 0, 14], ["mean", "TEST", 38, 42]]], ["For opinion-based survey items, responses provided using the five-point Likert scale were summarized using mean and standard deviation.", [["Likert scale", "TEST", 72, 84]]], ["The percentages of participants that were in agreement (i.e. responded Agree or Strongly Agree), neutral (i.e. responded Neither Agree or Disagree), and in disagreement (i.e. responded Disagree or Strongly Disagree) were also reported for each survey item.", [["participants", "SPECIES", 19, 31]]], ["The significance of differences in agreement between two related survey items (e.g. comfortability with two different methods of communication) was assessed by comparing the percentage of participants that were in agreement with each item using McNemar\u2019s test for paired nominal data [26].Qualitative Analysis ::: MethodsAudio recordings of each interview were professionally transcribed for analysis.", [["participants", "SPECIES", 188, 200], ["McNemar\u2019s test", "TEST", 245, 259], ["analysis", "TEST", 392, 400]]], ["A conventional content analysis approach was used to examine the transcripts [24].", [["A conventional content analysis approach", "TEST", 0, 40]]], ["This process was repeated until all transcripts had been coded and a consensus had been reached on the main themes emerging from the analysis.", [["the analysis", "TEST", 129, 141]]], ["All qualitative analyses were completed using NVivo v12.0.0 (QSR International, Melbourne).Patient Survey ::: ResultsA total of 101 patients (62 female/39 male, aged 54.2 \u00b1 17.5 years) completed a survey.", [["patients", "ORGANISM", 132, 140], ["Patient", "SPECIES", 91, 98], ["patients", "SPECIES", 132, 140], ["All qualitative analyses", "TEST", 0, 24], ["NVivo v", "TEST", 46, 53]]], ["Table 1 summarizes the demographic and clinical characteristics of the surveyed patients.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88]]], ["Amongst the participants, 62% reported having no monthly household income, and only 8% reported a monthly income greater than 500,000 Ugandan shillings.", [["participants", "SPECIES", 12, 24]]], ["Over 60% of individuals possessed a primary school education or less, while 30% of patients self-identified as illiterate.", [["individuals", "ORGANISM", 12, 23], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91]]], ["More than half of patients (54%) were New York Heart Association class III or IV.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["The primary HF causes were cardiomyopathy (42%), hypertension (24%), and rheumatic heart disease (17%).", [["heart", "ANATOMY", 83, 88], ["HF", "DISEASE", 12, 14], ["cardiomyopathy", "DISEASE", 27, 41], ["hypertension", "DISEASE", 49, 61], ["rheumatic heart disease", "DISEASE", 73, 96], ["heart", "ORGAN", 83, 88], ["cardiomyopathy", "PROBLEM", 27, 41], ["hypertension", "PROBLEM", 49, 61], ["rheumatic heart disease", "PROBLEM", 73, 96], ["cardiomyopathy", "OBSERVATION", 27, 41], ["hypertension", "OBSERVATION", 49, 61], ["rheumatic", "OBSERVATION_MODIFIER", 73, 82], ["heart", "ANATOMY", 83, 88], ["disease", "OBSERVATION", 89, 96]]], ["A mobile device was accessible (either owned or borrowed) by 98% of individuals, while only 16% had access to a smartphone.", [["A mobile device", "TREATMENT", 0, 15], ["a smartphone", "TREATMENT", 110, 122], ["mobile device", "OBSERVATION", 2, 15]]], ["Only 12% and 17% of individuals had access to a weighing scale and blood pressure cuff, respectively.Patient Survey ::: ResultsResponses to opinion-based survey items (Table 3) revealed that 54% of patients agreed that they need to weigh themselves every day, while 77% agreed that it is important to check their blood pressure at home.", [["blood", "ANATOMY", 67, 72], ["blood", "ANATOMY", 313, 318], ["individuals", "ORGANISM", 20, 31], ["blood", "ORGANISM_SUBSTANCE", 67, 72], ["patients", "ORGANISM", 198, 206], ["blood", "ORGANISM_SUBSTANCE", 313, 318], ["Patient", "SPECIES", 101, 108], ["patients", "SPECIES", 198, 206], ["a weighing scale", "TREATMENT", 46, 62], ["blood pressure cuff", "TEST", 67, 86], ["their blood pressure", "TEST", 307, 327], ["pressure cuff", "OBSERVATION", 73, 86]]], ["Nearly half (48%) disagreed that they knew what to do in response to changes in their HF symptoms, with 47% of patients responding with Strongly Disagree.", [["HF", "DISEASE", 86, 88], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["their HF symptoms", "PROBLEM", 80, 97]]], ["A significantly larger proportion of patients agreed that they were comfortable using their phone for mobile money services (63%), when compared to using their device for short message service (SMS) messaging (46%, P < 0.001) and interactive voice response systems (47%, P = 0.002).Overview of Interview Results ::: Patient & Clinician Interviews ::: ResultsSemi-structured interviews were completed with 19 HF patients, three informal caregivers, seven physicians, and three nurses.", [["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 411, 419], ["patients", "SPECIES", 37, 45], ["Patient", "SPECIES", 316, 323], ["patients", "SPECIES", 411, 419], ["interactive voice response systems", "TEST", 230, 264], ["P", "TEST", 271, 272], ["significantly", "OBSERVATION_MODIFIER", 2, 15], ["larger", "OBSERVATION_MODIFIER", 16, 22]]], ["Seven themes emerged in the qualitative analysis of the patient and clinician interviews.", [["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63]]], ["Correlated themes were grouped to form a hierarchical theme structure involving four theme clusters: Overdependence on Clinic, Inconvenience of Attending Clinic, Inconsistent Self-Care at Home, and Technological Literacy (Figure 1).", [["Overdependence", "DISEASE", 101, 115]]], ["It is worth noting that three themes were categorized within two separate theme clusters, given the multifactorial contributions of these themes to patients\u2019 lived experiences.Theme Cluster 1: Overdependence on Clinic ::: Patient & Clinician Interviews ::: ResultsThe first theme cluster was an apparent overdependence of patients on the clinic.", [["patients", "ORGANISM", 148, 156], ["patients", "ORGANISM", 322, 330], ["patients", "SPECIES", 148, 156], ["Patient", "SPECIES", 222, 229], ["patients", "SPECIES", 322, 330]]], ["Patients demonstrated a dependence on the clinic for virtually all information related to their condition and its management.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["its management", "TREATMENT", 110, 124]]], ["In many cases, the clinic appeared to be the lone source of HF-specific information available to the patient.Theme Cluster 1: Overdependence on Clinic ::: Patient & Clinician Interviews ::: ResultsThis overdependence on the clinic was also evidenced by the fact that very few patients were informed on how to alter self-care behaviours in response to symptoms.", [["patient", "ORGANISM", 101, 108], ["patients", "ORGANISM", 276, 284], ["patient", "SPECIES", 101, 108], ["Patient", "SPECIES", 155, 162], ["patients", "SPECIES", 276, 284], ["HF", "PROBLEM", 60, 62], ["symptoms", "PROBLEM", 351, 359]]], ["As an example, only three of the interviewed patients demonstrated knowledge of a common HF self-care behaviour: taking extra diuretics in response to fluid overload.", [["fluid overload", "DISEASE", 151, 165], ["patients", "ORGANISM", 45, 53], ["fluid", "ORGANISM_SUBSTANCE", 151, 156], ["patients", "SPECIES", 45, 53], ["extra diuretics", "TREATMENT", 120, 135], ["fluid overload", "PROBLEM", 151, 165], ["fluid overload", "OBSERVATION", 151, 165]]], ["Instead, patients often reported that they would simply come to the clinic if they noticed any change in their symptoms.Theme Cluster 1: Overdependence on Clinic ::: Patient & Clinician Interviews ::: ResultsIn addition to the dependence on the clinic for information, patients were also found to be heavily reliant on clinicians to provide comfort and peace of mind regarding their condition.", [["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 269, 277], ["patients", "SPECIES", 9, 17], ["Patient", "SPECIES", 166, 173], ["patients", "SPECIES", 269, 277], ["any change in their symptoms", "PROBLEM", 91, 119]]], ["Patients often described coming to the clinic with fears and anxieties associated with their diagnosis.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["anxieties", "PROBLEM", 61, 70]]], ["In particular, it was noted that patients frequently viewed and described their health using dichotomous language.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41]]], ["Patients would often describe themselves as either healthy or dying, with little acknowledgement of the state of health in between.Theme Cluster 1: Overdependence on Clinic ::: Patient & Clinician Interviews ::: ResultsAs expected, patients would typically report to the clinic when their self-perceived health status tended towards the negative half of this health dichotomy.", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 232, 240], ["Patients", "SPECIES", 0, 8], ["Patient", "SPECIES", 177, 184], ["patients", "SPECIES", 232, 240]]], ["However, when given the opportunity to discuss their symptoms with a physician, patients would often leave the clinic with confidence that their condition was, in fact, manageable.Theme Cluster 1: Overdependence on Clinic ::: Patient & Clinician Interviews ::: ResultsThe theme of an apparent expectancy on physicians to provide hope also emerged in the clinician interviews.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["Patient", "SPECIES", 226, 233], ["their symptoms", "PROBLEM", 47, 61]]], ["Clinicians noted that the relationship between the physician and the patient remains largely one-sided in Uganda.", [["patient", "ORGANISM", 69, 76], ["patient", "SPECIES", 69, 76]]], ["This paternalistic relationship allows clinicians to play a large role in influencing changes in health behaviours; however, it also places an immense burden on clinicians to be the source of both information and comfort in their patients\u2019 lives.Theme Cluster 2: Inconvenience of Attending Clinic ::: Patient & Clinician Interviews ::: ResultsThe second cluster of themes highlighted the significant degree of inconvenience associated with patient visits to the clinic.", [["patients", "ORGANISM", 230, 238], ["patient", "ORGANISM", 440, 447], ["patients", "SPECIES", 230, 238], ["Patient", "SPECIES", 301, 308], ["patient", "SPECIES", 440, 447], ["large", "OBSERVATION_MODIFIER", 60, 65], ["significant", "OBSERVATION_MODIFIER", 388, 399], ["degree", "OBSERVATION_MODIFIER", 400, 406]]], ["Patients frequently described the immense financial burden associated with a typical clinic visit.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["This burden included direct treatment costs (e.g. consultations, investigations, medications), as well as indirect expenses associated with the often-long distance travelled to attend the clinic (e.g. transportation, food, accommodations).", [["direct treatment costs", "TREATMENT", 21, 43], ["medications", "TREATMENT", 81, 92]]], ["These financial costs were typically incurred either directly by patients or by family members providing financial support.Theme Cluster 2: Inconvenience of Attending Clinic ::: Patient & Clinician Interviews ::: ResultsAnother concern voiced by patients was the large time cost required to attend the clinic.", [["patients", "ORGANISM", 65, 73], ["patients", "ORGANISM", 246, 254], ["patients", "SPECIES", 65, 73], ["Patient", "SPECIES", 178, 185], ["patients", "SPECIES", 246, 254], ["financial support", "TREATMENT", 105, 122]]], ["Several patients reported arriving at the clinic in the early morning and not departing until the late afternoon.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16]]], ["Some patients had previously waited in the clinic for an entire day, only to be told to return the following day to be seen by a clinician.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["This time cost was even larger for patients living outside of Kampala, who also had to factor in time for travel both to and from the clinic.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["larger", "OBSERVATION_MODIFIER", 24, 30]]], ["For many patients, this inconvenience also led to time lost from work, further adding to the financial challenges listed above.Theme Cluster 2: Inconvenience of Attending Clinic ::: Patient & Clinician Interviews ::: ResultsThese frustrations with long waiting periods were shared by clinicians, many of whom insisted that their greatest challenge was the sheer number of patients coming to the clinic.", [["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 372, 380], ["patients", "SPECIES", 9, 17], ["Patient", "SPECIES", 182, 189], ["patients", "SPECIES", 372, 380]]], ["Due to the large volume of patients being seen each day, several clinicians admitted that they were often unable to provide their patients with a complete picture of the HF condition.Theme Cluster 2: Inconvenience of Attending Clinic ::: Patient & Clinician Interviews ::: ResultsA further frustration held by clinicians was the fact that many patients report to the clinic far too late.", [["HF", "DISEASE", 170, 172], ["patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 130, 138], ["patients", "ORGANISM", 344, 352], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 130, 138], ["Patient", "SPECIES", 238, 245], ["patients", "SPECIES", 344, 352], ["the HF condition", "PROBLEM", 166, 182], ["large", "OBSERVATION_MODIFIER", 11, 16], ["volume", "OBSERVATION_MODIFIER", 17, 23]]], ["Clinicians claimed that patients often delay visiting the clinic until they present with an adverse event, at which point the heart is at risk of experiencing irreparable damage.", [["heart", "ANATOMY", 126, 131], ["patients", "ORGANISM", 24, 32], ["heart", "ORGAN", 126, 131], ["patients", "SPECIES", 24, 32], ["an adverse event", "PROBLEM", 89, 105], ["irreparable damage", "PROBLEM", 159, 177], ["heart", "ANATOMY", 126, 131], ["irreparable", "OBSERVATION_MODIFIER", 159, 170], ["damage", "OBSERVATION", 171, 177]]], ["Many clinicians attributed these late presentations to the financial and time costs associated with treatment, while others believed the delays to be caused by limited patient understanding of the condition and its severity.Theme Cluster 3: Inconsistent Self-Care at Home ::: Patient & Clinician Interviews ::: ResultsThe third theme cluster centred around the lack of continuity in patient self-care behaviours.", [["patient", "ORGANISM", 168, 175], ["patient", "ORGANISM", 383, 390], ["patient", "SPECIES", 168, 175], ["Patient", "SPECIES", 276, 283], ["patient", "SPECIES", 383, 390], ["treatment", "TREATMENT", 100, 109], ["continuity", "OBSERVATION_MODIFIER", 369, 379]]], ["Instead of self-care being continuous with minimal disruptions, it was often described by patients as being cyclical in nature.", [["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["self-care", "TREATMENT", 11, 20], ["minimal disruptions", "PROBLEM", 43, 62]]], ["As described previously, patients typically come to the clinic in response to changes in their symptoms or an adverse event, and subsequently leave the clinic with updated medications and newfound confidence in their self-care behaviours.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["their symptoms", "PROBLEM", 89, 103], ["updated medications", "TREATMENT", 164, 183]]], ["Following a clinic visit, patients generally experience a substantial improvement in their state of health.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["substantial", "OBSERVATION_MODIFIER", 58, 69], ["improvement", "OBSERVATION", 70, 81]]], ["However, patients often reported that their effective self-care behaviours then deteriorate over time.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17]]], ["The most commonly cited cause of this breakdown in self-care was patients finishing a medication and not refilling it immediately, often due to a lack of funds or an incomplete understanding of the drug\u2019s utility.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["this breakdown", "PROBLEM", 33, 47], ["a medication", "TREATMENT", 84, 96], ["most commonly", "OBSERVATION_MODIFIER", 4, 17], ["breakdown", "OBSERVATION_MODIFIER", 38, 47]]], ["This lapse in self-care is then generally followed by a regression in patients\u2019 health.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78]]], ["Naturally, worsening patients return to the clinic, restarting the cycle and further reinforcing the aforementioned burden on the clinic.Theme Cluster 3: Inconsistent Self-Care at Home ::: Patient & Clinician Interviews ::: ResultsPatients reported several financial challenges associated with adequately caring for themselves at home.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["Patient", "SPECIES", 189, 196], ["the cycle", "TREATMENT", 63, 72], ["worsening", "OBSERVATION_MODIFIER", 11, 20]]], ["Many patients reported that, even upon leaving the clinic, they could not afford all of the medications prescribed by their clinicians.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["the medications", "TREATMENT", 88, 103]]], ["Patients noted that diuretics were often the only medications available to them at no cost, with most medications having to be purchased from the clinic or an external pharmacy.", [["Patients", "ORGANISM", 0, 8], ["diuretics", "SIMPLE_CHEMICAL", 20, 29], ["Patients", "SPECIES", 0, 8], ["diuretics", "TREATMENT", 20, 29], ["medications", "TREATMENT", 50, 61], ["most medications", "TREATMENT", 97, 113]]], ["The financial challenges also expanded into other aspects of the HF self-care regimen.", [["The financial challenges", "TREATMENT", 0, 24], ["the HF self-care regimen", "TREATMENT", 61, 85]]], ["Many patients reported that they were unable to adhere to dietary recommendations received at the clinic, given the increased cost and decreased availability of the suggested foods.Theme Cluster 3: Inconsistent Self-Care at Home ::: Patient & Clinician Interviews ::: ResultsIn addition to the financial challenges faced by patients, clinicians also attributed the fragmented self-care to patients\u2019 limited understanding of the severity of the HF condition.", [["HF", "DISEASE", 444, 446], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 324, 332], ["patients", "ORGANISM", 389, 397], ["patients", "SPECIES", 5, 13], ["Patient", "SPECIES", 233, 240], ["patients", "SPECIES", 324, 332], ["patients", "SPECIES", 389, 397], ["the increased cost", "PROBLEM", 112, 130], ["the HF condition", "PROBLEM", 440, 456], ["increased", "OBSERVATION_MODIFIER", 116, 125], ["cost", "OBSERVATION", 126, 130]]], ["Specifically, clinicians noted that many patients fail to acknowledge the severity of their condition and hold firm to the belief that they will eventually be cured of HF.", [["HF", "DISEASE", 168, 170], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["HF", "PROBLEM", 168, 170]]], ["This expectation of a cure for HF emerged in several patient interviews.Theme Cluster 3: Inconsistent Self-Care at Home ::: Patient & Clinician Interviews ::: ResultsFurther gaps in understanding of the HF condition and its management were highlighted in the patient interviews.", [["HF", "DISEASE", 31, 33], ["HF", "DISEASE", 203, 205], ["patient", "ORGANISM", 53, 60], ["patient", "ORGANISM", 259, 266], ["patient", "SPECIES", 53, 60], ["Patient", "SPECIES", 124, 131], ["patient", "SPECIES", 259, 266], ["HF", "PROBLEM", 31, 33], ["the HF condition", "PROBLEM", 199, 215]]], ["Most patients did not seem to fully understand the causes of their various HF symptoms.", [["HF", "DISEASE", 75, 77], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["their various HF symptoms", "PROBLEM", 61, 86]]], ["Very few patients mentioned exercise as being a part of their self-care regimen.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["their self-care regimen", "TREATMENT", 56, 79], ["few", "OBSERVATION_MODIFIER", 5, 8]]], ["While some patients noted dietary recommendations from their clinicians, such as avoiding foods high in salt and fat, many patients emphasized medication adherence as the sole method of managing their condition at home.Theme Cluster 4: Technological Literacy ::: Patient & Clinician Interviews ::: ResultsThe final cluster of themes centred on the technological literacy of the interviewed patients.", [["patients", "ORGANISM", 11, 19], ["salt", "SIMPLE_CHEMICAL", 104, 108], ["fat", "TISSUE", 113, 116], ["patients", "ORGANISM", 123, 131], ["patients", "ORGANISM", 390, 398], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 123, 131], ["Patient", "SPECIES", 263, 270], ["patients", "SPECIES", 390, 398], ["medication adherence", "TREATMENT", 143, 163]]], ["While virtually every patient had access to a mobile phone, most patients possessed a low-cost non-smartphone.", [["patient", "ORGANISM", 22, 29], ["patients", "ORGANISM", 65, 73], ["patient", "SPECIES", 22, 29], ["patients", "SPECIES", 65, 73]]], ["It became immediately clear that patients\u2019 preferred method of communication was calling.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41]]], ["Very few patients reported using SMS messaging, and virtually all patients reported a preference for calling over SMS.Theme Cluster 4: Technological Literacy ::: Patient & Clinician Interviews ::: ResultsInternet and social media usage were found to be quite rare amongst the patient population.", [["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 66, 74], ["patient", "ORGANISM", 276, 283], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 66, 74], ["Patient", "SPECIES", 162, 169], ["patient", "SPECIES", 276, 283], ["SMS messaging", "TREATMENT", 33, 46]]], ["However, almost all patients had experience using a mobile money service on their device.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["their device", "TREATMENT", 76, 88]]], ["Most patients reported using mobile money independently, while the remainder had at least used the system with support from a friend, a family member, or a mobile money service provider.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["Furthermore, patients frequently reported that they found mobile money easy to use on their mobile devices.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21]]], ["Even patients who disliked or were uncomfortable with SMS messaging appeared to use mobile money with ease.Theme Cluster 4: Technological Literacy ::: Patient & Clinician Interviews ::: ResultsInterestingly, low socioeconomic status appeared to be not so much a barrier to mobile money usage, but a factor that increased the likelihood of an individual having experience with the system.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["Patient", "SPECIES", 151, 158], ["SMS messaging", "TREATMENT", 54, 67]]], ["This unexpected result was caused by the fact that indigent, rural-dwelling individuals would often have their family send them funds via mobile money to cover the high costs of medication.DiscussionThe qualitative themes that emerged in this analysis offer important insight regarding the intricacies of HF management at a cardiac care centre in Kampala, Uganda.", [["cardiac", "ANATOMY", 324, 331], ["HF", "DISEASE", 305, 307], ["individuals", "ORGANISM", 76, 87], ["the high costs of medication", "TREATMENT", 160, 188], ["HF management", "TREATMENT", 305, 318]]], ["The large patient dependence on the clinic for HF-specific information and emotional support (Theme Cluster 1) leads to challenges for both patients and clinicians.", [["patient", "ORGANISM", 10, 17], ["patients", "ORGANISM", 140, 148], ["patient", "SPECIES", 10, 17], ["patients", "SPECIES", 140, 148], ["The large patient dependence", "PROBLEM", 0, 28], ["HF", "PROBLEM", 47, 49], ["emotional support", "TREATMENT", 75, 92], ["large", "OBSERVATION_MODIFIER", 4, 9]]], ["Because the clinic is tasked with an immense patient volume (Theme Cluster 2), clinicians are forced to decide between a) providing a complete picture of HF management at the cost of seeing fewer patients or b) efficiently highlighting the critical aspects of HF management to an increased number of patients.", [["HF", "DISEASE", 154, 156], ["HF", "DISEASE", 260, 262], ["patient", "ORGANISM", 45, 52], ["patients", "ORGANISM", 196, 204], ["patients", "ORGANISM", 300, 308], ["patient", "SPECIES", 45, 52], ["patients", "SPECIES", 196, 204], ["patients", "SPECIES", 300, 308], ["HF management", "TREATMENT", 154, 167], ["HF management", "TREATMENT", 260, 273], ["increased", "OBSERVATION_MODIFIER", 280, 289]]], ["As the clinicians \u2013 through no fault of their own \u2013 generally opt for the latter of the two options, patients end up with an incomplete understanding of their condition and its necessary self-care behaviours (Theme Cluster 3).", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109]]], ["Unfortunately, these unmet information needs presumably result in increased dependence (Theme Cluster 1) and patient burden (Theme Cluster 2) on the clinic, which in turn creates a vicious cycle.DiscussionOne key finding in the analysis was a failure to empower HF patients to adequately care for themselves.", [["HF", "DISEASE", 262, 264], ["patient", "ORGANISM", 109, 116], ["patients", "ORGANISM", 265, 273], ["patient", "SPECIES", 109, 116], ["patients", "SPECIES", 265, 273], ["increased dependence", "PROBLEM", 66, 86], ["a failure", "PROBLEM", 241, 250], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["dependence", "OBSERVATION_MODIFIER", 76, 86], ["vicious cycle", "OBSERVATION", 181, 194]]], ["This theme emerged in the interview phase and was supported by the large proportion of surveyed participants who disagreed that they know what to do in response to changes in their symptoms.", [["participants", "SPECIES", 96, 108], ["changes in their symptoms", "PROBLEM", 164, 189]]], ["Though patients should feel free to visit the clinic when they experience abrupt changes in their HF symptoms, study participants did not appear to have the knowledge required to care for themselves even if they had the desire to do so.", [["HF", "DISEASE", 98, 100], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["participants", "SPECIES", 117, 129], ["abrupt changes in their HF symptoms", "PROBLEM", 74, 109]]], ["This finding correlated with results from a 2017 study by Namukwaya et al., who found that \u201cone of the greatest unmet needs from [Ugandan HF] patients was for information on the illness, its treatment, prognosis and how to self-care\u201d [27].DiscussionThe unmet information needs and limited self-care abilities amongst the Ugandan HF patients present a clear target for a future digital health intervention.", [["HF", "DISEASE", 138, 140], ["illness", "DISEASE", 178, 185], ["HF", "DISEASE", 329, 331], ["patients", "ORGANISM", 142, 150], ["patients", "ORGANISM", 332, 340], ["patients", "SPECIES", 142, 150], ["patients", "SPECIES", 332, 340], ["a 2017 study", "TEST", 42, 54], ["a future digital health intervention", "TREATMENT", 368, 404]]], ["Specifically, it appears that the target population could benefit from a system that provides patients with HF-specific information and reassurance in their self-care abilities.", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["HF", "PROBLEM", 108, 110], ["reassurance", "TREATMENT", 136, 147]]], ["By empowering patients with information regarding their condition and its management, such a system could lead to several potential benefits, namely increased self-care efficacy, improved quality of life, fewer clinic visits, and reduced information requirements during patient-clinician interactions.DiscussionBased on the technological literacy reported by patients, the ideal platform for such an intervention would resemble existing mobile money services in Uganda.", [["patients", "ORGANISM", 14, 22], ["patient", "ORGANISM", 270, 277], ["patients", "ORGANISM", 359, 367], ["patients", "SPECIES", 14, 22], ["patient", "SPECIES", 270, 277], ["patients", "SPECIES", 359, 367], ["its management", "TREATMENT", 70, 84], ["an intervention", "TREATMENT", 397, 412]]], ["These services use Unstructured Supplementary Service Data (USSD), a communication protocol that is accessible from any GSM-enabled mobile device (i.e. smartphone or non-smartphone).", [["a communication protocol", "TREATMENT", 67, 91], ["mobile device", "TREATMENT", 132, 145]]], ["USSD creates an open connection between the user\u2019s device and a network or server, allowing the user to navigate through a decision tree by inputting numbers that correspond to desired actions [28].", [["the user\u2019s device", "TREATMENT", 40, 57], ["open", "OBSERVATION", 16, 20]]], ["The workflow of a USSD-based system resembles interactive voice response systems commonly used in North America; however, the lists of options are presented to the user in the form of text rather than being spoken aloud by an automated system.", [["a USSD", "TEST", 16, 22]]], ["In the presented study, USSD-based mobile money services appeared to be well-adopted amongst participants of all socioeconomic classes.", [["participants", "SPECIES", 93, 105], ["the presented study", "TEST", 3, 22], ["USSD", "TEST", 24, 28]]], ["This existing familiarity with USSD technology and its functionality could greatly mitigate the usability challenges associated with designing a system specifically for users of low socioeconomic status.", [["USSD technology", "TREATMENT", 31, 46], ["low socioeconomic status", "PROBLEM", 178, 202]]], ["As a result of these potential benefits, a small number of digital health interventions currently deployed in LMICs are using USSD [313233], including a recent USSD-based intervention developed to track COVID-19 symptoms in Ghana [34].", [["digital health interventions", "TREATMENT", 59, 87], ["a recent USSD", "TREATMENT", 151, 164], ["based intervention", "TREATMENT", 165, 183], ["COVID", "TEST", 203, 208], ["symptoms", "PROBLEM", 212, 220], ["small", "OBSERVATION_MODIFIER", 43, 48]]], ["As the identified interventions primarily focus on infectious disease tracking and maternal-fetal medicine, there is a need for further research into the applicability of USSD to digital health interventions for chronic disease management.DiscussionIn addition to the various findings of the research study, it is important to acknowledge the numerous benefits that resulted from early engagement of local patients and clinicians.", [["fetal", "ANATOMY", 92, 97], ["chronic disease", "DISEASE", 212, 227], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 92, 97], ["patients", "ORGANISM", 406, 414], ["patients", "SPECIES", 406, 414], ["infectious disease tracking", "PROBLEM", 51, 78], ["digital health interventions", "TREATMENT", 179, 207], ["chronic disease management", "TREATMENT", 212, 238], ["the research study", "TEST", 288, 306], ["infectious", "OBSERVATION", 51, 61], ["chronic", "OBSERVATION_MODIFIER", 212, 219], ["disease", "OBSERVATION", 220, 227]]], ["While a user-centred design process has been shown to be imperative for the success of digital health interventions in high-income countries [19], it remains underutilized in global health initiatives [22].", [["digital health interventions", "TREATMENT", 87, 115]]], ["By engaging the target population, the authors gained an appreciation of the various challenges faced by HF patients and clinicians in Uganda, as well as the technological channels available to the eventual users of the proposed digital health intervention.", [["HF", "DISEASE", 105, 107], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["the proposed digital health intervention", "TREATMENT", 216, 256]]], ["The discovery of the patient-preferred USSD platform effectively demonstrates the benefit of early and direct end-user engagement.DiscussionThe study is not without limitations.", [["patient", "ORGANISM", 21, 28], ["patient", "SPECIES", 21, 28], ["The study", "TEST", 140, 149], ["not without", "UNCERTAINTY", 153, 164]]], ["All presented information was collected at a semi-private cardiac care centre, which may have skewed patient-related data towards HF patients with a means of paying for cardiac services.", [["cardiac", "ANATOMY", 58, 65], ["cardiac", "ANATOMY", 169, 176], ["HF", "DISEASE", 130, 132], ["patient", "ORGANISM", 101, 108], ["patients", "ORGANISM", 133, 141], ["cardiac", "ORGAN", 169, 176], ["patient", "SPECIES", 101, 108], ["patients", "SPECIES", 133, 141], ["cardiac services", "TREATMENT", 169, 185]]], ["This study population also limited the analysis to individuals that had made the decision to seek treatment at a cardiac clinic.", [["cardiac", "ANATOMY", 113, 120], ["This study population", "TEST", 0, 21], ["the analysis", "TEST", 35, 47]]], ["Accordingly, the views of the study population may not be representative of the Ugandan HF community as a whole.", [["the views of the study population", "TEST", 13, 46]]], ["The qualitative analysis was also limited by the fact that neither of the two reviewers were native Ugandans, which may have led to a lack of context in reviewing the transcripts.", [["The qualitative analysis", "TEST", 0, 24]]], ["This final limitation was mitigated through consistent feedback, consultation and oversight from the two Ugandan investigators included in this research study.ConclusionsIn Uganda, HF presents a large and increasing burden on both patients and the healthcare system.", [["HF", "DISEASE", 181, 183], ["patients", "ORGANISM", 231, 239], ["patients", "SPECIES", 231, 239], ["this research study", "TEST", 139, 158], ["HF", "PROBLEM", 181, 183], ["a large and increasing burden", "PROBLEM", 193, 222], ["large", "OBSERVATION_MODIFIER", 195, 200], ["increasing", "OBSERVATION_MODIFIER", 205, 215], ["burden", "OBSERVATION_MODIFIER", 216, 222]]], ["As digital health interventions have been shown to improve self-care efficacy and quality of life amongst HF patients living in high-income countries, such interventions could play a role in mitigating the burden of HF in Uganda.", [["HF", "DISEASE", 106, 108], ["HF", "DISEASE", 216, 218], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["digital health interventions", "TREATMENT", 3, 31], ["such interventions", "TREATMENT", 151, 169], ["HF", "PROBLEM", 216, 218]]], ["We interviewed and surveyed Ugandan HF patients and clinicians regarding HF management and technological literacy.", [["HF", "DISEASE", 73, 75], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["HF management", "TREATMENT", 73, 86]]], ["Qualitative analysis identified an overdependence of patients on the clinic, an inconvenience associated with clinic visits, inconsistent patient self-care behaviours at home, and technological abilities that favoured USSD-based services.", [["patients", "ORGANISM", 53, 61], ["patient", "ORGANISM", 138, 145], ["patients", "SPECIES", 53, 61], ["patient", "SPECIES", 138, 145], ["Qualitative analysis", "TEST", 0, 20]]], ["The patient survey supported themes emergent in the interviews, specifically a self-perceived inability for patients to adequately care for themselves, as well as a preference for the USSD platform.", [["patient", "ORGANISM", 4, 11], ["patients", "ORGANISM", 108, 116], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 108, 116]]], ["Based on the results, future digital health interventions for HF patients in Uganda should incorporate USSD technology and focus on empowering patients to better care for themselves.Data Accessibility StatementThe data collected and analyzed in the presented study are available from the corresponding author on reasonable request.", [["HF", "DISEASE", 62, 64], ["patients", "ORGANISM", 65, 73], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 143, 151], ["HF", "PROBLEM", 62, 64], ["USSD technology", "TREATMENT", 103, 118], ["The data", "TEST", 210, 218], ["the presented study", "TEST", 245, 264]]]]}